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Thesis Summary 
During placental development, the pathways that regulate the invasion of trophoblasts into the 
decidua will lead to remodelling the uterine vasculature and will eventually give rise to placenta 
formation. The same pathways get reactivated during cancer development and can lead to tumour 
cell invasion and the metastatic process. As a consequence, there are striking similarities between 
the behaviour of tumour cells and the trophoblasts, due to their similar gene expression pattern 
and protein profile and we set about to determine whether factors which have been shown to play 
important roles in cancer biology are also expressed and regulate trophoblast function. 
In this study we have focused on three different metastasis-associated proteins with well-defined 
roles in cancer progression, which have been closely linked with poor prognosis for cancer 
patients but have not been greatly studied in the context of placental development. The proteins 
are a small calcium-binding protein S100P, the ERM protein ezrin and the cytoskeleton-
membrane linking protein, IQGAP1. After showing their expression and localisation pattern in 
human placental villi, we showed that these proteins are highly expressed during the earlier stages 
of the gestation, suggesting a potential role in early placenta development and implantation. We 
then studied their expression and localisation in trophoblast cell lines and primary trophoblasts. 
Using the trophoblast cell lines, through loss-of-function, and where relevant, gain of function 
studies, we showed that these three metastasis-associated proteins promote trophoblast motility 
and invasion.  
We also investigated some of the possible mechanisms that might have been involved in the 
mentioned pathways including changes in focal adhesions, protein localisation and 
phosphorylation. We have yet to investigate the underlying mechanisms that link these three 
proteins to trophoblast motility and invasion, and whether all or two of them work together to 
make these processes possible. 
[Keywords: placenta, S100P, ezrin, IQGAP1, focal adhesion] 
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1.1. Placenta implantation  
1.1.1. Placenta types 
The placenta is a temporary organ that physically attaches the growing embryo/foetus to its 
mother, and facilitates the metabolic interchange between them, while forming a barrier against 
the transmission of many bacteria (Gude et al. 2004). In the beginning of placenta formation, six 
layers separate maternal and foetal blood, three of which are foetal membranes: the endothelium 
of the foetal capillaries, connective tissue, and epithelium of the chorion (the outermost layer of 
foetal membranes).The other three are of maternal origin: the endothelium lining of the 
endometrial blood vessels, connective tissue and the endometrial epithelial cells (Figure 1.1). 
Depending on the species, some of the maternal layers are destroyed in the process of placentation 
(Bowen 2011).  
 
Figure 1.1 Six layers separate the foetal and the maternal blood during early pregnancy.  
(Adapted with modification from Bowen 2011).  
 
Placenta types in placental mammals (eutherians) can be classified based on the number of layers 
between foetal and maternal blood: 1. Epitheliochorial, the least invasive type, in which three 
layers of maternal tissue separate the foetal and maternal blood from each other, found in horses, 
pigs, and ruminants. 2. Endotheliochorial, which is partially invasive as it has lost the maternal 
epithelial layer, found in cats and dogs. 3. Haemochorial, the most invasive type, in which all 
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three maternal layers are destroyed, letting the foetal tissues to come in direct contact with the 
maternal blood, found in humans and rodents (Furukawa, Kuroda & Sugiyama 2014). 
Another categorisation of the placenta is based on its morphology and the contact points between 
the maternal and the foetal side: 1. Diffuse, in which the placenta covers the entire surface of the 
endometrium, found in horses and pigs. 2. Cotyledonary, in which there are numerous contact 
points between the maternal and foetal vascular system, instead of a single placenta, found in 
ruminants. 3. Zonary, in which the placenta forms a complete or incomplete band surrounding 
the foetus, found in carnivores. 4. Discoid, in which the placenta forms a discoid form, found in 
primates and rodents (Furukawa, Kuroda & Sugiyama 2014). 
In this work, we will be focusing on the haemochorial discoid placenta found in humans. 
1.1.2. Implantation 
Implantation, a critical step in viviparous birth in mammals, is the process of invasion and 
attachment of the conceptus into the inner surface of the uterus, which later brings the growing 
vessels of the embryo into functional contact with the maternal circulation, via the placenta; if 
successful, this can result in the growth and development of a new offspring (Dey et al. 2004). 
For successful implantation, effective cross-talk between the blastocyst and the endometrium 
needs to take place (Hantak, Bagchi & Bagchi 2014). The stages of implantation are described as 
follows. 
1.1.3. Blastocyst formation 
Before moving down the Fallopian tube, the fertilised ovum (zygote) stays in the tube for 3-4 
days, during which a number of ordinary mitotic divisions make it into a mulberry-like mass of 
cells, called the morula (Alberts et al. 2014). In humans, around 5 days after fertilisation, a hollow 
sphere of 16-32 cells known as the early blastocyst is formed, which has a cavity, known as the 
blastocoel, as well as two distinct layers of cells. The trophectoderm forms the outermost layer 
of the blastocyst and is made out of trophoblasts (Greek trephein: to feed, and blastos: germinator) 
that later will form the placenta. The inner compact mass of cells will eventually give rise to the 
definitive structures of the foetus (Alberts et al. 2014). After another two days, the zona pellucidae 
membrane degrades (known as zona hatching), forming the late-stage blastocyst, and trophoblast 
cells form two distinct layers of cells: the relatively undifferentiated cytotrophoblast, with distinct 
boundaries that later form the villi, to physically attach the placenta to the uterus, and 
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differentiated syncytiotrophoblasts, the external layer of cells with no distinct boundaries, formed 
by the fusion of mononuclear cytotrophoblasts (Hill 2019) (Figure 1.2). 
Figure 1.2 Blastocyst formation. Panel A shows blastocyst formation from the ovary to the 
uterus; Upon release from the follicle into the Fallopian tube, the ovum will move along the tube, 
where fertilisation occurs, and the zygote will be formed. The first divisions will also happen 
within the tube, while the first differentiation will happen soon after the multicellular morula 
enters the uterus, giving rise to the blastocyst, which has invading capabilities (Adapted from Hill 
2019). Panel B shows blastocyst implantation at 8-9 days following fertilisation. 
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1.1.4. Placenta development 
The implantation of the blastocyst (summarised from Hill 2019) happens during the receptive 
window of implantation. This process starts with loose adherence of the newly hatched blastocyst 
to the endometrium (adplantation); the blastocyst then moves to the final site of implantation 
(rolling), and finally firmly adheres to the endometrium, which will result in hormonal feedback, 
mainly human chorionic gonadotropin (hCG), secreted from the syncytiotrophoblast, to the 
corpus luteum in the ovary (Jarvela, Ruokonen & Tekay 2008). 
In early gestational age, the embryo is fully covered with chorionic villi (villi which are formed 
from the chorion, the outermost membrane around the embryo). During the first two weeks, the 
villi are made solely out of trophoblasts, are small in size and do not contain any vasculature 
(known as primary villi. In a few days, however, the villi grow in size and mesoderm starts 
growing in them (known as secondary villi); in a day or two, they become vascularised (known 
as tertiary villi). The tertiary villi (made out of trophoblasts, mesoderm and vasculature) either 
remain floating (known as free villi) and disappear after the first trimester from all around the 
embryo, or anchor themselves to the basal plate, the region that is in contact with the uterine wall 
(known as anchoring villi or stem villi). 
Around weeks 2-4 of gestation, the cells located at the maternal side of the trophoblast columns, 
which are clusters of cytotrophoblasts at the tip of the anchoring villi, start to further differentiate 
into another subtype of trophoblasts known as the extravillous trophoblasts (EVTs) (Aplin 1991; 
Pollheimer et al. 2018) (Figure 1.3). 
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Figure 1.3 Trophoblasts at the foeto-maternal interface. The EVTs are an invasive 
subpopulation of cytotrophoblasts, that leave trophoblastic columns and invade the endometrium 
(Hill 2019) (Figure adapted with modification from (Liu et al. 2004). 
 
The EVTs are characterised by high proliferative and invasive properties, which gives them the 
ability to leave the basement membrane of the villi, penetrate into the endometrium by digesting 
the uterine epithelial cells and then the stroma through phagocytic capabilities and the expression 
of matrix metalloproteinases (MMPs) 2, 9, 14 (Isaka et al. 2003; H. Wang et al. 2014; Welsh & 
Enders 1987) and membrane-type matrix metalloproteinase 1 (MT1-MMP) (Hiden et al. 2013). 
Soon after appearing, EVTs will give rise to two distinct subpopulations: the interstitial EVTs 
that invade the decidua and the inner third of the myometrium and anchor the placenta to the 
uterus, and the endovascular EVTs with phagocytic capabilities that remodel the maternal spiral 
arteries, allowing maternal blood flow through the intra-villus space inside the placenta bed. 
Interstitial EVT may also differentiate into endovascular EVTs or into giant cells, with endocrine 
capabilities (Fu et al. 2013; Red-Horse et al. 2004; Wang & Zhao 2010) (Figure 1.4).  
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Figure 1.4 Trophoblast differentiation.  (Adapted from Fu et al. 2013). 
 
Towards the end of the second trimester, stem villi and terminal villi along with three other less 
differentiated villi types make up the villous “tree”, the main structure of the placenta. Stem villi 
give stability to the villus tree and terminal villi (which are attached to the stem villi by 
intermediate structures) are covered with the syncytiotrophoblast layer that further erodes the 
uterine wall and capillaries, by the secretion of lytic enzymes and pro-apoptotic factors, and 
comes into direct contact with maternal blood, making the terminal villi a place for diffusive 
exchange. This provides the growing foetus with nutrition, waste elimination, and 
thermoregulation (Hill 2019). 
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1.2. Cellular migration and invasion 
1.2.1. Migration 
Cell migration is a multi-step process that requires the dissociation of cell-cell contacts, changes 
in the dynamic of cell adhesion to the matrix and extension of membrane protrusions. From single 
cell organisms like amoeba to complex multi-cellular organisms, movement capabilities, in 
response to chemical and mechanical signals, are crucial for survival (Manahan et al. 2004). Any 
motility-related process in cells, such as cell migration, invasion, adhesion, division, endocytosis 
or morphologic changes, cannot take place without spatially and temporally controlled 
cytoskeletal actin dynamics (assembly and disassembly) (Dormann & Weijer 2006; Kaksonen, 
Toret & Drubin 2006; Pollard & Borisy 2003; Rafelski & Theriot 2004). Any abnormal activation 
or deactivation caused to the steps of this highly regulated process can have disastrous effects, 
such as cancer, inflammation, vascular diseases and viral and bacterial infections (Vicente-
Manzanares, Webb & Horwitz 2005). 
Directional migration requires cell adhesion and cell polarity to collaborate in response to a 
complex network of signalling cascades (Carmona-Fontaine, Matthews & Mayor 2008). This 
type of migration (known as adhesive crawling) is generally composed of two major steps: 1. The 
displacement of cytoplasm at leading edge 2. The removal of debris accumulated at the trailing 
edge (Petrie, Doyle & Yamada 2009).  
Cell adhesion attaches cells to neighbouring cells and/or to the extracellular matrix (ECM), a gel-
like network of proteoglycans and fibrous proteins produced intracellularly by cells and secreted 
into the spaces surrounding them, with the help of single-pass transmembrane proteins located 
on the cell surface, known as cell adhesion molecules (CAMs) (Alberts et al. 2014; Frantz, 
Stewart & Weaver 2010). CAMs are divided into four major groups: immunoglobulin 
superfamily cell adhesion molecules (IgCAMs), cadherins, integrins and selectins (Gonzalez-
Amaro & Sanchez-Madrid 1999; Joseph-Silverstein & Silverstein 1998). 
Cellular motility and sub-cellular force generation are regulated by a highly conserved chemo-
mechanical process that requires the inherently contractile cytoskeletal actin-myosin complexes 
(actomyosin), in which the ATP-dependent myosin motor proteins pull on actin filaments (which 
polymerise with the help of actin regulator families Wiskott–Aldrich syndrome protein (WASP) 
and formin, along with actin nucleator Arp2/3 complex) in both the skeletal muscle, and non-
muscle cells (Breitsprecher & Goode 2013; Cooper 2000; Zigmond 2000). Actomyosin provides 
protrusive forces at the leading edge of the cell by ruffling fan-like lamellipodium and filopodial 
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spikes that spread beyond the lamellipodium border (Pollard & Borisy 2003). Actomyosin also 
forms stress fibres, i.e. bundles of 10–30 actin filaments, linked together by α-actinin, anchored 
to focal adhesion (FA) complexes, which connect the actin cytoskeleton to the ECM (Tojkander, 
Gateva & Lappalainen 2012). Another type of stress fibre that does not directly bind to FAs forms 
arc-shaped actin bundles that run parallel to the leading edge of the cell in lamellipodium (known 
as the transverse arc network), and contribute to cell migration (Hotulainen & Lappalainen 2006). 
When the cell body has moved forward, rear retraction fibres anchored to the front adhesions pull 
the trailing end of the cell along (Ridley et al. 2003). 
Microtubules, on the other hand, regulate the polarity of the actin cytoskeleton and help 
organelles and proteins move throughout the cell by providing a polarised network (Omelchenko 
et al. 2002). To make cell protrusions, actin filaments need to cooperate with microtubules to 
induce a polarised morphology in the cell by asymmetrically distributing the cytoskeleton and 
the signalling molecules within the cell (Krause & Gautreau 2014; Watanabe, Noritake & 
Kaibuchi 2005). This cooperation is regulated by Rho family GTPases (G proteins subfamily of 
the Ras superfamily, which cycle between the  inactive GDP-bound state and the active GTP-
bound state) including Ras homolog gene family, member A (RhoA), Ras-related C3 botulinum 
toxin substrate 1 (Rac1) and cell division control protein 42 homolog (Cdc42) (Boureux et al. 
2007; Bustelo, Sauzeau & Berenjeno 2007), along with several downstream members of the 
protein kinase family (Kiley et al. 1999; Tang et al. 2008). The affected pathways result in the 
capture and stabilisation of microtubules, through their effectors such as cytoplasmic linker 
protein (CLIP-170) and adenomatous polyposis coli (APC), at the cell cortex, leading to the 
formation of a polarised microtubule array (Heasman & Ridley 2008; Watanabe, Noritake & 
Kaibuchi 2005). The cell migration steps have been visualised in a simplified diagram in Figure 
1.5. 
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Figure 1.5 Cell migration steps. The migration starts with the formation of actin containing 
protrusion at the leading edge of the cell known as lamellipodia, which contain spike-like 
filopodia (a). Then, the plasma membrane of the protrusion needs to adhere the surface (b). Stress 
fibres will then push the cell body and the nucleus forward (c).  Lastly, the rear of the cell is 
pulled along by retraction fibres (d) (Arjonen, Kaukonen & Ivaska 2011; Kumar et al. 2006). 
(Adapted with modification from Mattila and Lappalainen 2008).  
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Despite being the most common and the best-characterised type, adhesive crawling (which 
includes sheet-like, 2D lamellipodium) is not the only type of migration in advanced eukaryotic 
cells. Macrophages, neutrophils and metastatic tumour cells exhibit an adhesion-independent 
amoeboid type of migration, in which the cytoplasm slides, forming a 3D actin-filled structure, 
called pseudopodium, which pulls the cell forward (Allen & Allen 1978; Titus & Goodson 2017) 
and spermatozoa show flagellar locomotion (Ishijima, Oshio & Mohri 1986). 
1.2.2. Invasion  
Cellular invasion is a multi-step process that includes cytoskeletal alterations (including 
formation of feet-like invadopodia), which cause changes in ECM by the secretion of proteases 
including matrix metalloproteinases (MMPs) and cytokines such as interleukins and growth 
factors, which eventually make cell migration to a nearby tissue possible (Friedl & Alexander 
2011). It should be noted that migration and invasion of cancer cells follow similar mechanisms 
to those of normal cells, which take place during embryo development and leucocyte migration, 
and it is the tumour cells’ lack of physiological “stop signals” that leads to problems (Friedl & 
Alexander 2011; Krakhmal et al. 2015).  
Tumour invasion is seen as the first and the foremost step of metastasis, a very complex process 
during which the cancer cells extend and penetrate into the neighbouring tissues, breaching the 
barriers between the tissue, and travel into a new site via the circulation (Cancer Australia 2019). 
The invasive movement of cells takes place in either or both of the patterns explained below 
(Cavallaro & Christofori 2004; Friedl, Zanker & Brocker 1998; Giampieri et al. 2009; Palecek et 
al. 1997; Sahai & Marshall 2003):  
1. Collectively: In this pattern, a group of cells, located at the leading edge, detach from the 
primary tumour. These include elongated fibroblast-like mesenchymal leading cells, that have 
gone through epithelial-mesenchymal transition (EMT), forming pseudopodia at their leading 
front and a lagging cell body at their rear end. These mesenchymal leading cells can digest and 
remodel the ECM, creating a path for migrating cells and are accompanied by tightly 
interconnected (by cadherin–β-catenin–α-catenin complex) following cells. In this pattern, 
migration takes place slowly. 
2. Individually: In this pattern, individual cells acquire round shape and amoeboid migration 
capability, which enable them to migrate through the ECM, faster than mesenchymal cells. 
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These two types of invasive/migratory (mesenchymal and amoeboid) cells show high degrees of 
plasticity and are able to transient into one another, as a result of their interaction with their 
surrounding environment (Krakhmal et al. 2015; Pankova et al. 2010).  
1.3. Metastasis-associated proteins and implantation  
1.3.1. Metastasis-associated proteins 
Metastatic lesions and colonisation of the organs with tumour cells can lead to organ failure and 
death (van Zijl, Krupitza & Mikulits 2011), making metastasis accountable for 90% of cancer-
related deaths (Le, Denko & Giaccia 2004). The occurrence of metastasis, into an ectopic 
microenvironment (host tissue), is a multi-step process regulated by numerous genetic and 
epigenetic changes (Langley & Fidler 2011). These steps include: 1. aberrant cell growth and 
proliferation, due to enhanced survival and angiogenesis of tumour cells, 2. detachment of tumour 
cells from their microenvironment, due to disrupted adhesion, 3. degradation the ECM and the 
basement membrane, due to acquired invasiveness, 4. entering the blood or lymphatic vessels 
(intravasation), due to acquired motility, 5. traveling to a new site, while sustaining their viability, 
6. leaving the circulation (extravasation), due to vascular permeability, 7. settling and 
proliferating in the host tissue, and 8. eventually giving rise to secondary tumours in distant 
organs and tissues (Hanahan & Weinberg 2011) (Figure 1.6). 
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Figure 1.6 Metastasis steps.  The main steps in tumour metastasis along with some of their main 
effectors have been summarised in this chart. (Based on data reported in Hanahan and Weinberg 
2011). 
The factors involved in metastasis also can be categorised according to the seed and soil 
hypothesis, which states that cancer cells (seeds) can give rise to metastasis, wherever the 
microenvironment (soil) allows them to (Langley & Fidler 2011): 
1.   The pro-metastatic factors of tumours include:  
• Cancer stem cells, which can provide the tumour with a heterogeneous 
population of cells 
• Circulating tumour cells, which have shed into the vasculature 
• EMT and its reverse, mesenchymal to epithelial transition (MET) 
•  Metastatic dormancy, in which tumour cells disseminate to secondary sites and 
become dormant for long periods before giving rise to metastasis, tumour-
secreted factors such as cytokines 
• Chemokines and extracellular vesicles 
• Autophagy 
2.   The pro-metastatic factors in the primary host include:  
• Hypoxia 
• Proteins expressed by tumour-associated macrophages, mesenchymal cells, 
endothelial cells and adipocytes, which enhance tumour invasion  
Growth
Adhesion loss
Angiogenesis
Invasion
Motility
Intravasation
Extravasation
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• Tumour perfusion 
• Physical properties of the ECM, which usually is stiffer than normal tissues, due 
to excess activities of lysyl oxidase, which cross-links collagen fibres and 
elevated levels of  fibronectin and collagen (Lu, Weaver & Werb 2012) 
3.   The pro-metastatic factors in the distant organ or the secondary host tissue 
microenvironment, which make the tumour growth within the lung, liver, bone, and brain 
more likely compared to other organs.   
The over-expression of a certain group of proteins have been related to clinical manifestation 
of tumour metastasis, aggressive phenotype and poor prognosis for cancer patients. These 
proteins are known as “Metastasis-associated proteins”  (Ho et al. 2009). These proteins can 
be involved in any of the steps of metastasis, such as the proto-oncogene tyrosine-protein 
kinase Src (Summy & Gallick 2003), small integrin-binding ligand N-linked glycoprotein 
family (Bellahcene et al. 2008), SPARC protein family (Bradshaw 2012), integrins 
(Desgrosellier & Cheresh 2010), thrombospondins (Lawler & Lawler 2012), T-lymphoma 
invasion and metastasis-inducing protein-1 (Izumi et al. 2019), vimentin, and tropomyosin 
(Sun et al. 2008). The injection of mice with benign tumour cells that have been induced to 
express of some of these proteins such as S100A4 (Davies et al. 1993), S100P (Wang et al. 
2006) and anterior gradient homologue 2 (Liu et al. 2005) (these three proteins are also 
known as metastasis-inducing proteins) lead to metastasis in mice. 
In the existing literature the term “metastasis-associated proteins” (abbreviated as MTA 
proteins), other than the way described in this work, may also refer, specifically, to a protein 
family, that has been shown to have a role in cancer progression by regulating chromatin 
remodelling (Sen, Gui & Kumar 2014). 
1.3.2. Tumour metastasis and implantation similarities 
The resemblance between the development of solid tumours and the placenta was reported for 
the first time in the early 20th century (Beard 1905). “Cancer, a developmental biology” was a 
theory proposed in late 20th century suggesting that tumorigenesis and embryology have a lot in 
common, assuming that tumour cells are in fact embryonic cells that continue their proliferation 
into the body (Pierce 1983). Later in the 21st century, the progress in molecular biology showed 
similarities between embryonic and tumour cells (Figure 1.7), in terms of gene expression and 
the protein profile, which makes both cell types immortal, undifferentiated and invasive, features 
that are known to attribute to the ‘pseudo-malignant’ phenotype of trophoblasts (Monk & Holding 
2001; Rousseaux et al. 2013). 
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Developing cytotrophoblasts and metastatic tumour cells both go through EMT. During this 
process they obtain mesenchymal phenotype, separate from the epithelium and migrate away 
from their originating epithelial layer (the tips of the villous columns for trophoblasts) and invade 
into a new tissue (uterine lining for trophoblasts) (DaSilva-Arnold et al. 2018). Cells that go 
through EMT show loss of cell junctions and epithelial markers (i.e. E-cadherin) and elevated 
matrix degradation and expression of mesenchymal markers including N-cadherin, fibronectin 
and laminin (Vergara et al. 2016). EMT “switch” is mediated by transcription factors such as 
Snail, zinc-finger E-box-binding and basic helix-loop-helix transcription factors (Lamouille, Xu 
& Derynck 2014). Additionally, transforming growth factor-β (TGFβ) family signalling plays a 
prominent role in initiating and controlling EMT (Lamouille, Xu & Derynck 2014). 
 
Figure 1.7 Strong similarity between tumour invasion and trophoblast invasion. The 
placenta and tumour cells express proteins that will give them the ability to invade, maintain 
adequate blood and nutrient supply and grow in a new environment (adapted from Holtan et al. 
2009). 
 
Moreover, placental mammals (eutherial), especially those with highly invasive haemochorial 
placentas, have higher rates of malignancies compared with other animals. Conversely, metastatic 
carcinomas and sarcomas are rarely reported in non-mammalian organisms, and the incidence of 
solid tumours seems to be mostly locally invasive (Albuquerque et al. 2018). These striking 
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similarities between placental cell invasion and tumour invasion provide a rationale for the 
hypothesis that many metastasis-associated proteins could possibly play crucial roles in placental 
implantation. 
 
1.3.3. Why study metastasis-associated proteins in implantation?  
Successful embryo implantation, consisting of three steps, i.e. apposition, attachment and 
invasion of the blastocyst, as a result of the cross-talk of a receptive endometrium and a healthy 
embryo; however, it only  occurs in only 50% of all human implantations (Achache & Revel 
2006; Dekel et al. 2010). While approximately 5-10% of otherwise successful pregnancies can 
be affected by preeclampsia, a pregnancy-related disorder caused by a maternal inflammatory 
response to placentation, characterised by hypertension and proteinuria. It is known as the main 
cause maternal/foetal morbidity and mortality; 1% can be affected by an even more serious 
variant of the disease known as HELLP syndrome, which stands for haemolysis (H), elevated 
liver enzymes (EL) and low platelet count (LP), both of which are mainly accompanied by 
reduced placental perfusion due to abnormal implantation (Haram, Mortensen & Nagy 2014; 
Roberts & Lain 2002). 
Preeclampsia and its accompanying disorders, which can include intrauterine growth restriction 
(IUGR), preterm birth (PTB) and miscarriages, have been linked with oxidative stress and a 
reduction in angiogenic factors (Ahmed, Rezai & Broadway-Stringer 2017). These disorders are 
associated with inadequate invasion of EVTs into the decidua and abnormal artery remodelling 
(Ball et al. 2006; Brosens, Robertson & Dixon 1972; Khong et al. 1986; Reister et al. 2006). 
When compared with other mammal species, humans have about a 50% lower chance of 
successful pregnancy in a menstrual cycle, making it rather inefficient (Edwards 2007). 
Therefore, in spite of all the advances in knowledge and technology related to pregnancy-related 
issues, it is fair to say that implantation is still in need of more thorough research in terms of the 
relevant cellular pathways. 
This work aims to study the effect of three different metastasis-associated proteins that have been 
closely linked with tumour cell motility and invasion, S100P (a member of the S100 family), 
ezrin (a member of the ERM family) and IQGAP1 (a member of the IQGAP family), on the 
physiological process of implantation and how their expression affects trophoblast motility and 
invasion, processes that are crucial for successful remodelling of maternal arteries in order to 
provide an adequate blood supply to the foetus (Sato, Fujiwara & Konishi 2011). To achieve our 
aim, the expression of these proteins was studied in human placenta tissue sections from different 
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gestational ages to learn more about their levels and cytological differences. Further work was 
carried out using human trophoblast cell lines to study the changes in their motile and invasive 
capabilities and some of the molecular mechanisms involved during the above mentioned 
processes. 
1.4. S100 family of proteins 
S100 proteins are members of a large super-family of Ca2+-binding proteins with EF-hands (Ca2+ 
-binding domains with two alpha helices linked by a loop region, found in Ca2+-binding protein 
such as calmodulin, paravalbumin and troponin C), in which “S100” refers to their solubility in 
100% ammonium sulphate at neutral pH (Moore 1965).  
1.4.1. Genetics 
About 25 members of this family of proteins have been identified exclusively in all vertebrates 
(Zimmer et al. 2013), which include 16 S100A proteins (S100A1–S100A16) and others (such as 
S100B, S100G, S100P and S100Z). S100 genes have been divided into four major subgroups 
based on their phylogenic relationships, the oldest of which (A1/A10/A11/B/P/Z subgroup) 
appeared around the same time as the vertebrates (about 500 million years ago). The other three 
subgroups (A13/A14/A16, A2/A3/A4/A5/A6, and A7/A8/A9/A12/G) emerged later around the 
same time as the appearance of the common ancestor of reptiles, birds and mammals, by a series 
of tandem gene duplication; Therefore, they are believed to be paralogues (Gross et al. 2014; 
Zimmer et al. 2013). S100A1-A16 are located on chromosome 1 (1q21), while S100B, S100G, 
S100P, S100Z, S100G. S100Z and S100P are located on chromosomes 21, X, 5 and 4, 
respectively (Shang, Cheng & Zhou 2008). 
1.4.2. Structure 
S100 proteins are small (10-12 KDa) acidic proteins with no enzymatic activities (in most cases) 
that have remarkably diverse functions due to their ability to form homo- and  (less commonly) 
heterodimers (S100A1-S100B, S100A8-S100A9 S100A1-S100A4, S100A1-S100P, and 
S100A11-S100B ) as well as multimeric forms (S100B multimer and S100A4 multimer) along 
with being expressed in a highly cell- and tissue-specific manner (Marenholz, Heizmann & Fritz 
2004; Oslejskova et al. 2009; Ostendorp et al. 2007; Rambotti et al. 1999; Schafer & Heizmann 
1996; Spratt et al. 2019). Most S100 proteins contain two EF-hands (Figure 1.8): a C-terminal 
canonical EF-hand with a typical sequence of 12 amino acids loop (which is similar to EF-hands 
in other Ca2+-binding proteins) and a higher affinity (Kd = 20-50 µM)  for Ca2+ along with an N-
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terminal unconventional or pseudo EF-hand with a 14 amino acid loop and a lower affinity (Kd = 
200-500 µM) for Ca2+ (which is unique to S100 proteins) (Donato 1986; Kawasaki, Nakayama & 
Kretsinger 1998). Kd or the equilibrium dissociation constant refers to the ratio of dissociation 
reaction (Koff)/association reaction (Kon), where Koff shows the rate at which the two molecules 
separate and Kon shows the rate at which the two molecules bind to each other. The constant 
indicates the strength of the interaction a between a molecule to its ligand and the lower the Kd, 
the greater the affinity (Eaton, Gold & Zichi 1995). 
Despite structural similarities between the family members, they differ in function, post-
transitional modification, spatial/temporal expression patterns and binding orientations for target 
proteins (Ikura & Ames 2006). Other than binding to Ca2+, some S100 proteins can bind to Zn2+ 
(Schafer & Heizmann 1996; Zimmer et al. 1995) and Cu2+ (Nishikawa et al. 1997; Schafer et al. 
2000), while at least one member of the family (S100A10) can function independently of Ca2+, 
due to a mutation in its EF-hands, which makes them permanently active and unable to bind to 
Ca2+  (Rety et al. 1999).  
 
Figure 1.8 Schematic diagram of the secondary structure of a monomeric S100 protein. 
S100 proteins consist of an N-terminal (non-canonical) and a C-terminal (canonical) EF hand that 
are attached together by an intermediate hinge region. The regions marked in red boxes show the 
most variability among the members of the S100 protein family (Image adapted from Rohde et 
al. 2010). 
 
Similar to other Ca2+-binding proteins, such as calmodulin and troponin C, S100 proteins undergo 
a conformational change upon binding to Ca2+, which acts as a switch that exposes their 
hydrophobic target-binging region, allowing binding to target proteins, and subsequent exertion 
of their biological effects (Drohat et al. 1998; Sastry et al. 1998; Smith & Shaw 1998). 
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1.4.3. Function 
S100 proteins have been linked to diseases such as diabetes, cardiomyopathy, neurodegenerative 
disorders and different types of cancers ( reviewed by Marenholz et al. 2004).Several, intra- and 
extracellular, target proteins (including nucleic acids, enzymes, cytoskeletal elements, receptors 
and transcription factors) have been identified for S100 proteins, involved in controlling different 
cellular functions. Some proteins might interact with more than one of the family members and 
result in similar activities. The main cellular functions that have been linked to S100 proteins 
have been summarised as follows:  
1.4.3.1. S100 proteins and cellular proliferation and differentiation 
S100A1 and S100B interact with microtubules using their C-terminal domain and control their 
disassembly at the onset of mitosis in a pH- and Ca2+-dependent manner in glial cells, and 
therefore might be potential regulators of proliferation (Sorci et al. 1998; Sorci, Agneletti & 
Donato 2000). S100A2 and S100A4 interact with tumour suppressor P53 and lead to the 
regulation of cell proliferation by stimulating its transcriptional activity and enhancing its 
expression (Mueller et al. 2005; Orre et al. 2013; Pan et al. 2018). Moreover, S100A1, S100A6, 
S100A12, S100B, and S100P interact with calcyclin-binding protein/Siah-1-interacting protein 
and can potentially enhance survival and tumourigenesis by inhibiting β-catenin degradation 
(Filipek et al. 2002).  S100A3 has a role in the differentiation of hair follicular cells and the 
formation of the mature hair shaft, through regulating transglutaminase type 1 (an enzyme with 
the ability to form proteolysis-resistant protein crosslinking bonds) (Kizawa et al. 1998). S100A9 
induces apoptosis upon P53 activation (Li et al. 2009) and, by making a heterocomplex with 
S100A8, can regulate proliferation and differentiation (Voss et al. 2011). S100A9 can also induce 
survival upon interacting with nuclear factors, via the stimulation of NADPH oxidase and down-
regulation of p38 mitogen-activated protein kinase (MAPK) (Kuwayama et al. 1993; Nemeth et 
al. 2009). S100A16 induces adipocyte differentiation and proliferation as well as insulin 
resistance (Liu et al. 2011). S100A12 has a role in vascular remodelling by increasing MMP2 
expression as well as phosphorylation and nuclear translocation of Smad2 (a member of SMAD 
protein family that are signal transducers and transcriptional modulators) (Hofmann Bowman et 
al. 2010). 
1.4.3.2. S100 proteins and Ca2+ homeostasis 
S100A1 and S100B control intercellular Ca2+ homeostasis; this is important as Ca2+ plays a 
critical role in the stability of voltage-gated ion channels, preventing them from opening/closing 
spontaneously and leading to hyper-/hypo-activity of muscle and nerve cells. S100A1 and S100B  
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can also have enzyme activities (Boden & Kaplan 1990; Rambotti et al. 1999). A deficiency in 
S100A1 in the myocardium and skeletal myofibres impedes Ca2+ cycling in the sarcoplasmic 
reticulum, and can lead to impaired contractile performance (Prosser et al. 2008; Rohde et al. 
2010).  
1.4.3.3. S100 proteins and cellular migration/invasion 
The majority of S100 proteins (S100A1, S100A2, S100A4, S100A6, S100A7, S100A8, S100A9, 
S100A8-S100A9 heterodimer, S100A10, S100A11 S100A12, S100B, and S100P) have been 
associated with cellular motility and invasion under both normal and pathological conditions, by 
either directly binding to actin filaments or to actin binding proteins as well as enzymes and 
transcription factors (reviewed by Donato et al. 2013; Gross et al. 2014). The identified cellular 
mechanisms involved in S100 protein-mediated migration include the dynamics of filamentous 
actin (F-actin) polymerisation (Nagy et al. 2001; Yang et al. 2001), actin cross-linking (Bowers 
et al. 2012; Du et al. 2012; Ford & Zain 1995; Goh Then Sin et al. 2011), as well as the activation 
of the receptor for advanced glycation endproducts (RAGE) (Fuentes et al. 2007; Kataoka et al. 
2012; Lawrie et al. 2005). S100A4, A10 and A14 are involved in invasion via the activation of 
plasmin pathway and MMPs (Chen et al. 2012; Sapkota et al. 2011; Semov et al. 2005; L. Wang 
et al. 2012; Zhang, Fogg & Waisman 2004). 
1.4.4. S100P 
S100 calcium-binding protein P (S100P), also known as migration-inducing gene 9 protein 
(MIG9), is a member of the S100 protein family (Donato 2001). The protein consists of 95 amino 
acid residues, weighs 10.4KDa, and was isolated from human placenta for the first time in 1992 
(Becker et al. 1992). It functions as a homodimer or a heterodimer with S100A10 and S100A6 
(Wang et al. 2004; Whiteman et al. 2007). 
1.4.4.1. S100P Expression 
The S100P gene is located on chromosome 4 (4p16) (Shang et al. 2008) and is expressed in many 
human tissues, such as the placenta, where it shows high expression levels, as well as the lung, 
skeletal muscle, and heart (Jin et al. 2003). Most of the studies related to this protein have, 
however, focused primarily on cancer. 
Despite the high expression levels of this protein both physiological states or cancer tissues, little 
is known about how its expression is regulated. At the transcriptional level, three cis-
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regulatory elements (CREs), with binding sites for STAT/CREB, SMAD and SP/KLF have been 
identified in the promoter region of the S100P gene (Gibadulinova et al. 2008).  
1.4.4.2. S100P-interacting proteins 
A series of proteins interacting with S100P in cancer cells have been identified (Table 1.1). While 
ezrin, NMII and IQGAP1 cacyBP/SIP are localised inside the cell, RAGE, integrin α7 and 
cathepsin-D are present at the cell surface, suggesting that S100P can function both intra and 
extracellularly. Most of these interactions suggest that S100P has a role in the regulation of cancer 
cell migration and invasion, whilst data reporting the interaction of S100P with any of these 
factors in the context of non-pathological conditions is not clear (Du et al. 2012; Filipek et al. 
2002; Heil et al. 2011; Hsu et al. 2015; Kikuchi et al. 2019; Koltzscher et al. 2003; Mercado-
Pimentel et al. 2015). 
S100P binding partners Possible effect on the cell 
NMIIA Enhanced motility 
Ezrin Enhanced motility 
Integrin α7 Enhanced motility and invasion 
Cathepsin-D Enhanced invasion 
RAGE Enhanced proliferation 
IQGAP1 Reduced proliferation 
CacyBP/SIP Unknown 
Table 1.1 Proteins that interact with S100P and their effect on cancer. The interaction 
between S100P with NMII and ezrin up-regulates cellular motility (Du et al. 2012; Kikuchi et al. 
2019; Koltzscher et al. 2003), while its interaction with integrin α7 promotes both motility and 
invasion (Hsu et al. 2015). S100P might enhance cell proliferation through interacting with 
RAGE (Mercado-Pimentel et al. 2015) or reduce it though interacting with IQGAP1 (Heil et al. 
2011). S100P also binds to CacyBP/SIP, but the effects are not yet known (Filipek et al. 2002).  
 
1.4.4.3. S100P in cancer 
S100P over-expression has been reported in many cancers (Table 1.2). Ectopic expression of this 
protein in cancers is mainly due to hypomethylation (Sato et al. 2004), and it has been associated 
with sex hormones in cancers of the prostate  (Averboukh et al. 1996; Basu et al. 2008) and 
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(possibly) breast (Schor et al. 2006). S100P has been suggested to be used as a marker for early 
diagnosis in pancreas (Dowen et al. 2005; Ohuchida et al. 2006) and prostate cancer (Hu et al. 
2014). Since its elevated levels of expression have been associated with a poor prognosis, it has 
been recommended to be used as a prognosis marker for cancers of colon (Q. Wang et al. 2012), 
breast (Peng et al. 2016; Wang et al. 2006), liver (Yuan et al. 2013) and ovaries (Wang et al. 
2015). Moreover, S100P knockdown was not only shown to reduce tumour growth and 
metastasis, but seems to enhance the response to chemotherapeutic drugs as well (Arumugam et 
al. 2005; Arumugam, Ramachandran & Logsdon 2006). 
 
Cancer types associated with S100P expression 
Breast cancer (Peng et al. 2016; Wang et al. 2006) 
Colorectal cancer (Fuentes et al. 2007; Q. Wang et al. 2012) 
Hepatocellular carcinoma (Yuan et al. 2013)  
Invasive ductal carcinoma (Guerreiro Da Silva et al. 2000) 
Non-small cell lung carcinoma (Diederichs et al. 2004) 
Oral squamous cell carcinoma (Raffat et al. 2018)  
Ovarian cancer (Wang et al. 2015) 
Pancreatic carcinoma (Dowen et al. 2005; Ohuchida et al. 2006) 
Prostate cancer (Hu et al. 2014; Mousses et al. 2002) 
Table 1.2 The association between S100P expression and poor prognosis in cancer. 
 
1.5. ERM family of proteins 
The ERM family consists of three members including ezrin, radixin and moesin. These proteins 
are found at adhesion sites , lamellipodia, filopodia, ruffling membranes, the cleavage furrow of 
mitotic cells, apical microvilli as filopodia, lamellipodia, apical microvilli and contractile cell rear 
(known as the uropod or trailing edge), linking the cell membrane via transmembrane proteins, 
phospholipids and membrane-associated cytoplasmic proteins to the underlying cytoskeleton via 
interactions with F-actin. ERM proteins also play roles in cAMP and Rho GTPase signalling 
pathways (Fehon, McClatchey & Bretscher 2010; Tsukita & Yonemura 1999; Tsukita, Yonemura 
& Tsukita 1997; Wakayama et al. 2009).  
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In adult mammals, the expression of ERM members show tissue specificity: ezrin is predominant 
in epithelial cells, moesin in endothelial and radixin in hepatocytes (Fouassier et al. 2001; Hanzel 
et al. 1991). 
1.5.1. Genetics 
The three paralogue members of the ERM family likely arose by gene duplication. They are found 
in all vertebrates, while other species only contain a single ERM gene, and yeast have no ERM 
gene at all (Bretscher, Edwards & Fehon 2002; Turunen, Wahlstrom & Vaheri 1994). The 
primary structure of ERM proteins are highly conserved in different species; N-ERMAD (also 
known as FERM) and C-ERMAD domains of different ERM proteins in vertebrates and moesin 
and ERM-1, their homologues in Drosophila and C. elegans, respectively, share about 75% 
identity (Arpin et al. 2011).  In humans, the genes encoding ezrin, radixin and meosin are located 
on chromosome 6, 11 and X, respectively (Fehon, McClatchey & Bretscher 2010). 
1.5.2. Structure  
Ezrin, radixin, and moesin have an amino acid length of 585, 582, and 576 and 70-75 kDa in 
molecular weight, and are very similar to one another (Maresso, Baldwin & Barbieri 2004). They 
closely related to neurofibromatosis type 2 (NF2) tumour suppressor merlin (McClatchey & 
Fehon 2009) and regulate cortical organisation by binding to the cytoplasmic tails of membrane 
proteins, such CD43, CD44 and intracellular adhesion molecule 2 (ICAM-2), via their globular 
amino-terminus; this contains three lobes: F1, F2 and F3, which are also known as the four-point 
one, ezrin, radixin, moesin (FERM) domain. FERM is followed by an extended α-helical domain 
and a linker section, bound to a positively charged actin-binding carboxy-terminus domain, also 
known as the C-ERMAD tail (Tsukita, Yonemura & Tsukita 1997) (Figure 1.9). 
 
Figure 1.9 Primary structure of ERM family of proteins.  ERM proteins are composed of an 
N-terminal FERM domain linked to a C-terminal ERMAD by an α-helical and a linker region.  
(Adapted with modification from Ponuwei 2016). 
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The ERM proteins are found in two forms (Figure 1.10):  1. An inactive structure in which the 
C-ERMAD domain binds to the FERM domain with a high affinity (Kd =176 nM), covering he 
F2 and F3 domains and masking the F-actin-binding as well as the membrane-binding regions, 
forming a closed monomers (intramolecular binding), homo/hetero-dimers and oligomers (head-
to-tail intermolecular binding). 2. An open-active structure, where the head-to-tail interaction is 
disrupted (also can be found in the form of dimers, and oligomers) (Berryman, Gary & Bretscher 
1995; Bretscher, Gary & Berryman 1995; Fehon, McClatchey & Bretscher 2010; Gary & 
Bretscher 1993; Zhu, Liu & Forte 2005). This activation occurs upon binding of membrane 
phosphatidylinositol 4,5-bisphosphate (PIP2) to the FERM domain and phosphorylation of the 
conserved threonine residues Thr558, Thr564, Thr567 of C-ERMAD domain in human moesin, 
radixin and ezrin, respectively, resulting in a reduction in the affinity of the N-terminal FERM 
domain for C-ERMAD  (Fehon, McClatchey & Bretscher 2010; Fievet et al. 2004).  
 
 
Figure 1.10 Conformational forms of ERM proteins. Panel A shows different regions of the 
protein and panel B show the two conformations: and open (active) and two forms of closed 
(inactive). (Adapted from Clucas and Valderrama 2014).  
 
Protein kinase A (PKA) (Zhou et al. 2003), PKB (Akt2) (Shiue et al. 2005), PKCα (Ng et al. 
2001), PKCθ (Pietromonaco et al. 1998), and atypical PKCι (Wald et al. 2008), G protein-coupled 
receptor kinase 2 (GRK2) (Penela et al. 2008), mammalian STE20-like protein kinase 4 Mst4 
(Fidalgo et al. 2012; ten Klooster et al. 2009), mammalian Ste20-like Nck-interacting kinase 
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(NIK) (Baumgartner et al. 2006), mouse STE20-like protein kinase LOK (Belkina et al. 2009), 
sterile20-like kinase (Slik) (Cybulsky et al. 2017; Hipfner, Keller & Cohen 2004), and Rho-kinase 
phosphorylate the C-terminal threonine region of ERM proteins and result in their activation. 
(Matsui et al. 1998). Moreover, the α-helical region has also been shown to play a role in this 
conformational change though an interaction with ERM-binding proteins (Arpin et al. 2011). The 
active form of the protein can then establish membrane-cortex connections by binding to F-actin 
on one side and to the membrane from the other (Bosk et al. 2011) (Figure 1.11). 
 
 
 
Figure 1.11 Conformational change in an ERM protein (moesin) upon activation. ERM 
proteins consist of three domains. In their inactive form, the N-terminal and the C-terminal 
regions are bound together, preventing them from interacting with the membrane and F-actin. 
(Adapted form Pearson et al. 2000). 
 
1.5.3. Function 
1.5.3.1. ERM proteins and cellular proliferation and differentiation 
ERM proteins have also has been linked to EMT and increased proliferation through 
phosphoinositide 3-kinase/Akt pathway (Kong et al. 2016), and upon p38 and Rho kinase 
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activation (Huang et al. 2011). Ezrin inhibition has been associated with PKCα-mediated 
internalization and degradation of HER2 and apoptosis promotion (Jeong et al. 2019).  
1.5.3.2. ERM proteins and cell morphology 
 ERM protein activation by Rho and Rac promotes stress fibre and FA complex formation as well 
as actin polymerisation (Mackay et al. 1997). Ezrin degradation due to oxidative stress affects 
cell morphology (rounding up and blebbing) (Grune et al. 2002). During mitosis, moesin 
promotes roundness by enhancing cortical stiffness due to stress fibre loss (Kunda et al. 2008) 
and has been shown to promote epithelial integrity by regulating actin organization and polarity 
by the inhibition of the Rho pathway (Speck et al. 2003). 
1.5.3.3. ERM proteins and cell adhesion 
ERM proteins are usually localised at cell cortex, connecting the membrane to actin, while a 
smaller proportion of them can be seen in cell-cell as well as cell-ECM contacts though 
interacting with ICAM-1, ICAM-2 and CD44 (Heiska et al. 1998; Legg et al. 2002; Naba et al. 
2008; Tsukita et al. 1994). As expected, ERM downregulation leads defective and cell-cell and 
cell-ECM adhesion (Takeuchi et al. 1994). Likewise, moesin has been shown to promote E-
cadherin stabilisation in adherens junctions in primary embryonic epithelia (Pilot et al. 2006) and 
ezrin in mouse and ERM-1 in C. elegans embryos have been shown to play important roles in 
adherence junction formation on the apical surface of the differentiating epithelium (Dard et al. 
2001; Van Furden et al. 2004). 
1.5.3.4. ERM proteins and cellular migration/invasion  
ERM proteins have been shown to play a significant role in the metastasis by enhancing the 
migration and invasion of tumour cells (Ghaffari et al. 2019; Ou-Yang et al. 2011; Park et al. 
2017; Tang et al. 2019; Zhang & Wang 2019). Ezrin promotes cell migration through 
phosphorylation of the transmembrane receptor CD44 and subsequently interacting with it upon 
activation by PKC (Legg et al. 2002; Ng et al. 2001), as well as through colocalising Fes kinase 
at the leading edge of the cells and upon activation by hepatocyte growth factor (HGF) (Naba et 
al. 2008). GRK2 has been reported to phosphorylate radixin and enhance migration though rac1 
activation (Kahsai, Zhu & Fenteany 2010). However, consistently phosphorylated and active 
ezrin in T-lymphocytes reduces migration, though interruption of lamellipodia formation as well 
as increasing membrane tension (resistance to shape change) (Liu et al. 2012). ERM proteins also 
enhance invasion by promoting MMP-2 (Tang et al. 2019) and MMP-7 (Jiang, Wang & Chen 
2014) expression.  
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1.5.4. Ezrin   
Ezrin (also known as cytovillin or villin-2), a member of ERM protein family, was first identified 
as a component of the microvillus cytoskeleton of intestinal epithelial cells (Bretscher 1983) and 
gastric parietal cells (Yao, Thibodeau & Forte 1993). Other cell lines also express ezrin as a 
component of microvilli (Bretscher 1989; Goslin et al. 1989; Gould et al. 1986). Other than 
threonine 567 (Fehon, McClatchey & Bretscher 2010), ezrin also can be phosphorylated by 
different kinases on tyrosine residues Tyr81 (Bretscher 1989), Tyr353, Tyr145 (Errasfa & Stern 
1994), Tyr477 (Heiska & Carpen 2005), and serine 66 (Zhou et al. 2003). Changes in ezrin 
phosphorylation have been associated with changes in cellular function; for example, in gastric 
parietal cells, ezrin phosphorylation promotes changes its sub-cellular localisation (from apical 
vacuoles to microvillar membrane projections) and acid production through regulation of cell 
polarity and redistribution of cell membrane and cargo proteins (Urushidani, Hanzel & Forte 
1989; Zhou et al. 2005). In fibroblast-like synoviocytes of rheumatoid arthritis patients, ezrin 
leads to enhanced migration and invasion (Xiao et al. 2014).  
1.5.4.1. Ezrin expression  
Human ezrin gene, EZR or VIL2, is located on chromosome 6 (q25.3) (Bethesda (MD): National 
Library of Medicine (US) 2019). Ezrin protein is highly expressed in thyroid, adrenal glands, 
lymph nodes, lung, kidneys, urinary bladder, oesophagus, stomach, small intestine, colon and 
placenta (Bethesda (MD): National Library of Medicine (US) 2019). Within cells, it is localised 
mainly at the membrane, the cytoskeleton (Neisch & Fehon 2011) as well as the nucleus 
(Batchelor, Woodward & Crouch 2004). Ezrin plays an essential role in embryo development by 
regulating microvilli formation by having a role in the formation of the apical/terminal web, a 
structure at the surface of epithelial cells, which is located at the base of the apical microvilli. 
Ezrin is also important in cell polarisation (critical to morphogenesis in multicellular tissues); 
ezrin knockout mice die soon after birth, due to extensive structural malformations (Saotome, 
Curto & McClatchey 2004).  
1.5.4.2. Ezrin-interacting proteins 
Ezrin has multiple binding partners that promote different cellular behaviours (Table 1.3).  
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Ezrin binding partners  Possible effect on the cell 
EBP50 Membrane localisation of ezrin 
CD49 Enhanced cell-cell adhesion and motility 
CD49 Apoptosis  
Merlin Genome instability and tumorigenesis 
PI 3-kinase Enhanced survival 
PKA Proliferation 
NHERF1 Enhanced survival 
VCAM Enhanced survival 
ICAM1/ICAM2 Enhanced cell-cell adhesion 
S100P Enhanced motility 
IQGAP1 Recruits IQGAP1 to cell cortex 
Table 1.3 Proteins that interact with ezrin and their effect on cells. Ezrin–radixin–moesin 
(ERM)-binding phosphoprotein 50 (EBP50) has been shown to have a role in the localisation of 
ezrin in the apical membrane of polarised epithelial (Morales et al. 2004). The interaction of 
ezrin with CD43 enhances cell-cell contacts and motility through regulating cell morphology 
(Serrador et al. 1998), while its interaction with CD95 (FAS) promotes apoptosis (Fais, De 
Milito & Lozupone 2005; Parlato et al. 2000). When interacting with moesin-ezrin-radixin-like 
protein (merlin), ezrin can disrupt cell polarity and cause potential genome instability and 
tumorigenesis (Hebert et al. 2012). The interaction of ezrin with phosphatidylinositol 3-kinase 
(PI 3-kinase), vascular cell adhesion molecule 1 (VCAM-1) and sodium-hydrogen antiporter 3 
regulator 1 (NHERF1) can enhance cell survival via the AKT pathway (Barreiro et al. 2002; 
Chen, Zhang, and Massague 2011; Gautreau et al. 1999; Jeong et al. 2019).Ezrin anchoring to 
protein kinase A (PKA) induces cAMP-mediated T-cell activation and proliferation (Ruppelt et 
al. 2007). The interaction between ezrin and intercellular adhesion molecule 1 and 2 (ICAM-
1/ICAM-2) regulates cytoskeletal rearrangement and might lead to cell-cell adhesion (Heiska et 
al. 1998). The interaction of S100P with ezrin might promote cell motility (Austermann et al. 
2008). Ezrin can bind to and recruit IQGAP1 to the cell cortex (Nammalwar, Heil & Gerke 
2015). 
 
1.5.4.3. Ezrin in cancer 
Ezrin has been linked with poor prognosis and aggressiveness in a wide variety of cancers (listed 
in Table 1.4), and it has been suggested to be used as a tumour marker of significant clinical value 
(Bruce et al. 2007). Increases in ezrin expression (Bruce et al. 2007; Geiger et al. 2000; Huang et 
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al. 2010; Khanna et al. 2004; Yu et al. 2004; Zhou et al. 2014) and phosphorylation (Mak et al. 
2012; Sikorska et al. 2019; Zhou et al. 2014) are linked with metastasis and poor survival. 
Moreover, changes in the subcellular localisation of ezrin (Arslan et al. 2012; Elzagheid et al. 
2008; Jin et al. 2014; Sarrio et al. 2006; Schlecht et al. 2012) have been linked to metastasis and 
tumour progression in carcinomas, sarcomas and astrocytic cancers (Antelmi et al. 2013; Horwitz 
et al. 2016; Liang et al. 2017). For example, in breast tissue, the highest level of ezrin expression 
is at the apical membrane, the cytosol and the membrane in normal, low-grade and high-grade 
tumours, respectively, while levels of phospho-ezrin seem to positively correlate with the tumour 
grade and negatively with prognosis (Antelmi et al. 2013). Moreover, metastatic breast cancer 
cells show increased nuclear localisation (Halon et al. 2013), while highly metastatic 
hepatocellular carcinoma cells show less nuclear localisation when compared with less-metastatic 
tumours (Hago et al. 2017). 
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Cancer types associated with ezrin expression 
Astrocytic cancer (Geiger et al. 2000) 
Breast carcinoma (Sarrio et al. 2006) 
Cervical cancer (Kong et al. 2013) 
Colorectal cancer (Elzagheid et al. 2008; Patara et al. 2011) 
Cutaneous basal and squamous cell carcinoma (Abdou et al. 2011) 
Endometrioid carcinoma (Kobel et al. 2006) 
Endometrial hyperplasia and uterine adenocarcinoma (Ohtani et al. 2002) 
Gastric carcinoma (Zhao, Zhang & Xin 2011) 
Gastrointestinal stromal cancer (Wei et al. 2009) 
Head and neck squamous cell carcinoma (Madan et al. 2006) 
Hepatocellular carcinoma (Kang et al. 2010) 
Laryngeal squamous cell carcinoma (Wang, Liu & Zhao 2014) 
Lung cancer (Li et al. 2012; Suzuki et al. 2015) 
Nasopharyngeal carcinoma (Wang et al. 2011) 
Oesophageal squamous cell carcinoma (Xie et al. 2011) 
Oral potentially malignant disorders (Mohanraj et al. 2017) 
Osteosarcoma (Salas et al. 2007) 
Ovarian cancer (Song et al. 2005) 
Pancreatic adenocarcinoma (Akisawa et al. 1999) 
Rectal cancer (Korkeila et al. 2011) 
Soft tissue sarcomas (Carneiro et al. 2011) 
Uveal malignant melanoma (Makitie et al. 2001) 
Table 1.4 The association of ezrin expression with poor prognosis in many cancers. 
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1.6. IQGAP family of proteins 
IQ motif-containing GTPase-activating protein (IQGAP) proteins are scaffolding proteins (also 
known as scaffolins) that control signalling pathways, from cell surface receptors to the nucleus, 
by binding to the components of the pathway, assembling them into a specific part of the cell, 
and therefore enhancing the efficacy of the pathway through regulating the integration, crosstalk 
and feedback between the components (Abel et al. 2016; Pan et al. 2012). Although it regulates 
a wide range of fundamental cellular processes, yeast IQGAP1 was originally introduced as a 
crucial regulator of actin-ring formation and cytokinesis (Epp & Chant 1997; Lippincott & Li 
1998). 
1.6.1. Genetics 
IQGAPs are evolutionary conserved in eukaryotes. They are found with a single structure in 
fungi, known as IQGAP-related protein or Iqg1 in Candida albicans (Li, Wang & Wang 2008), 
Iqg1p or Cyk1p in Saccharomyces cerevisiae (Epp & Chant 1997; Osman & Cerione 1998; 
Shannon & Li 1999) and Rng2p in Chizosaccharomyces pombe (Chang, Woollard & Nurse 1996; 
Eng et al. 1998).  IQGAPs are also found in four types in amoeba Dictyostelium discoideum 
(ddIQGAP1, ddIQGAP2 ddIQGAP3 and a putative ddIQGAP4) (Vlahou & Rivero 2006), and 
three isotypes with a high degree of homology (IQGAP1, 2 and 3) in vertebrates, including 
humans (Hedman, Smith & Sacks 2015).  
IQGAP1, the most abundant and the best characterised isotype, appears to be ubiquitously 
expressed in all tissues (Choi & Anderson 2016; Weissbach et al. 1994), while IQGAP2 is highly 
expressed in the liver and platelets (Cupit et al. 2004). IQGAP3 has been mainly found in brain, 
lung and testis (Wang et al. 2007). In humans, IQGAP1 is encoded by the Iqgap1 gene, located 
on chromosome 15 (Abel et al. 2016). 
1.6.2. Structure 
IQGPAP1, 2 and 3 are composed of 1657, 1575 and 1631 amino acids, respectively (Watanabe, 
Wang & Kaibuchi 2015), forming five distinct domains (Figure 1.12):  
• Calponin homology (CH) domain, which facilitates cytoskeletal remodelling by binding 
to polymerised F-actin and has a role in protein dimerisation (Mateer et al. 2002, 2004). 
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•  Six coiled-coil domains, also known as heptad domains, which show homology to the 
myosin family, and bind to the FERM region of ezrin (Ho et al. 1999; Liu, Guidry & 
Worthylake 2014). 
• WW or proline-rich motif-binding domain, with two conserved tryptophan residues (W), 
that associate with Erk (Macias, Wiesner & Sudol 2002) and the proline-rich parts of 
other proteins (Macias, Wiesner & Sudol 2002). 
• Four isoleucine/glutamine-containing (IQ) domains, containing 20-25 amino acids, that 
bind to receptors  including epidermal growth factor receptor (EGFR) (McNulty et al. 
2011) and human epidermal growth factor receptor 2 (HER2) (White et al. 2011), as well 
as cytoskeletal components such as myosin (Weissbach, Bernards & Herion 1998) and 
calmodulin (Ho et al. 1999; Joyal et al. 1997). These domains also interact with signalling 
pathways, i.e. MAPK signalling (Roy, Li & Sacks 2005) and phosphoinositide signalling 
(PIPKIγ) (Choi & Anderson 2016), as well as S100B (Mbele et al. 2002) and S100P (Heil 
et al. 2011). 
• Ras-GAP domain (GRD) that binds to GTPases such as Cdc42 (Hart et al. 1996; Joyal et 
al. 1997), Rac1 (Hart et al. 1996; Noritake et al. 2005) and TC10 (Neudauer et al. 1998) 
in their GTP-bound form, and has homology with  Ras-GTPase activating proteins (Ras-
GAPs). However this domains lacks GAP function, as it contains a conserved threonine 
instead of the arginine finger, which is essential for GTP hydrolysis (Briggs & Sacks 
2003; Kurella et al. 2009).  
• Ras-GAP C-terminus (RGCT) which interacts with cell adhesion proteins such as E-
cadherin (Kuroda et al. 1998) and β-catenin (Briggs, Li & Sacks 2002) and cytoskeleton 
regulators such as neural Wiskott-Aldrich syndrome protein (N-WAS), Arp2/3 (Le 
Clainche et al. 2007), CLIP-170 (Fukata et al. 2002) and APC (Watanabe et al. 2004). 
 
 
Figure 1.12 Schematic diagram of IQGAP1 structure with its multiple domains and binding 
partners. (Adapted from Brown and Sacks 2006). 
 
51 
 
IQGAP1 exists in three proposed conformational forms (Figure 1.13): a closed inactive form, 
where there is an intramolecular interaction between the N- and C- termini that  can be relieved 
by phosphorylation of conserved serine residue 1443 located between the GRD and RGCT 
domains, by PKCϵ, allowing for binding of type Iγ phosphatidylinositol 4‐phosphate 5‐kinase 
(PIPKIγ) to the IQ domain (Choi et al. 2013; Grohmanova et al. 2004; Li et al. 2005). This 
generates the partially open form, and a fully open form, in which Rho GTPases Rac1 and Cdc42 
are bound to the GRD domain or PIP2 is bound to the RGCT domain (Brandt & Grosse 2007; 
Choi & Anderson 2016; Fukata et al. 2002; Watanabe et al. 2004). The RGCT domain in the fully 
open form of IQGAP1 can then interact with the actin polymerisation regulators neural Wiskott-
Aldrich syndrome protein (N-WAS) and Arp2/3 complex (Le Clainche et al. 2007) as well as 
regulators of microtubule dynamics, i.e. APC and CLIP-170 (Choi & Anderson 2016; Fukata et 
al. 2002; Watanabe et al. 2004). 
 
Figure 1.13 IQGAP1 exists in three conformations. In the autoinhibited closed structure, GRD 
and RGCT are bound together and there is a second fold that binds the N and C termini together. 
Opening of the latter fold by phosphorylation partially opens the protein, allowing for PIPKIγ 
binding and the subsequent binding of PIP2 and Rho GTPases, making the fully open form 
(Adapted from Choi and Anderson 2016). 
 
Similar to many proteins, including receptors, transcription factors, ion channels and enzymes 
that need to form dimers and oligomers to function normally (Marianayagam, Sunde & Matthews 
2004), IGQAP1 also forms  parallel (head to head) dimers and oligomers though intermolecular 
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interactions between an area localised between amino acids 763-63, enabling it to bind to 
cofactors such as Cdc42, Rac and calmodulin, also giving it the ability to crosslink actin (Bashour 
et al. 1997; Liu et al. 2016; Mateer et al. 2002; Ren et al. 2005). 
1.6.3. Function  
IQGAPs play crucial roles in several physiological process including:  
• Lung function: IQGAP1 has a role in airway smooth muscle contractility and is 
significantly downregulated in samples from asthma patients compared with healthy 
controls (Bhattacharya et al. 2014). 
• Insulin secretion: IQGAP1 plays a role in insulin secretion by facilitating vesicle 
trafficking in response to glucose stimulation (Kimura et al. 2013; Rittmeyer et al. 2008). 
• Neuronal function: IQGAP1 expression is associated with neurite outgrowth by 
facilitating alterations in the actin cytoskeleton (Li et al. 2005) and has a role neuronal 
proliferation and migration (Kholmanskikh et al. 2006). IQGAP1 also plays a role in 
neurogenesis (generation of neurons from progenitor cells) (Balenci et al. 2007). 
• Kidney function: IQGAP1 is involved in cell adhesion in kidney tubules and glomeruli 
(Lehtonen et al. 2005), as well as the slit diaphragm, which are the junctions between the 
foot processes of podocytes, i.e. the cells that wrap around glomerular capillaries 
(Grahammer, Schell & Huber 2013; Rigothier et al. 2012). 
• Cardiovascular system: IQGAP1 plays a role in cardiac remodelling and morphology 
(Sbroggiò et al. 2011) and promotes angiogenesis by enhancing endothelial cell 
migration and proliferation (Kohno et al. 2013; Yamaoka-Tojo et al. 2004). 
IQGAP1 is also associated with carcinogenesis by enhancing tumour proliferation, invasion, and 
angiogenesis (Jadeski et al. 2008; Jameson et al. 2013). 
The main cellular functions that have been linked to IQGAPs have been summarised as follows. 
1.6.3.1. IQGAPs and scaffolding diverse pathways 
IQGAPs acts as a scaffold protein for the RAS-RAF-MEK-ERK signalling pathway by directly 
binding to ERK1, ERK2, MEK1, MEK2 and B-RAF (Bardwell et al. 2017; Ren, Li & Sacks 
2007; Roy, Li & Sacks 2005). IQGAPs are also involved in Wnt signalling. They regulate the 
canonical Wnt pathway by binding to leucine-rich repeat-containing G-protein coupled receptor 
4 (LGR4) and its ligands R-spondins (RSPOs) as well as the non-canonical pathway by binding 
Ca2+/calmodulin and Cdc42 (Briggs & Sacks 2003; Carmon et al. 2014; Osman & Cerione 
1998).. 
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1.6.3.2. IQGAPs and cytoskeletal dynamics 
IQGAP1 is highly concentrated at the cell cortex, where it colocalises with cortical actin 
filaments, directly binds (using its CH domain) to and cross-links actin filaments (by linking 
Cdc42 to F‐actin), and stimulates the branched nucleation of actin filaments (Bashour et al. 1997; 
Le Clainche et al. 2007; Erickson, Cerione & Hart 1997; Hart et al. 1996; Mateer et al. 2002). Its 
participation in F-actin organisation can be affected by the Ca2+ concentration. Calmodulin, an 
important mediator of Ca2+ signalling, binds to the IQ motif of IQGAP proteins (Hart et al. 1996) 
and, with a lower affinity, to the CHD domain (Ho et al. 1999). Higher concentrations of Ca2+ 
enhance IQGAP1 and calmodulin association, while decreasing the association between IQGAP1 
and Cdc42 and F-actin (Ho et al. 1999; Joyal et al. 1997; Mateer et al. 2002). 
1.6.3.3. IQGAPs and cytokinesis 
IQGAPs in fungi, amoeba, C. elegans, and mammals have been shown to play a crucial role the 
formation of contractile ring between parent and daughter cells during cytokinesis (Adachi et al. 
1997; Bielak-Zmijewska et al. 2008; Epp & Chant 1997; Faix & Dittrich 1996; Skop et al. 2004). 
1.6.3.4. IQGAPs and proliferation and differentiation 
IQGAP1 promotes proliferation through interactions with Cdc42 and mTOR kinase (Wang et al. 
2009), while its interaction with β-catenin also promotes both proliferation and differentiation 
(Jin et al. 2015; Su, Liu & Song 2017). IQGAP1 phosphorylation at serine residues 1441 and 
1443, by PKC, promotes the appearance of new projection from neurons (neurite outgrowth) (Li 
et al. 2005). IQGAP1 and IQGAP3 promote epidermal growth and differentiation by activating 
EGFR and regulating MAPK (Monteleon et al. 2015). 
1.6.3.5. IQGAPs and cellular migration/ invasion  
IQGAP1 has been shown to regulate motility by interacting with actin cytoskeleton and actin 
modulating proteins. For example, it links the fibroblast growth factor to Arp2/3 complex-
dependent actin assembly (Bensenor et al. 2007), binds to Cdc42 and/or Rac1 and subsequently 
increases their levels at the leading edge of cells (Mataraza et al. 2003), regulates adhesion site 
dynamics by interacting with calmodulin, β-catenin, E-cadherin and (Foroutannejad et al. 2014; 
Fukata et al. 1999; Noritake et al. 2005), and affects cell polarity by interacting with microtubule 
plus-end scaffold proteins CLIP170 and APC (Fukata et al. 2002; Watanabe et al. 2004). 
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IQGAP1 has been shown to regulate invasion by acting as a downstream effector of endothelin-
1 receptor signalling and recruitment of membrane-type 1 MMP, MMP2 and MMP9 to 
invadopodia (Chellini et al. 2019; Sakurai-Yageta et al. 2008).  
1.6.4. IQGAP1  
IQGAP1 (also known as p195), a 190 kDa protein, is the most-studied member of the IQGAP 
family (Weissbach et al. 1994). Like other scaffold proteins, IQGAP1 binds to many proteins and 
regulates many essential cellular processes such as cell adhesion, cell migration and cytokinesis 
(Brown & Sacks 2006). Similar to other members of the IQGAP family, IQGAP1 is a key 
mediator of multiple signalling pathways such as MAPK, β-catenin and Rac1, by integrating the 
signals from receptors such as EGFR (Erickson, Cerione & Hart 1997), M3 muscarinic 
acetylcholine receptor (Ruiz-Velasco, Lanning & Williams 2002), vascular endothelial growth 
factor receptor type 2 (VEGFR2) (Yamaoka-Tojo et al. 2004), CD44 (Bourguignon et al. 2005), 
and glutamate receptor 4 (GluR4) (Nuriya, Oh & Huganir 2005) directly or through second 
messengers such as PKC, Ca2+, Ras GTPase, and PKA. This results in response outputs such as 
cell migration, adhesion and differentiation (Brown & Sacks 2006). Moreover, IQGAP1 has a 
role in actin polymerisation at the leading edge of the cells (Le Clainche et al. 2007) as well as 
actin ring formation (Lippincott & Li 1998). The activity of IQGAP1 can be regulated by changes 
in its sub-cellular localisation, binding to other proteins, dimerisation, post-translational 
localisation and phosphorylation (Brown & Sacks 2006).  
Other than having a role in physiological functions such as in the kidney (Rigothier et al. 2012), 
neurons (Li et al. 2005), cardiovascular system (Kohno et al. 2013; Yamaoka-Tojo et al. 2004), 
lung (Bhattacharya et al. 2014) and  insulin secretion (Kimura et al. 2013; Rittmeyer et al. 2008), 
IQGPAP1 also is a potential therapeutic target in cancer (Jadeski et al. 2008) as well as  bacterial 
(Brown et al. 2008; Karlsson et al. 2012) and viral infections (Morita et al. 2007). 
1.6.4.1. IQGAP1 expression 
IQGAP1 is ubiquitously expressed at high levels in animals, protists and fungi (Schwanhausser 
et al. 2011; Weissbach et al. 1994). The IQGAP1 gene is located on chromosome 15 (q26) 
(Bessède et al. 2016). The protein is localised in the plasma membrane, apical membrane, 
cytoplasm, nuclear envelope and cell junctions, colocalising with actin; its altered expression and 
localisation have been reported in metastatic tumours (Rotoli et al. 2017). 
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IQGAP1 knockout mice are viable and develop normally, but have been shown to be prone to 
late-onset gastric hyperplasia (Li et al. 2000) and heart malfunctions when they were subject to 
chronic conditions of pressure overload (Sbroggio et al. 2011). 
1.6.4.2. IQGAP1-interacting proteins 
Being a large multi-domain protein, IQGAP1 binds to more than 50 proteins in malignant as well 
as normal cells (Brown & Sacks 2006), some of which have been listed in Table 1.5. None of 
these protein interactions have been reported in trophoblasts. 
 
IQGAP1 Binding partner Potential effect on the cell 
Calmodulin Enhanced cell proliferation, motility and adhesion 
Cdc42  Enhanced cell proliferation, motility and adhesion 
β-Catenin Enhanced cell proliferation and cell-cell adhesion 
B-Raf Enhanced cell proliferation and angiogenesis  
Protein 4.1R Enhanced migration 
Rac1 Regulation of cell-cell adhesion  
Arf6 Enhanced cell migration and invasion 
ERK1/2 Enhanced cell invasion   
MEK1/2 Enhanced cell invasion   
Sec3/8 Enhanced cell invasion   
Rap1 Regulation of cell-cell adhesion 
CXCR2 Regulation of endosome trafficking 
S100B Rearrangement of cell membrane morphology 
S100P Reduced Proliferation  
Ezrin Promotes cortical localisation of IQGAP1 
Table 1.5 Proteins that interact with IQGAP1 and their effect on cells. IQGAP1 interacts 
with a large number of proteins, some of which have been summarised in this table: calmodulin 
and Cdc42 have compete with one another in biding to IQGAP1 and their interaction 
subsequently regulate cell proliferation, migration and adhesion (Hart et al. 1996; Ho et al. 1999; 
Joyal et al. 1997; Kuroda et al. 1996; Wang et al. 2009). Moreover, calmodulin can modulate the 
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binding of IQGAP1 to β-catenin, which enhances cell-cell adhesion and proliferation (Briggs, Li 
& Sacks 2002). IQGAP1 interaction with B-Raf increases B-Raf activity and therefore enhances 
proliferation and angiogenesis (Meyer, Sacks & Rahimi 2008; Ren, Li & Sacks 2007). IQGAP1 
can form a complex with APC and CLIP-170 and regulate morphology, cell polarisation and 
directional migration (Swiech et al. 2011; Watanabe et al. 2004). Protein 4.1R (a cytoskeletal 
protein) enhances cell migration by binding to and recruiting IQGAP1 into the leading edge of 
the cell (Ruiz-Saenz et al. 2011). IQGAP1 can regulate cell adhesion by interacting with GTPases 
Rac1 (Hart et al. 1996; Noritake et al. 2004) and Rap1 (Jeong et al. 2007). ADP-ribosylation 
factor 6 (ARF6) forms a complex with IQGAP1 and Rac1, and enhances cell migration and 
invasion (Hu et al. 2009). IQGAP1 regulates MAPK signalling pathway by binding to ERK1/2 
and MEK1/2, and therefore enhances invasion (Jadeski et al. 2008; Roy, Li & Sacks 2005). 
IQGAP1 also promotes invasion by interacting with Sec3 and Sec8 subunits of exocyst (a protein 
involved in vesicle trafficking), leading to MMP accumulation in the invadopodium, by 
enhancing the transportation of the MMP-containing exomes towards the  leading edge of the cell 
(Sakurai-Yageta et al. 2008). IQGAP1 binds to C-X-C motif chemokine receptor 2 (CXCR2) and 
enhances endosome trafficking and signal transduction (Bamidele et al. 2015; Neel et al. 2011). 
S100 family members S100B (Mbele et al. 2002) and S100P (Heil et al. 2011) bind to IQGAP1 
in the membrane, regulating cell morphology and proliferation, respectively. Ezrin can promote 
the membrane localisation of IQGAP1 (Nammalwar, Heil & Gerke 2015).  
 
1.6.4.3. IQGAP1 in cancer 
Unlike IQGAP2, which seems to be a tumour suppressor, IQGAP1 expression has been widely 
associated with carcinogenesis (White, Brown & Sacks 2009) and its over-expression has been 
linked with many cancers (Table 1.6). Moreover, invasive cancer cell lines of different origins 
express high levels of the protein, mainly localised within the membrane, especially in the 
invasive front of cells (Johnson, Sharma & Henderson 2009). IQGAP1 over-expression been 
indicated as a marker for poor prognosis in cancers of glial cells, head and neck, sinonasal 
squamous cells, laryngeal squamous cells, thyroid, liver, stomach, breast, pancreas, endometrium 
and colorectal cells (P. Dong et al. 2016; Hu et al. 2019; Jin et al. 2012; Li et al. 2017; Liu et al. 
2010; McDonald et al. 2007; Nabeshima et al. 2002; Walch et al. 2008; X.-X. Wang et al. 2014; 
Wang et al. 2018; C.-C. Wu et al. 2018; Zeng et al. 2018). 
  
57 
 
Cancer types associated with IQGAP1 expression 
Breast cancer (Zeng et al. 2018) 
Colorectal carcinomas (Nabeshima et al. 2002) 
Endometrial cancer (P. Dong et al. 2016) 
Gastric cancer (Walch et al. 2008) 
Glioma (McDonald et al. 2007) 
Head and neck squamous cell carcinoma (C.-C. Wu et al. 2018) 
Hepatocellular carcinoma (Jin et al. 2015; Li et al. 2017) 
Laryngeal squamous cell carcinoma (Wang et al. 2018) 
Ovarian carcinomas (Dong et al. 2006) 
Pancreatic cancer (Hu et al. 2019; Wang et al. 2013) 
Sinonasal squamous cell carcinomas (Jin et al. 2012) 
Squamous cell carcinoma of the oesophagus (X.-X. Wang et al. 2014) 
Thyroid cancer (Liu et al. 2010) 
Table 1.6 The association of IQGAP1 expression with poor prognosis in many cancers. 
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1.7. Hypothesis 
Our hypothesis for this work was that S100P, ezrin and IQGAP1, which are associated with 
tumour metastasis, are equally important in trophoblast motility and invasion and therefore 
placenta development.  
1.7.1. Aims 
To study the role of S100P, ezrin and IQGAP1 in trophoblast motility and invasion. 
1.7.2. Objectives 
• Establish the expression of S100P, ezrin and IQGAP1 in human placenta samples at 
different stages of gestation 
• Establish the expression of S100P, ezrin and IQGAP1 in trophoblast cell lines. 
• To test whether modulating the expression of S100P, ezrin and IQGAP1 affects 
trophoblast motility. 
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Chapter 2.  
Materials and Methods 
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2.1. Materials 
All equipment (Table 2.1), regents (Table 2.2) and cell lines (Table 2.5 Cell lines.) used 
throughout this work were obtained from either Dr Stephane Gross’s laboratory at Aston 
University or Prof. Melissa Westwood’s laboratory at the University of Manchester. Where 
required, the solutions and utensils were sterilised by either autoclaving at 121°C or filtering 
through Millex PES syringe filters (Thermo Fisher Scientific, UK). 
Company  Equipment (and software) 
Acculabs Diagnostics UK Ltd, Billingham, 
UK 
ATILON Portable Digital Scale 
Appleton Woods, Birmingham, UK 24- and 96-well plates 
35- and 150-mm petri dishes 
200 μl pipette tips 
AppJET pipette controller 
Autoclave tapes 
Gyro Rocker SSL3 
Nitrile gloves 
T25 and T75 tissue culture flasks  
BANDELIN electronic GmbH & Co. KG, 
Berlin, Germany 
SONOPLUS ultrasonic homogenizer 
 
Bio-Rad, Hemel Hempstead, UK 1.0 mm and 0.75 mm 10-well combs 
Bio-Rad mini-Protean II electrophoresis 
system 
Casting stand 
Extra Thick Blot Filter Paper 
Mini Trans-Blot Cell 
PowerPac™ Basic Power Supply 
Mini cell buffer dam 
Polyvinylidene difluoride (PVDF) membrane 
short plates and spacer plates 
Trans-Blot SD Semi-Dry Transfer Cell 
BioTek Potton, Bedfordshire,UK Plate Reader EL800 
Bioquell, Andover, UK Microflow Class II advanced biological 
safety cabinet 
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Carl Zeiss Microscopy GmbH, Oberkochen, 
Germany 
Cell Observer system with CCD camera 
(AxioCam MRm) 
Cole-Parmer Instrument Co Ltd, St Neots, 
UK 
Advanced Jenway pH Meter 3510 
Corning Limited, Flintshire, UK Matrix Matrigel 
DJB Labcare Ltd, Buckinghamshire, UK Eppendorf Centrifgue 5810R 
ELGA LabWater, High Wycombe, UK Purelab Option DV35 Water Purification 
System 
GraphPad Software Inc., San Diego, USA Prism 7.04 
Greiner Bio-one, Stonehouse, UK Cell scraper 
Sterile cryovial (2.0 ml) 
ThinCert™ Cell Culture Inserts (Transwells) 
for 24 well plate, 8µm pore size 
Hamamatsu Photonics, Japan NanoZoomer-XR Whole Slide Scanner 
Keison Products, Chelmsford, UK Stuart Gyro-Rocker (SSL3) 
Lab Unlimited UK - Carl Stuart Group, 
Camberley, UK 
Stuart Hotplate Stirrer SB 162-3 
Leica Microsystems Ltd, Milton Keynes, UK Inverted epifluorescence microscope 
(DM14000B) 
AxioVision Version 4.7 software 
Leica HI1210 water bath 
Leica RM2245 microtome 
LI-COR Environmental - UK Ltd, 
Cambridge, UK 
C-DiGit Blot Scanner  
Image Studio Lite Ver 5.2 
Microsoft, Redmond, UK Microsoft Office 365 
National Institutes of Health, Maryland, USA Fiji-ImageJ 
Nikon Ltd, London, UK Nikon ECLIPSE TS100 Microscope 
Sigma-Aldrich, Poole, UK 1 ml Plastic Pasteur pipettes 
1-14 Microfuge 
PAP pen for immunostaining 
Protease Inhibitor Cocktail 
Sigma 2-6 Benchtop Centrifuge 
Trypsin Solution (2.5%) 
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Thermo Fisher Scientific, Loughborough, 
UK 
Aluminium foil 
Bottle Borosilicate Screw cap (250 ml, 500 
ml, 1000 ml) 
Cling Film 
EVOS XL Core Cell Imaging System 
Falcon 15 ml and 50 ml Conical Centrifuge 
Tubes 
Fujifilm Corporation RX NIF Sheet X-ray 
Films 
Microscope glass slides 
Microcentrifuge tubes (0.5 ml, 1.5 ml, 2.0 
ml) 
Millex Syringe Filter PES (0.22 μm pore) 
MINI LAB ROLLER ROTATOR W/36X1 
Mr. Frosty Freezing container 
NanoDrop™ 1000 UV/VIS 
Spectrophotometer (NanoDrop Software) 
Nickel Electro Clifton Bath Lab Armor 
Parafilm 
Plastipak Syringe disposable (10 ml, 20 ml) 
Polypropylene universal tubes (30ml) 
Sanyo CO2 Incubator MCO-17AIC 164L 
Zeiss, Birmingham, UK AxioCam Hrc Microscope 
Table 2.1 Equipment and software. 
 
Company  Reagents 
Abcam, Cambridge, UK Anti-cytokeratin 7 antibody (mouse) 
Anti-ezrin (phospho T567) antibody (rabbit) 
Anti-ezrin antibody (mouse) 
Anti-HLA-G (mouse) 
Anti-IQGAP1 antibody (rabbit) 
Anti-paxillin antibody (mouse) 
Anti-S100P (Rabbit) 
Anti-tubulin antibody (mouse) 
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Agilent Technologies UK Limited, Cheadle, 
UK 
FITC-conjugated rabbit anti-mouse antibody 
FITC-conjugated swine anti-rabbit antibody 
HRP-conjugated rabbit anti-goat antibody 
TRITC-conjugated rabbit anti-mouse 
antibody 
Bio-Rad, Hemel Hempstead, UK DC protein assay reagent A 
DC protein assay reagent B 
Carl Zeiss Ltd, Hertfordshire, UK Immersol™ Immersion oil 
CEAC, Aston University, UK Ethanol, methanol, propanol 
Cell Signaling Technology, London, UK 
 
Anti-mouse IgG, HRP-linked antibody 
Anti-rabbit IgG, HRP-linked antibody 
Geneflow Ltd EZ-PCR Mycoplasma test kit 
Melford Laboratories Ltd, Ipswich, UK Amphotericin B 250 µg/ml solution  
Gentamicin sulfate 
Merck, Feltham, UK Disodium hydrogen orthophosphate 
(Na2HPO4) 
Ezrin Inhibitor, NSC668394 – Calbiochem 
Potassium dihydrogen orthophosphate 
(KH2PO4) 
Oy Reagena Ltd, Finland  Quick Diff staining kit 
PAN Biotech, Dorset, UK Ham’s F12 without phenol red 
Trypsin Powder, porcine origin 1:250 
Lymphocyte separating medium, Pancoll 
human, density: 1.077 g/ml 
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QIAGEN, Manchester, UK FlexiTube S100P siRNA-1 target sequence: 
CAGGAGGAGGTGGGTCTGAA 
FlexiTube S100P siRNA-4 target sequence: 
TAGCACCATGACGGAACTAGA 
FlexiTube S100P siRNA-5 target sequence: 
CAGGCTTCCTGCAGACTGGAA 
FlexiTube S100P siRNA-6 target sequence: 
TAGGCTGAGCCTGCTCATGTA 
FlexiTube ezrin siRNA-5 target sequence: 
AACACCGTGGGATGCTCAAAG 
FlexiTube ezrin siRNA-7 target sequence: 
CAGGACTGATTGAATTACGGA 
FlexiTube ezrin siRNA-8 target sequence: 
AAGAGTGATGGACCAGCACAA 
FlexiTube ezrin siRNA-9 target sequence: 
ACCGTGGGATGCTCAAAGATA: 
FlexiTube IQGAP1 siRNA-1 target sequence 
CTGGGAGATAATGCCCACTTA: 
FlexiTube IQGAP1 siRNA-2 target sequence 
CAGGCGCTAGCTCATGAAGAA: 
FlexiTube IQGAP1 siRNA-3 target sequence 
AAGGCATATCAAGATCGGTTA: 
FlexiTube IQGAP1 siRNA-5 target sequence 
AAGGAGACGTCAGAACGTGGC: 
negative control siRNA 
R&D Systems, Abingdon, UK Anti-S100P (goat) 
Scientific Laboratory Supplies, Nottingham, 
UK 
Histo-Clear 
 
Sigma Aldrich Co, Dorset, UK Ham's F12 media 
Kodak® GBX fixer 
2-n-morpholino ethansulfon acid (MES) 
Acrylamide 
Acrylamide/bis-acrylamide (40% w/v) 
Ammonium persulphate (APS) 
Bisacrylamide 
Dimethyl sulphoxide (DMSO) 
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Ethylene glycol tetraacetic acid (EGTA) 
Epsilon-aminocaproic acid (ACA) 
Ethylenediaminetetraacetic acid (EDTA) 
Fibronectin from human placenta 
Glycine 
Hydrogen peroxide solution 30% (w/w) in 
H2O 
Kodak® BioMax® light film 
L-Glutamine solution 200 mM 
Luminol 97% 
Magnesium chloride (MgCl2) 
MEM (Minimum essential medium) 
N,N,N′,N′-Tetramethylethylenediamine 
(TEMED) 
Nuclease-free water 
Paraformaldehye (PFA) powder 
Phosphate buffered saline tablets (PBS) 
Poly-L-lysine solution 0.1% (w/v) in H2O 
Sodium chloride (NaCl) 
Potassium chloride (KCl) 
Sodium dodecyl sulphate (SDS) 
Triton X-100 
p-Coumaric acid (≥ 98.0%) 
Thermo Fisher Scientific, Loughborough, 
UK 
2-Mercaptoethanol (β-mercaptoethanol) 
Alexa Fluor® 568 phalloidin 
Bovine serum albumin powder (BSA) 
Bromophenol blue 
Hygromycin B (50 mg/ml) 
MTT (3-(4,5-Dimethylthiazol-2-yl)-2,5-
diphenyltetrazolium bromide) 
Non-essential amino acids solution (100x) 
(NEAA)  
Opti-MEM® reduced serum medium (no 
phenol red) 
Prestained Protein Ladder 
RPMI 1640 Medium 
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Sodium chloride (NaCl) 
Tris Base Ultra-Pure 
Trypan blue solution, 0.4% 
Weighing boat polysterene square (250 ml) 
Virkon 
Vector Laboratories Ltd, Peterborough, UK Biotinylated goat anti-rabbit IgG antibody 
Biotinylated goat anti-mouse IgG antibody 
BLOXALL® endogenous peroxidase and 
alkaline phosphatase blocking solution 
Haematoxylin 
ImmPACT® DAB peroxidase substrate 
VECTASTAIN® avidin-biotin complex 
(ABC) HRP kit (peroxidase, standard) 
VectaMount® permanent mounting medium 
Vectashield hard set mounting medium 
containing 4’-6-diamidino-2-phenylindole 
(DAPI) 
VWR International, Leicestershire, UK 
INTERFERin® siRNA transfection reagent  
Table 2.2 Reagents. 
 
2.2. Methods 
2.2.1. Immunohistochemistry (IHC) 
All placenta samples were collected following elective termination of pregnancy, using 
mifepristone and misoprostol (for first and second trimester samples) or from pregnancies 
delivered by elective Caesarean (third trimester) and were fixed using formaldehyde and 
embedded into paraffin wax by our colleagues from Aston Medical school: first trimester of 
gestation (8–11 weeks; n = 3), second trimester (15–20 weeks; n = 3), and  third trimester (32–38 
weeks; n = 3) or were generous gifts from Prof. Melissa Westwood (University of Manchester 
and Royal Manchester Children’s Hospital): first trimester of gestation (6 weeks + 3 days, 6 
weeks + 3 days and 6 weeks + 4 days; n = 3), second trimester (17 weeks + 2 days, 18 weeks + 2 
days, 19 weeks + 2 days; n = 3), and third trimester (39 weeks; n = 4). The ethical approval for 
collecting and working with human placenta samples was granted by Health Research Authority 
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(The Research Ethics Committee. (REC) reference number: 15/WM/0284). A copy of the ethical 
approval confirmation letter can be found in the appendix section. 
2.2.1.1. Preparing slides from tissue sections 
In order to prepare the slides, glass slides (Thermo Fisher Scientific, UK) were coated with drops 
of 0.1% (w/v) poly-L-lysine solution (Sigma-Aldrich, UK) in H2O and were left to dry on the 
bench for 30 minutes. The paraffin-embedded sample were chilled on ice to harden the wax, prior 
to trimming at 30 µm thickness and then cutting at 5 µm thickness, using a microtome (Leica 
Microsystems Ltd, UK) to obtain section ribbons. The sections were separated with tweezers and 
flattened on 45°C water surface, using a histology water bath (Leica Microsystems Ltd, UK).  
The poly-L-lysine covered glass slides were then used to pick the sections out of the water, prior 
to being dried upright in a slide rack at 37°C overnight.  
2.2.1.2. Staining  
The dry slides were placed in racks and were warmed up at 60°C for 10 minutes to soften the 
wax. They were then dewaxed in Histo-clear (Scientific Laboratory Supplies, UK) for 5 minutes, 
3 times (in fume hood), hydrated in 100% ethanol for 2 minutes (twice), 70% ethanol 2 minutes 
(twice), and finally in running tap water and incubated for 5 minutes. For antigen retrieval, the 
rack containing the hydrated slides was placed into a container with 400 ml 0.01 M sodium citrate 
buffer (1x) (Table 2.3), covered with two layers of cling film, and were boiled for 10 minutes at 
full power (800 W) in a microwave. The slides were then left to cool down for 20 minutes at 
room temperature and then were moved to another container filled with tap water. The sections 
were marked by drawing a hydrophobic circle around them using a PAP pen (Sigma-Aldrich, 
UK). The sections the were blocked at room temperature using BLOXALL (Vector laboratories, 
UK) for 10 minutes, washed with PBS for 5 minutes and then were incubated with 2.5% (v/v) 
goat serum in PBS for 30 minutes. The sections were then incubated with 50 µl desired primary 
antibody: S100P (Abcam, UK), ezrin (Abcam, UK), IQGAP1 (Abcam, UK), HLA-G (Abcam, 
UK) or cytokeratin 7 (Abcam, UK) diluted in 2.5% goat serum (dilutions in Table 2.4) at 4°C in 
a humidified chamber, overnight. Mouse (10µg/ml) and rabbit (5 µg/ml) IgGs (Santa Cruz 
Biotechnology, USA) were used as negative control for the secondary antibodies. On the next 
day, the sections were washed with PBS for 5 minutes 3 times and incubated with 200 µl 
appropriate secondary biotinylated antibodies: anti-mouse or anti-rabbit (Vector Laboratories, 
UK) diluted in PBS (dilutions in Table 2.4) for 30 minutes at room temperature, following 
washing with PBS for 5 minutes. While waiting to the secondary antibody incubation, the ABC 
reagent (Vector Laboratories, UK) was prepared by adding one drop reagent A and one drop B 
into 5 ml PBS, stirred and incubated at room temperature for 30 minutes prior using. The sections 
68 
 
were then incubated with a drop of ABC reagent for 30 minutes, prior to washing with PBS for 5 
minutes. Then, 3,3'-diaminobenzidine (DAB) chromogen was prepared fresh, by adding one drop 
of DAB peroxidase substrate (Vector Laboratories, UK) into 1 ml diluent (Vector Laboratories, 
UK) and stirring. Drops of diluted DAB were incubated on each section for 30 seconds, until the 
brown colour was developed. To stop further staining, the sections were washed with PBS 
multiple times.  For counter staining, the sections were incubated with Haematoxylin (Vector 
Laboratories, UK) for 1 minute and then were washed with 1x tris-buffered saline (TBS) (Table 
2.3). The slides were once again placed in the rack to dehydrate the sections by placing in tab 
water, then in 70% ethanol for 3 minutes (twice), 95% ethanol for 3 minutes (twice) and 100% 
ethanol for 3 minutes (3 times). Then, they were moved to Histo-clear for 2, 10 and 20 minutes. 
Lastly, glass coverslips were mounted on the slides using VectaMount mounting medium (Vector 
Laboratories, UK) and were left to dry overnight under the fume hood. 
Buffers Ingredients 
10x TBS 0.05M Tris base, 3M NaCl in 1 litre deionised 
(di) H2O pH 7.6 
0.1 M Citrate buffer (10x) 29.41g sodium citrate in 1 litre diH2O 
pH6.0 
Table 2.3 The buffers used for IHC, and their ingredients. 
 
Antibodies Dilution in either 2.5% goat serum (for 
primary antibodies) or PBS (for secondary 
antibodies) 
Monoclonal anti-ezrin antibody (mouse) 1:200 (5 µg/ml) 
Monoclonal anti-IQGAP1 antibody (rabbit) 1:400 (0.5 µg/ml) 
Monoclonal anti-HLA-G (mouse) 1:100 (10 µg/ml) 
Monoclonal anti-cytokeratin (mouse) 1:100 (10 µg/ml) 
Monoclonal anti-S100P (rabbit) 1:1500 (0.578 µg/ml) 
Biotinylated goat anti-rabbit IgG (secondary) 1:200  
Biotinylated goat anti-mouse IgG (secondary) 1:200  
Mouse IgG (negative control) 1:100 (10 µg/ml) 
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Rabbit IgG (negative control) 1:2000 (5 µg/ml) 
Table 2.4 Antibody dilutions for IHC. 
 
2.2.1.3. Analysing IHC images with ImageJ 
In order to compare the intensity of the staining for a certain protein (S100P, ezrin or IQGAP1), 
the images were processed using Fiji-ImageJ (Schindelin et al. 2012), through optical density 
(OD) calibration, and then the following steps: run Image, Colour, Colour Deconvolution and H 
DAB. "Colour_2", which shows the brown DAB staining, and therefore is the equivalent of the 
expression of the protein of interest, was used to measure the OD. The desired areas in each image 
were selected through Analyse, Tools, ROI manager and manually choosing the areas with 
tissues. The OD in each image was measured by selecting Analyse and then Measure. Finally, 
the average ODs from each trimester where compared with each other. 
2.2.2. Cell culture 
2.2.2.1. Used cell lines: 
The cell lines used for the study have been listed in Table 2.5 and the specific culture media for 
each cell type have been listed in Table 2.6. 
Name Description 
Jeg-3 Human choriocarcinoma, gift from Dr. Emmanouil 
Karteris (Brunel University) 
BeWo Human choriocarcinoma, gift from Dr. Emmanouil 
Karteris (Brunel University) 
HTR8/SVneo Immortalised human first trimester EVT, from chorionic 
villi, transfected with a plasmid containing the simian 
virus 40 large T antigen (SV40) (Graham et al. 1993), gift 
from Prof. Graham Charles (Queen’s University, Canada). 
Transfected HTR8/SVneo 
clones 
 
Immortalised human first trimester EVTs, stably 
transfected with S100P-containing plasmid SGB217 (by 
in vivo recombination of pcDNA3.1) or control plasmid 
SGB16 (mock), made by Dr. Thamir Ismail, (University 
of Liverpool, UK). 
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SW71 
 
Immortalised human first trimester EVT, virally 
transfected with human telomerase reverse transcriptase 
hTERT (Straszewski-Chavez et al. 2009), gift from Prof 
Gil Mor (Yale University, USA) 
Saint George’s Hospital 
placental cell lines 4 and 5 
(SHPL-4/5) 
Immortalised human first trimester EVTs, transfected with 
SV40 (Choy, St Whitley & Manyonda 2000), gift from 
Guy St J. Whitley (St George’s University of London). 
Table 2.5 Cell lines. 
 
 
Cell type Media 
Jeg-3 MEM complete 
The medium was made by adding 10% (V/V) FCS (PAA 
Laboratories Ltd, UK), 1% pen/strep (PAA Laboratories 
Ltd, UK) and 2 mM L-glutamine (Sigma-Aldrich, UK) into 
500 ml MEM (Sigma-Aldrich, UK). 
MEM for serum starvation 
The medium was made by adding 0.5% FCS, 1% pen/strep 
and 2 mM L-glutamine into 500 ml MEM. 
BeWo Ham’s F12 complete 
The medium was made by adding 10% FCS, 1% pen/strep 
and 2 mM L-glutamine into 500 ml Ham’s F12 (Sigma-
Aldrich, UK). 
Ham’s F12 for serum starvation 
The medium was made by adding 0.5% FCS, 1% pen/strep 
and 2mM L-glutamine into 500ml Ham’s F12. 
HTR8/SVneo 
and  
RPMI-1640 complete 
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SGHPL-4/-5 The medium was made by adding 5% (V/V) (for 
HTR8/SVneo) or 10% (for SGHPL-4/-5) FCS, 1% 
pen/strep, 2 mM L-glutamine, without (for HTR8/SVneo) 
or with (for SGHPL-4/-5) 1% NEAA (Thermo Fisher 
Scientific, UK) into 500 ml RPMI-1640 (Thermo Fisher 
Scientific, UK). 
For SGB217 and SGB16 HTR8/SVneo clones, 50 µg/ml 
Hygromycin B was added to the media mixture as selection 
marker. 
RPMI-1640 for serum starvation 
The medium was made by adding 0.5% FCS, 1% pen/strep 
and 2mM L-glutamine into 500 ml RPMI-1640. 
For SGB217 and SGB16 containing HTR8/SVneo clones, 
50 µg/ml Hygromycin B was added to the mixture. 
SW71 DMEM: F12 complete 
The medium was made by mixing DMEM (PAA 
Laboratories Ltd, UK) and Ham’s F12 at 1:1 ratio and 
adding 10% FCS, 1% pen/strep, 2 mM L-glutamine and 
1% NEAA into the 500 ml mixture. 
DMEM: F12 for serum starvation 
The medium was made by mixing DMEM and Hams F12 
at 1:1 ration and adding 0.5% FCS, 1% pen/strep and 2 mM 
L-glutamine into 500 ml mixture. 
Table 2.6 Cell lines and their culture media. 
 
2.2.2.2. Growing the cells 
The cells were grown in T25 flasks and incubated at 37°C in a CO2 Incubator (Thermo Fisher 
Scientific, UK). The medium was changed every two days. 
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2.2.2.3. Passaging  
When the cells reached 80-90% confluency in their T25 flask, they were washed with 1 ml warm 
PBS (Sigma-Aldrich, UK) and detached using 1 ml warm 0.025% (v/v) trypsin- 2.5 mM EDTA 
(Sigma-Aldrich, UK) for 5-10 minutes. After detaching, 3 ml fresh complete medium was added 
on top and they were centrifuged using a benchtop centrifuge (Sigma-Aldrich, UK) at 160 x g for 
5 minutes. Then, the supernatant was removed and 1/4 - 1/6 of the pellet was seeded back into 
the flask and topped up with fresh medium to the final volume of 5-6 ml. 
2.2.2.4. Cryopreservation 
At the times that growing cells was not needed, they were cultured in T75 flasks until they reached 
80% confluency, prior to being washed with warm PBS, and then were trypsinised using 3 ml 
0.025% (v/v) trypsin- 2.5 mM EDTA for 5-10 minutes or until all cells were detached. 6 ml fresh 
complete medium was then added to the mixture and the mixture was centrifuged the same way 
as mentioned previously. After removing the supernatant, the pellet was re-suspended in 4 ml 
freezing mix made from FCS-10% DMSO (Sigma-Aldrich, UK), and was divided into four 
cryovials (Greiner Bio-one, UK) and transferred to -80°C in a freezing container (Thermo Fisher 
Scientific, UK) over-night and then to -196°C in liquid nitrogen tank for long-term storage. 
2.2.2.5. Culturing cells from frozen 
To regrow the frozen cells, they were thawed quickly, then they were transferred to a T25 culture 
flasks and warmed-up complete media was gently (drop by droop) added on top. The medium 
was changed after 2-3 hours, when the cells had attached to the bottom surface of the flask, to 
reduce the toxic effect of DMSO on the cells. 
2.2.3. Trypan blue exclusion viability assay 
To measure the cell growth rate, 15,000 Jeg-3 and SW71 cells, or 25,000 non-transfected 
HTR8/SVneo and transfected HTR8/SVneo clones were seeded in 24-well plates along with the 
desired treatments: 0.4 µg/ml S100P antibody (R&D Systems, UK), 10 mM epsilon-
aminocaproic acid (ACA) ( Sigma-Aldrich, UK), 5 nM siRNA targeting ezrin or IQGAP1, 5 µM 
ezrin inhibitor drug NSC668394 (Merck, UK), 0.01% DMSO, or without any treatment. During 
the following 24, 48 and 72 hours, the wells were washed once with 400 µl PBS and trypsinised 
with 200 µl 0.025% (v/v) Trypsin- 2.5 mM EDTA for 5-10 minutes, or until all the cells were 
detached from the plate. Then, the trypsin was neutralised, using 400 µl complete medium, and 
the cell suspension was centrifuged at 1180 x g using the 1-14 Microfuge (Sigma-Aldrich, UK) 
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for 5 minutes. The supernatant was then, discarded and the pellet was re-suspended in 200 µl 1:1 
mixture of complete medium and trypan blue (Thermo Fisher Scientific, UK). The viable cells, 
which could be distinguished from the dead cells by not having taken up the blue colour, were 
counted, using a haemocytometer and the average numbers were compared with each other. 
2.2.4. MTT viability assay 
The other way to confirm cell viability was to measure their metabolic activity by the MTT assay. 
Similar to the exclusion assay, 25,000 HTR8/SVneo and or 15,000 SW71 were seeded in 24 -well 
plates, while being treated or without any treatment as negative control.  Their metabolic activity 
was measured over the next 72 hours by adding 40 µl 5 mg/ml (in PBS) MTT (Thermo Fisher 
Scientific, UK) into each well, followed by mixing and  1hour o fincubation at 37°C. Then, the 
medium and MTT mixture was aspirated, the wells were washed with 200 µl PBS, followed by 
incubation with 200 µl DMSO for 10 minutes at 37°C.  Finally, the OD of the solutions at 570 
nm was measured, using a plate reader (BioTek Potton, UK). 
2.2.5. Primary EVT isolation and culture  
Following elected termination of pregnancy, placental samples, which had been collected 
surgically by vacuum aspiration, were transferred from Birmingham Women's Hospital to the lab 
in 50 ml Falcon tubes (Thermo Fisher Scientific, UK) filled with 1:1 mixture of DMEM and 
Ham’s F12  with 1% pen/strep, carried on ice.  The samples were emptied on a 150 mm dish 
(Appleton Woods, UK), and the large clots were removed with forceps, the remaining tissue was 
placed in a sterile 250 ml bottle with 20 ml Ham’s F12 without phenol red (PAN Biotech, UK) 
and gently stirred for 10 minutes. The samples were then placed in a clean petri dish and after 
removing the visible blood clots, the villi, which have a feathery appearance, were scraped from 
the membrane, using a scalpel and placed in a sterile 250 ml bottle with 75 ml EVT isolation 
trypsin solution (PAN Biotech, UK) (Table 2.7), and stirred on a heated stirrer at 37°C for 9 
minutes. Then, to quench the trypsin, the bottle contents were emptied into another sterile 250 ml 
bottle containing 15 ml FCS and 45 ml Ham’s F12 without phenol red, after having passed 
through a sterile gauze and a funnel. The filtrate was then divided into six universal tubes (Thermo 
Fisher Scientific, UK) and were centrifuged at 450 x g for 5 minutes. After discarding the 
supernatant, the pellets form each of the universal tubes were pooled together and resuspended in 
20 ml Ham’s F12 without phenol red and gently layered on top of two universal tubes containing 
8 ml Pancoll lymphocyte separating medium (PAN Biotech, UK). The tubes were centrifuged at 
710 x g for 20 minutes with the breaks off. After the spin, a white layer of cells in between the 
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two layers containing the EVTs, along with some small foetal red cells, mesenchymal core cells 
and syncytiotrophoblasts was collected and placed in a universal tube, topped up with Ham’s F12 
without phenol red and centrifuged at 500 x g for 5 minutes. The pellet was resuspended in 2 ml 
trophoblast complete medium (TCM) (Table 2.7) and seeded in one 35 mm petri dish, previously 
coated with fibronectin (the fibronectin-coated petri dishes were prepared previously by adding 
1 ml 20 µg/ml fibronectin (SIGMA-ALDRICH CO, UK) diluted in diH2O and were left to dry 
for an hour prior to removing the fibronectin solution) and incubated at 37°C for 1 hour for the 
EVTs to attach, prior to changing the medium. On the next day, the medium was changed again, 
and the cells were used for further experiments. 
 
Solution Ingredients 
EVT isolation trypsin solution 10.3 g glucose, 12 g NaCl, 0.3 g KCl, 1.725 g, Na2HPO4 
(disodium hydrogen orthophosphate), 0.3  g KH2PO4 
(potassium dihydrogen orthophosphate) dissolved in 1 
litre diH2O, the pH was adjusted to 7.4 and then 0.2 g 
trypsin and 0.2 g EDTA were added to the solution. 
Trophoblast complete medium 
(TCM) 
20% FCS, 1x pen/strep, 2 mM L-glutamine dissolved in 
Ham’s F12 without phenol red 
Table 2.7 The solutions used for EVT isolation and their ingredients. 
 
2.2.6. Protein expression measurement by western blot analysis 
All trophoblast cell lines (BeWo, Jeg-3, HTR8/SVneo, SW71, SGHPL-4 and -5) were probed for 
S100P, ezrin and IQGAP1 by performing western blot as follows: 
2.2.6.1. Cell lysate preparation 
To collect the cell lysates, the cells growing in 24-well plates were washed with PBS, prior to 
adding 50 µl of PBS containing 1x protease inhibitor cocktail (Sigma-Aldrich, UK) into each 
well and the cells were scrapped off, using a plastic cell scraper (Greiner Bio-one, UK) and were 
transferred into microcentrifuge tubes (Thermo Fisher Scientific, UK). They were then sonicated 
(Bandelin electronic GmbH & Co, Germany) on the lowest power for 10 seconds to disrupt the 
cells, followed by spinning down for 20 seconds at 16160 x g. Following the spinning, the pellet 
makes up the cellular debris, while the supernatant contains the soluble proteins.  5 µl cell lysate 
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was then taken for protein assay and the rest of the lysate was mixed with 1:3 diluted Laemmli 
sample buffer (Table 2.8). The samples were stored at -80°C. 
2.2.6.2. Protein assay 
To load desired amounts of cell lysate on sodium dodecyl sulfate-polyacrylamide gel 
electrophoresis (SDS-PAGE), the protein concentration was measured using detergent-
compatible (DC) protein assay kit (Bio-Rad, UK), with an assay similar to the Lowry protein 
assay (Bio-Rad Laboratories, 2019). For this purpose, 2 µl of cell lysate was loaded into two 
wells of a 96-well plate (Appleton Woods, UK), along with 0, 1, 2, 5, and 10 µg/ml BSA standard 
solution (BSA dissolved in diH2O) prior to the addition of 25 µl DC protein assay reagent A 
followed by 200 µl DC protein assay reagent B into each well, and waiting for 15 minutes for the 
blue colour to develop. Then, the OD of the solution was measured at 570 nm, using a plate 
reader. The standard curve was then produced in Excel by plotting the standard protein 
concentration on the x-axis and the OD readings on the y-axis. The trendline was added to the 
curve and the unknown concentration of the protein was measured using the formula: y = mx + 
b, where y is the sample’s OD, m is the slope of the trendline, b is the y-intercept, and x is the 
unknown concentration. 
2.2.6.3. SDS-PAGE 
To separate the bands with desired molecular weights, 15 μg cell lysate was loaded onto either of 
the two types of polyacrylamide gels: 
• 16% (w/v) tricine gel: for bands of 10-60 KDa (S100P, tubulin and ezrin) (Schägger, 
2006) (Table 2.8) 
• 10% (w/v) polyacrylamide gel: for bands of 50-190 kDa (tubulin, ezrin, phospho-ezrin 
and IQGAP1) (Table 2.9) 
15 µg of each sample was loaded on the appropriate gel using an electrophoresis system (Bio-
Rad, UK).  The running voltages and their times were: 70 V for 10 minutes, 100 V for 30 minutes, 
and 150 V for 1 hour or longer. 
Buffer Ingredients 
Laemmli sample buffer (4×) 10 ml Tris (1 M, pH 6.8), 4.0 g SDS, 20 ml glycerol, 10 
ml β-mercaptoethanol, 0.1 g bromophenol blue, add 
diH2O to 50 ml 
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16% (w/v) separating gel (x2) 3.3 ml 3x gel buffer, 3.3 ml acrylamide/bisacrylamide mix 
(48% acrylamide, 1.5% bisacrylamide), 1.36 ml diH2O, 2 
ml glycerol, 50 µl APS and 6 µl TEME 
4% (w/v) stacking gel (x2) 1.2 ml 3x gel buffer, 0.4 ml acrylamide/bisacrylamide mix 
(48% acrylamide, 1.5% bisacrylamide), 3.36 ml diH2O, 40 
µl APS and 4 µl TEMED 
Sealing gel (x2) 1 ml separating gel (without pre-added APS and 
TEMED), 20 µl APS and 2 µl TEMED 
3x bel buffer (GB) 18.16 g Tris and 0.75 ml 20% SDS in 50 ml diH2O (pH 
8.45) 
Cathode buffer 12.11 g Tris, 17.92 g tricine, and 5 ml 20% SDS in litre 
diH2O (pH 8.25) 
Anode buffer 12.11 g Tris in 1 litre H2O (pH 8.9) 
48% (w/v) acrylamide, 1.5% 
(w/v) bisacrylamide 
24.0 g acrylamide and 0.75 g bisacrylamide in 50 ml 
diH2O 
Table 2.8 SDS-PAGE buffers used for 16% tricine gel and their ingredients. 
 
Buffer Ingredients 
10% (w/v) separation gel (x2) 2.5 ml 50% glycerol, 2.5 ml 4x tris (pH 8.8), 2.5 ml 40% 
acrylamide/bisacrylamide, 2.3 ml diH2O, 100 µl 10% 
SDS, 100 µl 10% APS, 9 µl TEMED 
4% stacking gel (x2) 1 ml 50% glycerol, 1 ml 4x tris (pH 6.5), 0.5 ml 40%, 
acrylamide/bisacrylamide solution, 1.42 ml diH2O, 40 µl 
10% SDS, 40 µl 10% APS, 4 µl TEMED 
Sealing gel (x2) 1 ml separating gel (without TEMED), 5 µl TEMED 
1x Running buffer  3 g Tris base, 14.4 g glycine, 1 g SDS (pH 8.5) 
Table 2.9 SDS-PAGE buffers used for 10% polyacrylamide gel and their ingredients. 
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2.2.6.4. Western blot 
The separated proteins on the gel were transferred to PVDF membranes (Bio-Rad, UK) using a 
semi- dry electrotransfer cell (Bio-Rad, UK) for 2 hours at the current of 35 mA per gel (for bands 
of 10-60 KDa) or 80 mA (for bands of 50-190 KDa), using transfer buffer (Table 2.10). The 
blots were then washed once in PBS, blocked in 3% (w/v) BSA (Thermo Fisher Scientific, UK) 
in PBS for 30 minutes on an orbital shaker (Appleton Woods, UK) and incubated with primary 
antibodies against S100P (R&D Systems, UK), ezrin, phospho-ezrin (Abcam, UK) or IQGAP1, 
along with anti-α-tubulin (Abcam, UK) (as loading control) on a roller (Thermo Fisher Scientific, 
UK) at 4°C overnight (antibody dilutions have been listed in Table 2.11). On the next day, the 
blot was washed three times with PBS, blocked in 3% BSA for the second time and were 
incubated with secondary HRP-linked anti-goat (Agilent Technologies, UK) and HRP-linked 
anti-mouse and -rabbit (Cell Signaling, UK) antibodies (dilutions in Table 2.11) for 2 hours on 
a shaker at room temperate. Following PBS washing for three times, the bands were detected 
using enhanced chemiluminescence (ECL) detection mix (Table 2.10) either manually on X-ray 
films (Thermo Fisher Scientific, UK) and exposure times of 3 seconds (for detecting α-tubulin) 
or 20 seconds (for detecting the other proteins), or automatically by 6 minutes (standard) exposure 
on a blot scanner (LI-COR Environmental, UK). The images were then analysed using Image 
Studio Lite analysis software (LI-COR Environmental, UK), the expression of each protein was 
normalised to the expression of the house keeping gene (α-tubulin) and the graphs were produced 
by Microsoft Excel or Prism 7.04 (GraphPad Software Inc., USA). 
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Buffer Ingredients 
Electroblot transfer buffer (10x) 0.25 g Tris and 144.0 g glycine in 1 litre diH2O. 
 
To prepare 1x: mixed 50 ml of the above with 100 ml 
methanol and 350 ml diH2O 
ECL detection mix 
 
1.5 ml 0.5 M Tris, 6 ml diH2O, 37.5 μl Luminol, 18.75 
μl cumaric acid, and 2.25 μl hydrogen peroxide 
Developer 100 ml developer and 360 ml diH2O 
Fixer 100 ml fixer and 360 ml diH2O (kept in the dark) 
Stripping buffer 20 ml 10% (w/v) SDS, 12.5 ml 0.5 M tris (pH 6.8), 2.25 
μl diH2O, and 800 μl β-mercaptoethanol (added in fume 
hood) 
Table 2.10 The solutions used for western blot transfer and detection. 
 
Antibody Dilution in 3% BSA 
Anti-ezrin (mouse) 1:1000 (0.1 µg/ml) 
Anti-phospho ezrin (rabbit) 1:1000 (1 µg/ml) 
Ant-IQGAP1 (rabbit) 1:1000 (0.2 µg/ml) 
Anti-S100P (goat) 1:1000 (0.5 µg/mL) 
Anti-tubulin (mouse) 1:5000 
HRP-anti-goat 1:3000 
HRP-anti-mouse 1:3000 
HRP-anti-rabbit 1:3000 
Table 2.11 Primary and secondary antibody dilutions used in western blot. 
 
2.2.6.5. Blot stripping 
To detect protein bands with close molecular weights (ezrin and phospho-ezrin), PVDF 
membranes that had been probed and developed, were reused by stripping all the antibodies and 
then re-probed with different antibodies. For this purpose, the blots were submerged in stripping 
buffer (Table 2.10) and incubated for 20 minutes at 50°C with occasional agitation. The blots 
were washed several times with diH2O, to remove any residual stripping buffer, then washed with 
PBS three times and finally, the blots were blocked with 3% BSA in PBS (w/v) for 30 minutes at 
room temperature. 
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2.2.7. Protein knock-down 
Protein expression was knocked down by transient gene silencing. This was achieved by 
transfecting the cells with four different sequences (Table 2.2 Reagents.) of small interfering 
RNA (siRNA), also known as short interfering RNA or silencing RNA against each of the 
proteins: S100P (siRNA 1,4, 5, 6), ezrin (siRNA 5, 7, 8, 9) and IQGAP1 (siRNA 1,2, 3, 5). 
2.2.7.1. Transfecting different cell lines 
60,000 (HTR8/SVneo) or 30,000 cells (all other cell lines) were seeded in 24 well plates. They 
were left to grow for 24 hours for HTR8/SVneo, Jeg-3, SW71 and six days for the relatively 
slow-growing BeWo cells. Following the incubation, the media was changed (400 µl medium per 
well). The plate was incubated in the incubator for 30 minutes for the cells to settle. Meanwhile, 
the siRNA mixture was prepared with 100 µl Opti-MEM (Thermo Fisher Scientific, UK), 2 µl 
INTERFERin (VWR International, UK) and 0.5 µl siRNA (QIAGEN, UK), per well. The mixture 
was then added into each well (final siRNA concentration was 5 nM). The control reagent 
contained Opti-MEM only and mock transfection mixture (as negative control) contained Opti-
MEM and INTERFERin, plus a non-specific siRNA sequence, known as negative control siRNA 
(QIAGEN, UK). The cells were left to grow in the incubator for 48 hours, prior to changing the 
medium with the desired medium. 
2.2.8. Boyden chamber assays 
2.2.8.1. Motility assay optimisation 
Prior to choosing the most appropriate staining and fixation method for transwell motility assay, 
50,000 Jeg-3 cells suspended in 100 µl medium were seeded at the bottom of inverted 
transwells. The transwells were incubated at 37°C in CO2 incubator for 2 hours and then fixed 
with either 4% (w/v) PFA or methanol for 10 minutes continued by staining with either the 
Quick Diff staining kit (Oy Reagena Ltd, Finland), a commercial Romanowski stain variant, 
using the cytoplasmic (pink) stain and the nuclear (blue) stain, or Vectashield mounting 
medium containing DAPI (Vector Laboratories Ltd, UK). 
The transwells stained with Quick Diff were detected by bright-field microscopy (Nikon Ltd, 
UK), and the ones stained with DAPI were detected using an inverted epifluorescence microscope 
(Leica Microsystems Ltd, UK). 
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To find out what seeding number works best for the transwell assay using trophoblast cell lines, 
three different seeding numbers were considered at first: 100,000 cells, 50,000 cells and 25,000 
cells. To test each of these numbers, three separate groups of Jeg-3 cells were prepared: control, 
mock transfection and S100P siRNA 4 treated. Each group was adjusted in 100,000, 50,000 or 
25,000 cells in 300 μl serum starvation medium and they were seeded in transwells. The 
transwells were placed on 24 well plates while the lower well was filled with 750 μl complete 
medium. The plates were incubated at 37°C in a CO2 incubator for 24 hours, and then the 
transwells were fixed and stained. The transwell membranes were observed on 20x magnification, 
the cells on at least 5 random fields were counted and the average number was calculated. 
2.2.8.2. Boyden chamber motility assay 
Following the previous motility assay optimisations, the motility assay was performed as follows: 
The cells, which might have been pre-treated or not, were serum-starved for 24 hours, prior to 
washing with PBS, and trypsinisation for 5-10 minutes or until all cells had been detached from 
the bottom surface. The trypsin was neutralised with serum starvation medium and the following 
centrifugation, the cell suspension was adjusted at the following numbers in 300 µl serum 
starvation medium: 
25,000 for SW71 cells. 
50,000 for non-transfected and transfected HTR8/SVneo 
100,000 Jeg-3 and BeWo cells. 
35,0000 primary EVTs 
The cell mixture was seeded into 8 µm pore size transwells (Greiner Bio-one, UK), placed on 24-
well plates and were incubated at 37°C in CO2 incubator for 24 ours, while the lower wells were 
filled with 750 µl complete medium as chemoattractant. Following the incubation, the transwells 
were washed with PBS, fixed using methanol for 10 minutes, at room temperature and then were 
stained using the Quick Diff staining kit. The transwell membranes were observed at 20x 
magnification, the cells on at least 5 random fields were counted and the average number was 
calculated. 
2.2.8.3. Invasion assay optimisation 
To find out about the lowest concentration of the Matrigel that can polymerise and solidify to 
form a gel inside the transwells, the matrix Matrigel (Corning Limited, UK)  was diluted with the 
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appropriate serum free media in the following order of dilutions: 1:1, 1:1.5, 1:2, 1:2.5, 1:3, 1:3.5, 
1:4. 100 µl of diluted Matrigel was poured into the transwells and the polymerisation of the 
Matrigel was tested, the by observation of gel formation, following 2 hours of incubation at 37°C 
in a CO2 incubator. 
To find out what Matrigel volume and incubation time works best for the cells, 50,000 Jeg-3 cells 
were seeded on 10, 20 and 30 µl polymerised 1:3 diluted Matrigel and were incubated for 24, 48 
and 72 hours. The cells trapped in the transwell membrane were fixed and stained as explained 
earlier and the non-migratory ones were whipped using cotton swabs. The stained cells were 
counted using 20x magnification.  
2.2.8.4. Boyden chamber invasion assay 
The invasion assay was done in a similar way as the Boyden chamber motility assay (section 
2.2.8.2), except for the usage of 20 µl 1:3 diluted Matrigel that was used to coat the transwell 
membrane, 2 hours prior to seeding the cells inside them. 
2.2.8.5. Migration and invasion assays with protein knockdown 
To investigate the role of our different target proteins such as S100P, ezrin and IQGAP1 in 
motility and or invasion, the cells were treated either with siRNA after serum starvation for 24 
hours. Then the seeding numbers were adjusted accordingly, and the cells were left to migrate for 
24 hours, prior to fixation and staining.  
2.2.8.6. Migration and invasion assays with other treatments (S100P 
antibody or ezrin inhibitor)   
A T25 flasks with about 80% confluent Jeg-3, SW71 or HTR8/SVneo clones 3 (SGB16), 5 
(SGB217) and 7 (SGB217) were serum starved a for 24 hours, prior to trypsinisation (except for 
primary EVTs, which were collected without previous serum starvation). The cell suspensions 
were seeded inside the transwells, with or without Matrigel coating to test their migration and 
invasion respectively, as the lower wells contained complete media as chemo-attractant. Both the 
transwells and the bottom wells contained either of the following the treatments: 0.4 µg/ml goat-
anti-S100P (R&D systems, UK) monoclonal antibody, 10 mM ACA, 0.2% (v/v) goat serum as 
negative control (same volume as anti-S100P antibody), 5 µM ezrin inhibitor NSC668394 
(Merck, UK), or 0.01% (v/v) DMSO (the same volume as NSC668394 solution) as negative 
control. The migration and invasion assays were performed as explained earlier.  
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2.2.9. Immunofluorescence staining 
To investigate the localisation and the expression pattern of different cellular markers of either 
cell motility (paxillin, ezrin, phospho-ezrin and IQGAP1) or in order to confirm HLA-G 
expression in primary EVTs, the cells were stained with immunofluorescence as follows: 
Round glass coverslips were incubated with 4 μg fibronectin in μl 100 PBS per well, at room 
temperature for 1 hour. The unbound fibronectin was aspirated, and the coverslips were washed 
once with PBS. The coverslips were then placed in the wells of a 24-well plate, then exposed to 
UV for 15 minutes. 15,000-20,000 cells were seeded and left to attach for 24 hours at 37°C in a 
CO2 incubator. The coverslips were then washed with cytoskeleton buffer (CB) (Table 2.12) 
twice, prior to fixing with 4% (w/v) PFA in CB at 37°C for 10 minutes. Then, to quench any 
unreacted aldehyde, the cells were incubated with 30 mM glycine solution at room temperature 
for 10 minutes. Following this, in order to permeabilise the cells, 0.01% (v/v) Triton solution was 
added and the plate and incubated at room temperature for 10 minutes. The cells were then 
washed 3 times with CB, waiting for 5 minutes each time, at room temperature. Finally, the cells 
were blocked using 10% (v/v) goat serum in CB for 30 minutes at room temperature. The 
coverslips were then incubated with 50 µl primary antibodies diluted in 1% (v/v) goat serum in 
CB (or in 3% (w/v) BSA in PBS for ezrin antibody), for 45 minutes at room temperature (antibody 
dilutions have been listed in Table 2.13). The excess primary antibody was washed off with 1% 
(v/v) goat serum (or 3% (w/v) BSA for ezrin) twice and then with diH2O once. The cells were 
then incubated with fluorescein isothiocyanate (FTIC) or tetramethylrhodamine (TRITC) 
conjugated secondary antibodies (Agilent Technologies, UK) diluted in in 1% (v/v) goat serum 
in CB (or 3% BSA for ezrin) (dilutions in Table 2.13), along with 1:100 diluted rhodamine 
phalloidin (Thermo Fisher Scientific, UK), at room temperature for 45 minutes, to stain F-actin. 
The cells were washed again with 1% (v/v) goat serum in CB (or 3% BSA for ezrin) twice and 
once with diH2O to remove salt. The coverslips were then mounted onto glass slides with 
mounting medium containing DAPI, the edges were covered with clear nail varnish and the slides 
were left to dry for 30 minutes, before viewing under 63x magnification, with immersion oil (Carl 
Zeiss Ltd, UK) using an inverted epifluorescence microscope. 
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Solution Ingredients 
Cytoskeleton buffer (CB) 150 mM NaCl, 5 mM MgCl2, 5 mM EGTA, 5 
mM glucose, 11 mM MES in diH2O. pH 7.4 
4% PFA Dilute 16% PFA solution in CB 
1x glycine (30 mM) Dilute 20x glycine solution in CB 
0.01% triton-EDTA Dilute 100x triton-EDTA in CB 
10% and 1% goat serum solutions Dilute goat serum in CB  
Table 2.12 The solutions needed for preparing the cells for immunofluorescence staining. 
 
Antibody Dilution in 1% goat serum 
Alexa Fluor 568 phalloidin 1:100 
FITC secondary conjugate (mouse) 1:200 
FITC secondary conjugate (rabbit) 1:200 
TRITC secondary conjugate (rabbit) 1:200 
Monoclonal anti-ezrin antibody (mouse) 1:100 
Monoclonal anti-phospho-ezrin antibody 
(rabbit) 
1:100 
Monoclonal anti-HLA-G (mouse) 1:100 
Monoclonal anti-IQGAP1 antibody (rabbit) 1:100 
Monoclonal anti-paxillin antibody (mouse) 1:100 
Table 2.13 Antibody dilutions used in immunofluorescence staining. 
 
2.2.10. Statistical analysis 
GraphPad Prism software or Microsoft Excel were used for statistical analysis. The data are 
presented as ± standard deviation (SD) or ± standard error of the mean (SEM) and the groups 
have been compared to each other by two-tail Student’s t-test (two compare two groups of data 
to each other) or ANOVA (to compare more than two groups of data to each other) along with 
Dunnett's test (post hoc) to compare the mean of each group to the control mean. The number of 
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technical replicates (N) as well as the sample size of each experiment is mentioned in the 
corresponding figure legend.  
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Chapter 3.  
S100P regulates trophoblast motility 
and invasion 
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3.1. Introduction 
S100P, a Ca2+-binding protein and a member of S100P family of proteins, is expressed in 
numerous tissues including oesophagus, trachea, spleen, stomach, duodenum and large intestine, 
colon, prostate (with highest levels during teenage years), bone marrow and leukocytes (Parkkila 
et al. 2008). During embryonic stages, S100P has been shown to be expressed as early as week 
6, initially in the urogenital sinus as well as the developing gastrointestinal tract, and later in the 
urethra and bladder as well as the epithelium of the stomach and spleen, along with the allantois 
and in the hepatic vein (Prica et al. 2016). Its highest expression levels are found in the stomach 
and placenta, the latter being the organ where it was first discovered (Becker et al. 1992; Parkkila 
et al. 2008).  The role of this protein in the context of this tissue, or indeed in the non-pathological 
state of any organs is yet unknown. 
Similar to S100A 8, 10, and 11, S100P has been shown to be expressed in the endometrium 
(Baker et al. 2011; Bissonnette et al. 2016; Liu et al. 2006; Zhang et al. 2012). Endometrial S100P 
shows periodic changes in its expression levels (protein and mRNA) during the menstrual cycle, 
increasing significantly during the mid-secretory phase of cycle, referred to as the reception-ready 
phase or the implantation window (form the 20th day till 23rd day of the menstrual cycle), during 
which the physiological and morphological alterations of the tissue known as decidualisation 
occur (Dunn, Kelly & Critchley 2003; Tong et al. 2010; Zhang et al. 2012). Endometrial S100P 
is upregulated even more when pregnancy takes place. It peaks at the time of implantation, 
enhancing endometrial cell migration as well as embryo adhesion, and therefore promotes 
implantation (Zhang et al. 2012). 
Within the placenta, S100P has been shown to be highly expressed in cyto- and 
syncytiotrophoblasts during the first trimester, where most of trophoblast proliferation happens 
(Zhu et al. 2015). Moreover, co-culture of stroma cells with trophoblasts enhances their S100P 
expression (Popovici et al. 2006). 
In this chapter, we aimed to study the expression levels of S100P and characterise its histological 
localisation in human placenta and its levels during the different stages of pregnancy. We set 
about to gain further information about its expression in trophoblasts cells in culture and sought 
to determine its role in trophoblast motility and invasion. 
Aim 
To study the role of S100P in trophoblast motility and invasion. 
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Objectives 
• Establish S100P expression in human placental samples at different stages of gestation 
• Establish S100P expression in trophoblast cell lines 
• To test whether changes in the trophoblast microenvironment affects S100P expression 
• To test whether modulating S100P expression affects trophoblast motility and invasion 
• To decipher the molecular mechanisms for S100P-promoted motility and invasion in 
trophoblast cells 
3.2. Results 
3.2.1. Immunohistochemical staining optimisation 
The S100P protein was first isolated from placental samples demonstrating that it is endogenously 
expressed in these tissues (Becker et al. 1992). More specifically, it was later shown to be 
localised in syncytiotrophoblasts as well as cytotrophoblasts (Parkkila et al. 2008; Zhu et al. 
2015), but no information was provided regarding its localisation in the different placental 
structures. For this aim, we first optimised IHC with different primary antibody concentrations 
for two trophoblast marker proteins: cytokeratin 7, which is a marker of villous trophoblasts 
(Maldonado-Estrada et al. 2004), and HLA-G, which is a marker of EVTs, a sub-population of 
trophoblasts that leave the villi, invade the decidua and remodel the maternal arteries (Moser et 
al. 2011).  
In order to find the lowest concentrations of primary antibodies used for the IHC in this part (anti-
cytokeratin 7 and anti-HLA-G), dilutions of each antibody were tested for the staining of first 
trimester samples. Wax-embedded human placenta sections from first trimester human placenta 
villi were cut, mounted on glass slides prior to preparation and incubation with the following 
primary antibodies: anti-cytokeratin 7 and anti-HLA-G (20 µg/ml and 10 µg/ml) in 2.5% (v/v) 
goat serum, prior to secondary antibody incubation and development using avidin-biotin complex 
and DAB chromogen. The sections were counter stained with haematoxylin. 
Both concentrations showed efficient staining for cytokeratin 7 and HLA-G, with even our lowest 
antibody concentration at 10 µg/ml showing specific labelling (Figure 3.1). Cytokeratin 7 was 
found to be highly expressed within the cytoplasm of cytotrophoblasts as well as the apical 
membrane of the multi-nuclear syncytiotrophoblast, and to a lesser extent in the cytoplasm of 
syncytiotrophoblast as well as their membrane. HLA-G expression was primarily localised within 
the cytoplasm of the EVTs. 
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Figure 3.1 Primary antibody concentration optimisation for IHC. Wax-embedded human 
first trimester placental villi sections were prepared and incubated with two concentrations of 
primary anti-cytokeratin 7, anti-HLA-G and mouse IgG (as negative control), before being 
incubated with secondary antibodies, and finally were stained using avidin-biotin complex and 
DAB chromogen and then were counterstained using haematoxylin. The two images on the 
bottom are magnified fields from cytokeratin 7 and HLA-G staining.  
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3.2.2. Placental S100P expression gradually decreases during 
gestation 
To compare the expression levels in placenta sections, slides from first trimester, second 
trimester, and third trimester human placenta sections were prepared and stained by our 
colleagues in Aston Medical School were studied by taking several images at 20x magnification 
and analysing by densitometry using Fiji-ImageJ software. The OD form each section was 
compared with the OD from other sections. The highest levels of S100P expression was detected 
in samples from the first trimester, which express 40% more S100P compared with the second 
trimester sections (P<0.05), and 50% more than the third trimester sections (P<0.01). Third 
trimester samples showed 10% lower S100P expression compared with the second trimester, but 
the difference was not significant (Figure 3.2). 
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Figure 3.2 S100P expression in human placenta is the highest during first trimester of 
gestation. Relative S100P expression in human placenta sections from first, second and third 
trimesters (TM), which had been stained for S100P, was measured by densitometry. Panel A 
shows the images taken at 20x magnification and panel B shows relative S100P expression levels 
in each of the gestation ages. The error bars represent standard deviation (SD) (* P<0.05, ** 
P<0.001). N = 1. Sample size = 3 for each condition.  
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3.2.3. S100P is expressed in human trophoblasts and EVTs 
After showing that the expression of S100P in placenta is the highest in early stages of placental 
development and having optimised the IHC staining for trophoblast marker cytokeratin-7 and 
EVT marker HLA-G, we next wanted to gain insight intoS100P localisation within the placental 
villi, with serial staining for these two markers: cytokeratin 7 and HLA-G.  
For this purpose, serial sections of wax-embedded first trimester human placental villi were 
incubation with the following primary antibodies: anti-S100P, anti-cytokeratin 7 (trophoblast 
marker) and anti-HLA-G (EVT marker), followed by secondary antibody incubation.  
S100P colocalised with cytokeratin 7, confirming its localisation in cyto- and 
syncytiotrophoblasts, and a small proportion of it colocalised with HLA-G, confirming its 
localisation in the EVTs. S100P was localised in the cytoplasm of the trophoblasts and was also 
detectable in the apical plasma membrane of the syncytiotrophoblasts (highest expression level) 
as well as the EVTs with occasional localisation within the nuclei of the syncytiotrophoblasts and 
the EVTs. The stroma showed no detectable levels of S100P expression (Figure 3.3). 
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Figure 3.3 S100P expression in human trophoblasts and EVTs. Serial sections of wax-
embedded human first trimester placental villi were prepared and incubated with primary anti-
S100P, anti-cytokeratin 7, anti-HLA-G and mouse and rabbit IgG (as negative control), before 
being incubated with secondary antibodies, and finally staining using avidin-biotin complex and 
DAB chromogen and counters-staining using haematoxylin. The images were taken with 20x 
magnification. The image on the bottom right corner is a magnified filed from the S100P staining 
image. 
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3.2.4. S100P expression in human trophoblast cell lines  
Having now demonstrated significant expression of S100P in trophoblasts in placental sections, 
we wanted to determine if cell lines of trophoblastic origins also demonstrate endogenous 
expression of S100P.  
In this aim, a collection of cell lines was obtained. These corresponds to Jeg-3 and BeWo, which 
are human choriocarcinoma, from epithelial malignancy of trophoblasts, that have lost their 
villous organisation (Cheung et al. 2009), as well as a series of immortalised human first trimester 
EVT cell lines as follows: SW71, virally infected with human telomerase reverse transcriptase 
hTERT (Straszewski-Chavez et al. 2009), HTR8/SVneo, chorionic villi, transfected with a 
plasmid containing the simian virus 40 large T antigen (SV40) (Graham et al. 1993), SGHPL-4 
and SGHPL-5, which are also transfected with SV40 (Choy, St Whitley & Manyonda 2000). 
 To determine if S100P was expressed in these trophoblast cells, they were lysed in PBS with 1% 
(v/v) protease inhibitor cocktail and sonicated prior to proteins being separated by 16% SDS-
PAGE. Western blot was performed by transferring proteins on to PVDF membrane prior to 
incubation with either anti-S100P or anti-α-tubulin antibodies and then incubating with secondary 
antibodies and ECL detection. S100P expression levels were normalised to the housekeeping 
gene expression. Endogenous S100P expression was detected, in both of the available human 
choriocarcinoma trophoblast cell lines, namely Jeg-3 and BeWo, with BeWo expressing 80% 
higher amounts of S100P, compared with Jeg-3, but not in any of the EVT cell lines: 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5 (Figure 3.4). 
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Figure 3.4 Endogenous S100P expression in different trophoblast cell lines. Human 
choriocarcinoma trophoblast cell lines were collected in protease inhibitor cocktail and sonicated, 
prior to being separated by 16% SDS-PAGE. Then, S100P and α-tubulin were detected by 
western blot. Expression levels were quantified by Image Studio Lite software and S100P 
expression levels were normalised to the housekeeping gene expression. Panel A shows the 
western blot bands for S100P and α-tubulin, and panel B shows the densitometry. The error bars 
represent SD. N.S. = non-significant. N = 2. Sample size = 2 for each cell line. 
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3.2.5. S100P expression in different microenvironments 
mimicking physiological conditions  
In the previous section, we showed that S100P is expressed in two of our trophoblast cell lines: 
Jeg-3 and BeWo, but was not found expressed at detectable levels in the EVT cells SW71, 
HTR8/SVneo, SGHPL-4 and -5. Given that significant S100P expression could be seen in 
trophoblasts during the early stages of implantation (Figure 3.2), and since trophoblast 
phenotypes such as proliferation, invasion and motility are controlled by their molecular and 
cellular interactions with the maternal microenvironment (Staun-Ram & Shalev 2005; Toro et al. 
2014), we sought to investigate the effects of changes in trophoblast microenvironment including 
growing them on fibronectin, Matrigel and different concentrations of gelatine as well 24 hours 
of serum starvation on S100P expression in the choriocarcinoma cell line Jeg-3 and EVT cell 
lines: SW71, HTR8/SVneo, SGHPL-4 and SGHPL-5. 
Growing Jeg-3 cells on 1% (v/v) fibronectin and 2% (w/v) gelatine, significantly increased S100P 
levels by 50% compared to non-treated control cells (P<0.05 and P<0.0001 respectively), while 
Matrigel, reduced S100P expression to 70 percent compared to control (P<0.0001). Growing the 
cells on surfaces covered with lower that 2% (w/v) concentrations of gelatine did not significantly 
affect S100P levels compared to control (P>0.05). Serum starvation did increase S100P 
expression by 50% compared with control, this increase, however, was insignificant (P>0.05) 
(Figure 3.5 A and B). None of these conditions induced S100P expression in the non-S100P-
expressing EVT cell lines: HTR8/SVneo, SW71, SGHPL-4 and -5 (Figure 3.5 C).  
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Figure 3.5 S100P expression in physiological-like conditions enhances S100P expression. 
30,000 Jeg-3 cells were grown on different conditions including: F (on fibronectin coating), M 
(on Matrigel coating), S (without any coating, with 24 hours serum starvation), and G (on 3 
different concentrations of gelatine: 2, 1 and 0.5%). The samples were collected, lysed and 
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separated by 16% SDS-PAGE and S100P and α-tubulin were detected by western blot. 
Expression levels were quantified by Image Studio Lite software. S100P expression levels were 
normalised to the housekeeping gene expression. Panel A shows S100P expression in Jeg-3 cells 
grown in different microenvironments and B shows the densitometry. The error bars represent 
SD (* P<0.05, *** P<0.0001). Panel C shows the lack of S100P expression in EVT cell lines 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5, when grown in different microenvironments, 
along with S100P expression in Jeg-3, as positive control. The error bars represent SD. N = 3. 
Total sample size = 3 for each condition. 
 
3.2.6. S100P expression knockdown 
S100P expression has been linked with many cellular functions including proliferation, motility 
and invasion in cancer cells (Du et al. 2012; Heil et al. 2011; Hsu et al. 2015; Kikuchi et al. 2019; 
Koltzscher et al. 2003; Mercado-Pimentel et al. 2015; Whiteman et al. 2007), but it is not clear 
whether it plays any of these roles in trophoblasts. In order to study the role of S100P in 
trophoblast behaviour, we first optimised siRNA delivery to specifically modulate the expression 
of S100P in two trophoblast cell lines Jeg-3 and BeWo, where it is found endogenously expressed. 
To this aim, Jeg-3 and BeWo cells were treated by four different sequences of siRNA (1, 4, 5 and 
6) targeting S100P or mock treatment (treated with a nonspecific sequence of siRNA, as negative 
control). 3 days following the treatment, cell lysate was prepared and was separated by 16% SDS-
PAGE, prior to western blot analysis for both α-tubulin and S100P. S100P expression was 
normalised to tubulin expression. The expression levels were compared with the non-treated 
control. S100P was found to be endogenously expressed similarly in both control and mock 
treated Jeg-3 and BeWo cells, while treatment with a panel of different siRNA targeting S100P 
led to changes in the levels of protein expression (Figure 3.6). In Jeg-3 cells, siRNA 1 and 5 
significantly reduced S100P levels by 70% (P<0.0001), while siRNA 4 and 6 reduced S100P 
levels by 80% (P<0.0001) compared with non-treated control (Figure 3.6 A1 and A2). In BeWo 
cells, siRNA 1 and 5 reduced S100P levels by 50% (P<0.05), while siRNA 4 and 6 reduced S100P 
levels by 60% (P<0.01) (Figure 3.6 B1 and B2), compared with non-treated control. Therefore, 
it was confirmed that S100P expression knockdown using S100P siRNA transfection (four 
sequences) was accomplished successfully, and that siRNA 4 and 6 were found to be the most 
potent in both Jeg-3 and BeWo cell lines. 
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Figure 3.6 Knocking down S100P expression by siRNA transfection in Jeg-3 and BeWo 
cells. Jeg-3 and BeWo cells, were treated with S100P siRNA 1, 4, 5 and 6, along with mock 
treatment. The treated cells along with non-treated control cells were left to grow for 3 days prior 
to collection, lysing and sonication. The proteins were separated by 16% SDS-PAGE and S100P 
and α-tubulin bands were detected by western blot. Expression levels were quantified by Image 
Studio Lite software and S100P expression levels were normalised to the housekeeping gene 
expression. Panels A1 and B1 show S100P and α-tubulin bands in Jeg-3 and BeWo cells, 
respectively, while panels A2 and B2 show the densitometry in the mentioned cells in the same 
order. The error bars represent SD. (* P<0.05, * P<0.01 and **** P<0.0001). N = 3. Total sample 
size = 3 for each cell line. 
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3.2.7. Boyden chamber assay optimisation 
3.2.7.1. Migration assay optimisation  
Both cellular motility and invasion measurements can be performed using a plethora of 
techniques. In this study, we sought to assess the cells’ ability to migrate and invade using the 
Boyden chamber assays. In order to optimise transwell migration assay for trophoblast cell line 
Jeg-3, 100,000 cells were seeded in transwells and were left to migrate for 24 hours, before being 
fixed by two different fixation (4% PFA and ice-cold methanol) and staining methods (Quick 
Diff staining kit containing eosinophilic and basophilic staining reagents along with Vectashield 
mounting medium containing DAPI). The trapped cells inside the transwell membrane pores 
could be observed when either 4% PFA (Figure 3.7 A and C) or ice-cold methanol (Figure 3.7 B 
and D) were used as fixatives. However, methanol, which is less hazardous, was used for further 
experiments. Both DAPI (Figure 3.7 C and D) and Quick Diff staining (Figure 3.7 A and B) could 
stain the cells, but Quick Diff staining was used for further experiments due to its more convenient 
procedure.  
In order to establish an appropriate and workable number of cells migrating or invading 
throughout the transwells, we sought to determine the most appropriate cell seeding number to 
analyse motility capabilities of trophoblast using transwell assays. Therefore, three different 
seeding numbers were tested: 25,000, 50,000 and 100,000. The cells were then treated with S100P 
siRNA 4, which was shown to significantly reduce S100P expression (Figure 3.6), or negative 
control siRNA (mock transfection), along with non-treated control. 48 hours after the 
transfection, the media was replaced with serum starvation media and the cells were left to grow 
for one more day, before being collected. The collected cells (control, negative control and siRNA 
4 treated) were resuspended in serum starvation medium and the above-stated number of cells 
were seeded in transwells, while the lower wells contained complete media as chemoattractant, 
and were left to migrate for 24 hours, followed by fixation and staining. The cells were counted 
in six different files with 20x magnification and the average number of negative control and 
siRNA 4 treated cell counts were compared with the non-treated control of each group of cell 
counts. When 100,000 and 50,000 cells were seeded, there was a 70% reduction in Jeg-3 
migration in the S100P-knockdown cells compared with the control (P<0.01 for 100,000 and 
P<0.05 for 50,000), while seeding 25,000 cells did now show a significant change in migration 
due to S100P knock-down (P>0.05) (Figure 3.7 E). Therefore, these two seeding numbers 
(100,000 and 50,0000) were chosen as suitable numbers for further experiments.  
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Figure 3.7 Transwell migration assay optimisation results.  In the above panel, Jeg-3 cells 
were seeded on the bottom of inverted transwells and were incubated at 37°C for 2 hours before 
they were fixed with either 4% PFA (panels A and C) or 100% methanol (panels B and D) and 
stained with either Quick Diff stinging kit (panels A and B) or DAPI (panels C and D). The 
images were taken at 40% magnification using bright field (A and B) or florescent (C and D) 
microscopy. The lower panel (E) shows average cell count percentage for control, negative 
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control and S100P siRNA 4 treated samples with three different seeding numbers: 100,000 (black 
bars); 50,000 (dark grey bars); 25,000 (light grey bars) in six random fields of the transwell 
membrane at 20x magnification. The error bars represent SD (* P<0.05, ** p<0.01). N = 1. 
Sample size = 6 for each condition. 
 
3.2.7.2. Invasion assay optimisation 
To optimise the invasion assay in our hands, 1:3 diluted Matrigel was used to cover the bottom 
of the transwells (as the Matrigel quickly forms a gel at room temperature, it is more convenient 
to dilute it with the medium used for cell growth). Matrigel was polymerised and formed a gel 
after 2 hours of incubation at 37°C. The gel forms only when the proportion of Matrigel to 
medium is 1:3 or higher (data not shown).  
To find the maximum volume of Matrigel that the Jeg-3 trophoblast cells are able to digest and 
pass through and how much time they need for invasion, three different Matrigel volumes and 
three different incubation times were tested. The cells could digest 10 µl and 20 µl of polymerised 
Matrigel, while none of the incubation times (24 or 48 hours) were enough for the cells to digest 
30 µl of Matrigel (Figure 3.8). For further experiments, 20 µl diluted Matrigel was chosen as it is 
easier to spread on the membrane compared to 10 µl. As for the incubation time, 24 hours seemed 
to give the best results (Figure 3.8) as a longer incubation time lead to cells forming a clump of 
cells in the centre of the transwells and being too numerous and dense to count (Figure 3.8).  
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Figure 3.8 Transwell invasion assay optimisation results. 50,000 Jeg-3 cells were seeded in 
transwells coated with 10, 20 and 30 µl polymerised Matrigel (three transwells for each volume, 
total of nice transwells) and each of them were incubated for either 24, 42 and 72 hours prior to 
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fixation and staining with Quick Diff kit. The images were taken at 20x magnification (A) and 
the graph shows cell count per 20x field (B).  N = 1. Sample size = 1 for each condition. 
 
3.2.8. Knocking down S100P reduces trophoblast motility 
S100P has been shown to be a key regulator of cell motility in cancer cells (Austermann et al. 
2008; Du et al. 2012; Hsu et al. 2015).Therefore, we sought to determine whether S100P could 
equally regulate trophoblast motility. Given our ability to knock down S100P expression in 
trophoblast cell lines, Jeg-3 and BeWo using siRNA delivery, we now sought to establish whether 
such reduction would correlate with changes in motility.  
For this purpose, Jeg-3 and BeWo cells were treated with S100P siRNA (four different sequences) 
or negative control siRNA. 72 hours following the treatment, the cells were seeded in transwells 
and were left to migrate for 24 hours. The transwells were then fixed and stained and the migrated 
cells were counted in six random fields at 20x magnification. Knocking down S100P expression 
in Jeg-3 and BeWo cells, reduced cell migration compared with the controls in both cell types. 
This reduction was more significant for Jeg-3 (50% reduction for siRNA 1, 4, 5 and 60% for 
siRNA 6) (P<0.0001), than BeWo (50% reduction for siRNA1, 40% for siRNA4 and 60% for 
siRNA6) (P<0.01 for siRNA 1, P<0.05 for siRNA 4, P>0.05 for siRNA 5 and P<0.001 for siRNA 
6) (Figure 3.9).  
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Figure 3.9 S100P knockdown reduces trophoblast migration. Jeg-3 (A) and BeWo (B) cells 
were seeded in 24 well plates and treated with S100P siRNA 1, 4, 5 and 6, along with mock 
treatment and not treated control. They were left to grow for 48 hours before being serum starved. 
After another 24 hours of incubation, the cells were collected and were seeded in transwells. On 
the next day the transwells were fixed and stained. The cells were counted in fields of 20x 
magnification. Graphs A1 and B1 show average cell count percentage compared with control in 
Jeg-3 and BeWo cells respectively and the bars represent standard error of the mean (SEM) (* 
P<0.05, ** p<0.01 and **** p<0.0001). Panels A2 and B2 show representative fields of fixed 
and stained transwells for Jeg-3 and BeWo, respectively. N = 3 for each cell line. Total sample 
size = 18 for each cell line. 
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3.2.9. Knocking down S100P reduces trophoblast invasion 
S100P has been shown to be a key regulator of cell invasion, mainly in cancer lines, and its 
expression correlates with both cellular invasion (Mercado-Pimentel et al. 2015; Whiteman et al. 
2007) and overall metastasis (Arumugam et al. 2005) and poor prognosis (Wang et al. 2015). 
Given that S100P knockdown was shown to reduce trophoblast migration (Figure 3.9), here we 
sought to test the role of S100P protein on trophoblast invasion. 
For this purpose, Jeg-3 and BeWo cells were treated with S100P siRNA (four different sequences) 
or negative control siRNA. 72 hours following the treatment, the cells were seeded in transwells 
coated with Matrigel and were left to invade for 24 hours. The transwells were then fixed and 
stained and the migrated cells were counted in two fields at 20x magnification. Knocking down 
S100P expression in Jeg-3 and BeWo cells, reduced cell invasion in both Jeg-3 and BeWo cells, 
compared with control cells. In Jeg-3 there was a 60% reduction in invasion for siRNA 1 and 
70% reduction for siRNA 4, and 6 (P<0.0001). In BeWo on the other hand, there was 60% 
reduction in invasion for siRNA 4 and (P<0.0001) and 50% reduction for siRNA 6 (P<0.001), 
while siRNA 1 and 5 did not significantly affect invasion (Figure 3.10).  
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Figure 3.10 The effect of S100P knockdown on trophoblast invasion. Jeg-3 (A) and BeWo 
(B) cells were seeded in 24 well plates and treated with S100P siRNA 1, 4, 5 and 6, along with 
mock treatment and not treated control. They were left to grow for 48 hours before serum 
starvation. After another 24 hours of incubation, the cells were collected and were seeded in 
Matrigel-coated transwells. On the next day the transwells were fixed and stained. The cells were 
counted in fields of 20x magnification. Graphs A1 and B1 show average cell count percentage 
compared with control in Jeg-3 and BeWo cells respectively and the bars represent SEM (*** 
p<0.001 and **** p<0.0001). Panels A2 and B2 show representative files of fixed and stained 
transwells for Jeg-3 and BeWo, respectively. N = 3 for each cell line. Total sample size = 6 for 
each cell line. 
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3.2.10. Stable S100P transfection  
Initial work carried out with EVT cell lines (HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5), did 
not show detachable levels of S100P expression in these cells (Figure 3.4). Therefore, 
HTR8/SVneo cell lines were stably transfected with SGB217 plasmid containing S100P or 
SGB16 control plasmid. To confirm S100P expression in the clones transfected with S100P-
containing plasmid SGB217, the cells were collected, lysed and separated by 16% SDS-PAGE, 
before performing western blot analysis for both α-tubulin and S100P. S100P expression level 
was normalised to tubulin expression. HTR8/SVneo clones expressed different levels of S100P 
(Figure 3.11 A1 and A2): SGB217 clones 2, 5, 7, 14 and pools of SGB217 clones express 
moderate levels (300000-500000% compared to clone 1 baseline), clones 1, 8 and 12 express low 
or undetectable levels, and clones 3, 4, 9 and 10 express high amounts (900000-1100000% 
compared to clone 1 baseline), while the mock clone and the mock clones pool, which were 
transfected with SGB16 plasmid, do not show any detectable levels of S100P. Moreover, lysates 
of clones 5 and 7 (SB217) were loaded on the same gel along with Jeg-3 (which expresses S100P) 
as well as the mock clone  (SGB16) and were probed for S100P and α-tubulin as before, to 
compare S100P expression in these two HTR8/SVneo clones with the endogenous expression of 
Jeg-3. HTR8/SVneo clones 5 and 7 show similar expression levels of S100P, when compared 
with Jeg-3 (Figure 3.11 B1 and B2). 
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Figure 3.11 S100P expression in HTR8/SVneo SGB217 clones and their levels compared 
with Jeg-3 HTR8/SVneo clones 1, 2, 3, 4, 5, 7, 8, 9, 10, 12, 14 (SGB217), pool of SGB217 clones 
and pool of SGB16, and the mock clone (SGB16) as well as Jeg-3 samples were collected, lysed, 
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sonicated and loaded on 16% tricine gel. The bands were detected with ECL (panels A1 and B1) 
and the expression levels were quantified with Image Studio Lite software (panels A2 and B2). 
S100P signals were normalised to α-tubulin signals. N = 1. Sample size = 1 for each cell line. 
 
3.2.11. Moderate levels of S100P expression enhance trophoblast 
motility 
Endogenous S100P expression promotes motility and invasion in cancer cell motility 
(Austermann et al. 2008), and in trophoblasts (Figure 3.9 and Figure 3.10). Here, to further study 
the effect of exogenous S100P expression on trophoblast motility, HTR8/SVneo EVT clones with 
different levels of S100P expression (containing SGB217 plasmid): 250-300% higher (clones 9 
and 10), 90% lower (clone  12) and similar to Jeg-3 expression levels (clones 5 and 7) along with 
the mock clone (SGB16) were serum starved for 24 hours and then seeded in transwells (50,000 
cells per transwell) and were left to migrate for 24 hours. The transwells were then fixed and 
stained, prior to counting the migrated cells. S100P expression showed a hormetic effect on the 
migration of HTR8/Svneo cells. There was a significant increase in the migration of clones 5 
(250%) (P<0.0001) and 7 (50%) (P<0.05), when compared with mock clone (SGB16). Clones 12 
with lower S100P than Jeg-3, showed no difference in migration. Clones 9 and 10 with higher 
S100P than Jeg-3 levels showed a significant 50% and 80% reduction, respectively, when 
compared with the mock clone (P<0.05 for clone 9 and P<0.0001 for clone 10) (Figure 3.12). 
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Figure 3.12 S100P expression and trophoblast migration. S100P-expressing HTR8/SVneo 
clones with different levels of S100P expression: clones 9 and 10 (high), clone 12 (low) and 
clones 5 and 7 (similar to Jeg-3), were tested for migration (compared with the mock clone) by 
transwell migration assay. For this aim, the cells were serum starved for a day, before being 
collected. They were then seeded into transwells. The transwells were fixed and stained after 24 
hours. Panel A shows the average cell count for HTR8/SVneo clones 3 (SGB16), and SG217 
clones 5, 7, 9, 10 and 12, while panel B shows representative fields from migrated HTR8/SVneo 
clones 3 (SGB16), 5 (SGB217) and 7 (SGB217) at fields of 20x magnification. The error bars 
represent SEM (* p<0.05 and **** p<0.0001). N = 3. Total sample size = 18 for each cell line. 
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3.2.12. Moderate levels of S100P expression enhances trophoblast 
invasion 
Moderate S100P expression was shown to enhance trophoblast migration, previously. Here, to 
study the effect of exogenous S100P expression on trophoblast invasion, HTR8/SVneo EVT 
clones with different levels of S100P expression (containing SGB217 plasmid): 250-300% higher 
(SGB217 clones 9 and 10), 90% lower (clone  12) and similar to Jeg-3 levels (clones 5 and 7) 
along with the mock clone (SGB16) were serum starved for 24 hours and then seeded in Matrigel-
coated transwells and were left to invade for 24 hours. The transwells were then fixed and stained, 
prior to counting the invaded cells. clones 5 and 7 (SGB217), with the same levels of S100P as 
in Jeg3 showed significantly enhanced invasiveness (by 700% and 500%, respectively) compared 
to mock clone (SGB16) (P<0.0001 for both), while the other clones (9, 10, 12 SGB217) with 
either higher or lower levels were not significantly different form the mock clone (SGB16) in 
invasion (Figure 3.13). 
113 
 
 
Figure 3.13 S100P expression and trophoblast invasion. S100P-expressing HTR8/SVneo 
clones with different levels of S100P expression: clones 9 and 10 (high), clone 12 (low) and 
clones 5 and 7 (similar to Jeg-3), were tested for invasion (compared with the mock clone) by 
transwell invasion assay.  For this aim, the cells were serum starved for a day, before being 
collected and resuspended in serum starvation medium. 50,000 cells were then seeded into 
Matrigel-coated transwells, while the bottom wells contained complete medium. The transwells 
were fixed and stained after 24 hours. Panel A shows the average cell count for HTR8/SVneo 
clones 3 (SGB16), and SG217 clones 5, 7, 9, 10 and 12, while panel B shows representative fields 
from invaded HTR8/SVneo clones 3 (SGB16), 5 (SGB217) and 7 (SGB217) at fields of 20x 
magnification. The error bars represent SEM (**** p<0.0001). N = 3. Total sample size = 6 for 
each cell line. 
 
114 
 
3.2.13. S100P expression reduced the size and the number of focal 
adhesions 
Knocking down S100P in Jeg-3 and BeWo cells was shown previously to increase the number 
and the size of the FAs (Tabrizi et al. 2018). Here we sought to test whether S100P expression in 
HTR8/SVneo clones 5 and 7, which were shown to be significantly more motile and invasive 
than the mock clone (SGB16) (Figure 3.12 and Figure 3.13), also affects the number and/or the 
size of FAs, by staining the cells for paxillin, one of the components of the FA complex. For this 
aim, 10,000 HTR8/SVneo mock clone (control) and S100P-expressing clones 5 and 7 were 
seeded on fibronectin-coated coverslips and were left to grow for 48 hours, before fixing and 
permeabilisation. They were then incubated with primary anti-paxillin and then secondary 
antibody as well as phalloidin. The staining showed FAs formed on the cell surface, mostly along 
the actin bundles (Figure 3.14). There a significant 30% reduction in the average number of the 
FAs (Table 3.1) in S100P-expressing clones 5 (P<0.01) and 7 (P<0.05) compared to the mock 
clone, and the FAs look relatively smaller in clones 5 and 7 compared with 3 (Figure 3.14). 
 
Table 3.1 The average number of focal adhesions per cell in HTR8/SVneo clones, 
represented as percentages 
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Figure 3.14 The effect of exogenous S100P expression on focal adhesions in HTR8/SVneo 
EVT cells. HTR8/SVneo mock clone (containing the control SGB16 plasmid) as well as clones 
5 and 7 (containing S100P-exprssing SGB217 plasmid) were seeded on fibronectin-coated 
coverslips and FAs were visualised with immunofluorescence staining on paxillin, a marker of 
FAs, along with rhodamine phalloidin to stain F-Actin and DAPI to visualise DNA. The images 
were taken with 63x magnification (panel A). Panel B shows the average FA count per cell in 
each of the clones. The error bars represent standard SEM (* p<0.5, **P<0.01). N = 1. Sample 
size (number of images) = 34 for each cell line. 
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3.2.14. S100P expression does not affect the viability of 
HTR8/SVneo 
Migration and invasion abilities can sometimes be the result of cell growth. Moreover, S100P 
expression has been shown to promote proliferation in cancer cells (Arumugam et al. 2004, 2005; 
Guo et al. 2014; Liu et al. 2017). We already had shown that knocking down S100P in Jeg-3 and 
BeWo trophoblast cells does not affect their viability (Tabrizi et al. 2018). Since previously, it 
was shown that moderate levels of S100P expression in HTR8/SVneo EVT cell lines, 
significantly enhances their migration and invasion (Figure 3.12 and Figure 3.13), here, to rule 
out the possibility of changes in cell viability and proliferation due to S100P expression, we 
sought to find out whether S100P expression in HTR8/SVneo EVT cells, affects their viability 
compared to the control counterpart.  For this aim, an equal number of seeded HTR8/SVneo 
clones 3 (SGB16), and clones 5 and 7 (SGB217) were left to grow and their viability was tested 
during the next 24 and 48 hours, by the trypan blue assay. The assay showed that S100P-
expressing HTR8/SVneo clones have similar growth rates to the mock clone (Figure 3.15), 
validating that the S100P-induced increase in migration and invasion of HTR8/SVneo clones is 
not due to a difference in their viability.  
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Figure 3.15 S100P expression does do not affect the viability of HTR8/SVneo clones. 
HTR8/SVneo clones 3 (with control SGB16 plasmid), and clones 5 and 7 (with SGB217 S100P-
expressing plasmid) were seeded in 24- well plates and their viability were measured by trypan 
blue exclusion assay during the next 24 and 48 hours. The error bars represent SD. N = 3. Total 
sample size = 60 for each cell line. 
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3.2.15. Reversing the motile/invasive phenotype in HTR8/SVneo 
clones  
We have shown that expression of S100P results in increased levels of migration and invasion in 
the HTR8/SVneo cell background after stable transfection. To further demonstrate that this effect 
is due to the sole expression of S100P as opposed to clonal selection, we sought to further validate 
that the increase in migration and invasion of HTR8/SVneo clones 5 and 7 (SGB217) compared 
with mock clone (SGB16) is S100P-specific, via knocking down S100P expression and 
investigating  its effect on migration/invasion of these cells, as follows:  
3.2.15.1. S100P knock-down in S100P-expressing HTR8/SVneo clones 
To achieve S100P knockdown, S100P-expressing HTR8/SVneo clones 5 and 7 (SGB217) were 
seeded and treated with four different sequences of siRNA (1, 4, 5 and 6) targeting S100P along 
with mock treatment (treatment with a nonspecific sequence of siRNA, as negative control) and 
non-treated control.  The cells were left to grow for 72 hours, then the lysates were collected, 
loaded on 16% tricine gels and were then probed for S100P and α-tubulin by western blot. S100P 
expression levels were normalised to α-tubulin expression. Both siRNA 4 and 5 have significantly 
reduced S100P expression by 60% (P<0.05), in both clones 5 (black bars) and 7 (grey bars) 
compared with the non-treated control, while siRNA 1 and 6 had no significant effect in neither 
of the clones (P>0.05) (Figure 3.16).  
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Figure 3.16 Knocking down S100P expression in S100P-expressing HTR8/SVneo clones.  
HTR8/SVneo clones 5 and 7 (SGB217) were treated with S100P siRNA 1, 4, 5 and 6, or negative 
control siRNA (NC) for 72 hours, before being collected, lysed and separated by 16% SDS-
PAGE. S100P and α-tubulin were detected by western blot. Expression levels were quantified by 
Image Studio Lite software. S100P expression levels were normalised to the housekeeping gene 
expression. Panel A shows western blot bands for S100P and α-tubulin in HTR8/SVneo clones 5 
and 7, while panel B shows relative S100P expression levels in these cells. The error bars 
represent SD (* p<0.05). The double bands are artefacts that were seen only occasionally. N = 3. 
Total sample size = 3 for each condition. 
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3.2.15.2. S100P knock-down does not affect the viability of 
HTR8/SVneo clones 
To investigate the effect of S100P knockdown on mock HTR8/SVneo clones (SGB16 control) 
and clones 5 and 7 (S100P-expressing SGB217), the cells were treated with S100P siRNA 4, 
which was shown to significantly reduce S100P expression by 60%, as well as a nonspecific 
negative control siRNA (mock transfection), or without any treatment, as control. Following the 
transfection, an equal number of seeded cells were left to grow and their viability was tested 
during the next 48 and 72 hours, by performing the trypan blue exclusion assay. The assay 
revealed that there was no difference in the growth rate of the three clones without treatment 
(black bars), but there was a 50% decrease in mock transfection (dark grey bars) and siRNA 4 
treated samples (light grey bars) compared with the no treatment control samples (black bars) in 
all three clones. Comparing the mock treated samples and their siRNA 4 treated counterparts 
showed that there was no significant difference between these two, 48 or 72 hours following the 
treatment (Figure 3.17), validating the ineffectiveness of the siRNA treatment on HTR8/SVneo 
clones viability.  
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Figure 3.17 S100P expression and S100P knockdown do not affect the viability of 
HTR8/SVneo clones. Mock HTR8/SVneo clone  (with control SGB16 plasmid), and clones 5 
and 7 (with SGB217 S100P-expressing plasmid) were seeded in 24 well plates and were treated 
with S100P siRNA 4, or with negative control siRNA (mock), along with non-treated control. 
The viability of the cells was measured by the trypan blue exclusion assay  48 and 72 hours 
following the transfection. The differences between mock treated and their siRNA treated 
counterparts have been marked by different colours. The error bars represent SD (P-values are as 
follows. Between mock and mock after 24 hours = 0.35, between clone 5 and clone 5after 24 
hours = 0.60, between clone 7 clone after 24 hours 7 = 0.56, between mock and mock after 48 
hours = 0.35, between clone 5 and clone 5 after 48 hours = 0.45, between clone 7 clone after 48 
hours 7 = 0.64. N = 1. Sample size = 5 for each condition. 
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3.2.15.3. Knocking down S100P can reverse motile/invasive phenotype 
in S100P-expressing HTR8/SVneo clones 
We have shown that high expression of S100P results in increased levels of migration and 
invasion in HTR8 clones. To demonstrate that this effect is due to the sole expression of S100P, 
and not as the result of other mutations, we sought to further validate that the increase in migration 
and invasion of HTR8/SVneo clones 5 and 7 (SGB217) compared with mock clone (SGB16), is 
S100P specific, via S100P knockdown and investigating its effect on migration/invasion. 
For this, HTR8/SVneo clones 5 and 7 (SGB217) were treated with S100P siRNA 5, which was 
shown to significantly reduce S100P expression (Figure 3.16), along with negative control siRNA 
(mock transfection) for 48 hours. The cells were seeded in transwells with (for invasion assay) 
and without Matrigel (for migration assay). The cells were left to migrate and invade for 24 hours, 
before fixation and staining and counting the migrated/invaded cells. The results showed that 
there was a significant (P<0.0001) 300% (for clone 5) and 200% (for clone 7) reduction in 
migration and 300% (for clone 5) and 250% (for clone 7) reduction in invasion , when the clones 
were treated with S100P siRNA 5, which brought both the migration and the invasion down to 
almost same levels as the mock clone (Figure 3.18), validating that the increase seen in both 
migration and invasion of clones 5 and 7 compared with the mock clone, was indeed S100P-
dependent.  
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Figure 3.18 S100P knockdown in S100P-expressing HTR8/SVneo clones brings migration 
and invasion down to same levels as the control clone. HTR8/SVneo clone 5 and 7 (with 
SGB217 S100P-expressing plasmid) were seeded in 24 well plates and were treated with S100P 
siRNA 5, or negative control siRNA (NC), along with non-treated control. The treated cells were 
then seeded in transwells with (for invasion) and without Matrigel coating (for migration). The 
error bars represent SD (**** p<0.0001). N = 3 for each condition. Total sample size for each 
condition: 18 (migration) and 6 (invasion). 
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3.2.16. Regression analysis 
Predicting phenotypical traits based on gene expression in living organism is possible using 
mathematical modelling but remains challenging due to the complex nature of genetics (Carter et 
al. 2007; Hao et al. 2014). Here, we aimed to see whether there is a meaningful correlation 
between S100P expression and migration/invasion in our trophoblast cells, by regression 
analysis. To do this, S100P expression levels in trophoblast cells Jeg-3 and BeWo, with four 
sequences of S100P siRNA (1, 4, 5 and 6), mock transfection (with negative control siRNA), 
along with non-treated control (Figure 3.6) were correlated with their migration (Figure 3.9) and 
invasion (Figure 3.10). For HTR8/SVneo EVT cells, mock clone (with control SGB16 plasmid) 
and clones 5 and 7 (with S100P-expressiong GB217 plasmid) were used for the comparison 
between S100P-expression (Figure 3.11) and migration (Figure 3.12) as well as invasion (Figure 
3.13). Other clones with lower and higher expression levels than Jeg-3, which did not positively 
affect migration and invasion, were not used in the regression analysis. Pearson correlation 
coefficient, r, which can take a range of values from -1 to +1, was calculated and Student's t-
distribution was used to test the significance of the correlation. Regression analysis showed a 
positive correlation (r>0) between S100P expression and cell migration/invasion for all 
trophoblast cells: S100P expression and Jeg-3 migration r = 0.97 and invasion r = 0.96, S100P 
expression and BeWo migration r = 0.76 and invasion r = 0.49, S100P expression and 
HTR8/SVneo migration r = 0.88 and invasion r = 0.99. The correlation however, was only 
significant for Jeg-3 migration (P<0.001) and invasion (P<0.001) as well as HTR8/SVneo 
invasion (P<0.01) (Figure 3.19).  
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Figure 3.19 Positive correlation between trophoblast migration/invasion and S100P 
expression. S100P expression levels in trophoblast cell lines Jeg-3, BeWo and HTR8/SVneo 
(mock and clones 5 and 7) were correlated with migration and invasion and Pearson correlation 
coefficient, r, was calculated.  's t-distribution was used to test the significance. 
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3.2.17. Extracellular S100P promotes trophoblast migration and 
invasion  
Our work so far clearly shows that high levels of S100P promote an increase in both cellular 
migration and invasion in all trophoblast cells tested to date. We do not however have any 
information about the possible mechanisms of this regulation. 
The majority of the S100P-interacting partners identified so far (Table 1.1) suggest an internal 
localisation for the protein, with only two extracellular membrane-bound binding partners i.e. 
RAGE (Mercado-Pimentel et al. 2015) and integrin α7 (Hsu et al. 2015). Therefore, we aimed to 
investigate whether S100P regulates trophoblast migration and invasion while being located on 
the cell-surface or the extra-cellular environment. Moreover, S100P includes a C-terminal lysine 
in its amino acid sequence (Clarke et al. 2017), and therefore we hypothesised that it might 
regulate cell invasion (and possibly migration) though a pathway that involves an interaction with 
plasminogen (which has a lysine-binding site) and/or plasminogen activators (PAs), leading to 
the break-down of the ECM by plasmin (plasminogen’s active form) and MMPs, which are 
activated by plasmin (Holst-Hansen et al. 1996). 
In order to test our hypothesis (extracellular localisation of S100P and interaction with the 
plasminogen pathway), we aimed to study the effect of anti-S100P antibody and Epsilon-
aminocaproic acid (ACA), which is a derivative of the amino acid lysine and acts as a 
plasminogen inhibitor (Purwin et al. 2009), on trophoblast cell invasion and migration.  
3.2.17.1. S100P antibody and ACA do not affect trophoblast viability 
Prior to testing the effect of S100P antibody and ACA on trophoblast migration and invasion, we 
aimed to study how S100P antibody and ACA affect the viability of Jeg-3 cells and HTR8/SVneo 
clones 3 (non-S100P-expressing control SGB16) and clones 5 and 7 (S100P-expressing 
SGB217), to rule out toxicity. For this aim, 15,000 trophoblast cell lines Jeg-3, and 25,000 
HTR8/SVneo clones 3 (non-S100P-expressing control SGB16) and clones 5 and 7 (S100P-
expressing SGB217) were seeded and treated with either 0.4 µg/ml anti-S100P, or 10 mM 
plasminogen inhibitor ACA, along with non-treated control cells. The cells were left to grow, and 
their viability was measured during the next 24 and 48 hours following the treatment, by the 
trypan blue exclusion assay. The assay showed that the growth rates of Jeg-3, HTR8/SVneo mock 
clone (SGB16), HTR8/SVneo clone 5 (SGB217) and HTR8/SVneo clone 7 (SGB217) are not 
affected by either S100P antibody or ACA treatment, compared with control (Figure 3.20).  
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Therefore, the possibility of toxicity caused by these two compounds (S100P antibody and ACA) 
was ruled out. 
 
Figure 3.20 S100P antibody and ACA do not affect the viability of trophoblast cell lines Jeg-
3 and HTR8/SVneo clones 3, 5 and 7. Jeg-3, HTR8/SVneo mock clone (SGB16) S100P-
expressing clones 5 and 7 (SGB217) were seeded in 24-well plates, while being treated with anti-
S100P, plasminogen inhibitor, or without any treatment as control. Their viability was tested 
during the next 24 and 48 hours. The error bars represent SD. N = 3. Total sample size for each 
condition: 36 (for Jeg-3) and 24 (for each HTR8/SVneo clone). 
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3.2.17.2. The role of S100P antibody and ACA on trophoblast motility 
To investigate whether S100P can regulate trophoblast motility, while being localised on the cell 
surface and/or being soluble extracellularly, trophoblast cell lines Jeg-3 and HTR8/SVneo mock 
clone (non-S100P-expressing control SGB16) and clones 5 and 7 (S100P-expressing SGB217) 
were serum starved for 24 hours, before collection and resuspension in serum starvation medium 
and seeding in transwells with  either  0.4 µg/ml anti-S100P or 0.2% (v/v) goat serum, as negative 
control (S100P antibody was raised in goat). The cells were left to migrate for 24 hours, before 
fixing, staining and being counted. When compared with the non-treated control, S100P antibody 
reduced migration by 30% in Jeg-3 (P<0.0001) and by 20% in HTR8/SVneo clones 5 and 7 
(P<0.05), while the mock clone was not significantly affected (Figure 3.21). 
To test the involvement of plasminogen pathway in trophoblast migration, the same cells (Jeg-3 
and HTR8/SVneo clones) were treated with 10 mM plasminogen inhibitor ACA and their 
migration was measured as stated above. When compared with the non-treated control, ACA 
reduced migration by 30% in Jeg-3 (P<0.0001), the non-S100P-expressing HTR8/SVneo mock 
clone (P<0.01) and the S100P-expressing HTR8/SVneo clones 5 and 7 (P<0.01 and P<0.0001, 
respectively) (Figure 3.21). 
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Figure 3.21 The effect of S100P antibody and ACA on the migration of Jeg-3 and 
HTR8/SVneo clones Trophoblast-line Jeg-3, non-S100P-expressing HTR8/SVneo mock clone  
(SGB16), and S100P-expressing HTR8/SVneo clones 5 and 7 SGB217 were serum starved for 
24 hours and then were collected and seeded in transwells (while the lower wells contained 
complete medium as chemoattractant), while being treated with S100P antibody, ACA, or goat 
serum (as negative control), along with non-treated control, for 24 hours prior to fixation, staining 
and counting. The error bars represent SEM (* p<0.05, ** p<0.01, *** p<0.001, *** P<0.0001). 
N = 3 for each condition. Total sample size = 18 for each condition. 
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3.2.17.3. The role of S100P antibody and ACA on trophoblast invasion 
After showing the inhibitory effect of S100P antibody and ACA on migration in Jeg-3 and 
HTR8/SVneo trophoblast cells, we aimed to test their effect on trophoblast invasion. For this 
purpose, trophoblast cell lines Jeg-3 and HTR8/SVneo mock clone (non-S100P-expressing 
control SGB16) and clones 5 and 7 (S100P-expressing SGB217) were serum starved for 24 hours, 
before collection and resuspension in serum starvation medium and seeding in Matrigel-coated 
transwells with  either  0.4 µg/ml anti-S100P or 0.2% (v/v) goat serum, as negative control (S100P 
antibody was raised in goat). The cells were left to invade for 24 hours, before fixing, staining 
and being counted. When compared with the non-treated control, S100P antibody reduced 
invasion by 50% in jeg-3 (P<0.0001) and by 20% in S100P-expressing HTR8/SVneo clones 5 
and 7 (P<0.05 for clone 5 and P<0.01 for clone 7), while the mock clone was not significantly 
affected (Figure 3.22). 
To test the involvement of plasminogen pathway in trophoblast invasion, the same cells (Jeg-3 
and HTR8/SVneo clones) were treated with plasminogen inhibitor ACA and their invasiveness 
was measured as stated above. When compared with the non-treated control, ACA reduced 
invasion by 40% in Jeg-3 (P<0.0001), and by 30% in HTR8/SVneo clones 5 and 7 (P<0.01 for 
clone 5 and P<0.0001 for clone 7), while the mock clone was not significantly affected (Figure 
3.22). 
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Figure 3.22 The effect of S100P antibody and ACA on the invasion of Jeg-3 and 
HTR8/SVneo clones. Trophoblast-line Jeg-3, non-S100P-expressing HTR8/SVneo mock clone  
(SGB16), and S100P-expressing HTR8/SVneo clones 5 and 7 SGB217 were serum starved for 
24 hours and then were collected and seeded in Matrigel-coated transwells (while the lower wells 
contained complete medium as chemoattractant), while being treated with S100P antibody, ACA, 
or goat serum (as negative control), along with non-treated control, for 24 hours prior to fixation, 
staining and counting. The bars represent SEM (* p<0.05, ** p<0.01, *** p<0.001, *** 
P<0.0001). N = 3 for each condition. Total sample size = 6 for each condition. 
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3.2.17.4. Extracellular S100P inhibition does not affect the focal 
adhesions  
S100P knockdown in Jeg-3 cells has been shown increase the numbers and the size of FAs 
(Tabrizi et al. 2018). Here, we sought to test whether the extracellular S100P inhibition, which 
was shown to reduce trophoblast migration and invasion, also takes place with due to a similar 
effect on FA dynamics. For this aim, Jeg-3 cells were seeded on fibronectin-coated coverslips, 
while being treated with 0.4 µg/ml anti-S100P antibody, goat serum as negative control, or 
without any treatment as control, and were left to grow for 24 hours, before fixing and 
permeabilisation. They were then incubated with 1% (v/v) primary anti-paxillin antibody and 
0.5% (v/v) secondary antibody. The staining showed FAs formed on the cell surface, mostly along 
the actin bundles (Figure 3.23). There was no difference in the number or the relative size of the 
FAs (Table 3.2) in control and the anti-S100P treated cells (Figure 3.23). 
 
 
Table 3.2 The average number of focal adhesions per cell in Jeg-3 cells, represented as 
percentages 
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Figure 3.23 Extracellular S100P inhibition does not affect focal adhesions in Jeg-3 cells. Jeg-
3 cells were seeded on fibronectin-coated coverslips, while being treated with anti-S100P 
antibody, goat serum or without any treatments as control. The FAs were visualised with 
immunofluorescence staining on paxillin, a marker of FAs, along with rhodamine phalloidin to 
stain F-Actin and DAPI to visualise DNA. The images were taken at 63x magnification (panel 
A). Panel B shows the average FA count per cell in each condition. The error bars represent 
standard SEM. N = 3. Total sample size for each condition: 13 (control), 18 (goat serum) and 20 
(anti-S100P). 
 
 
 
 
134 
 
3.2.18. Primary EVT isolation 
S100P expression in human placenta was confirmed by IHC, showing strong expression of the 
protein in first trimester trophoblasts including in the EVTs. Endogenous S100P expression was 
also confirmed in our choriocarcinoma cell lines: Jeg-3 and BeWo, but to our surprise none of 
our EVT cell lines, HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5, showed detectable levels of 
the protein.  
To confirm S100P expression in human EVTs, even after they have been isolated from their 
surrounding placenta tissues, primary EVT cells were prepared from placenta samples with 12 
weeks of gestation age, collected by elective termination of pregnancy. The placenta samples 
were brought to the lab and the villi were scrapped off and digested with trypsin, and the EVTs 
were separated from the other cell populations, using lymphocyte separation medium. The 
isolated EVTs were cultured on fibronectin-coated plates and were left to attach overnight (Figure 
3.24). The cultured EVTs look slightly elongated, with some EVTs looking more elongated than 
others.  
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Figure 3.24 Primary EVT culture. Primary EVTs were isolated from first trimester placenta 
samples and cultured on fibronectin-coated coverslips. The image was taken at 40x magnification  
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3.2.18.1. HLA-G expression in primary EVTs 
To confirm that the isolated cells are EVTs, the cells were seeded on fibronectin-coated dishes. 
On the next day, the EVTs were collected and seeded on fibronectin-coated coverslips and were 
left to attach for 24 hours, prior to fixation and permeabilisation and eventually stained for HLA-
G (EVT marker), F-actin and DNA. HLA-G expression was detected in about 80% of the cells 
(Figure 3.25). 
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Figure 3.25 HLA-G staining in primary EVTs. Primary EVTs were fixed, permeabilised and 
stained for HLA-G, F-actin and DNA. Panel A shows HLA-G staining on EVTs at 63x 
magnification. Panel B shows the cells at 10x magnification. 
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3.2.18.2. S100P is expressed in primary EVTs 
To confirm S100P expression in primary EVTs, the cells were probed for the protein by western 
blot. For this purpose, the primary EVTs were collected a day after their isolation and the cell 
lysate was prepared in protease inhibitor cocktail and sonicated. The cell lysate was loaded on 
16% tricine gel along with HTR8/SVneo clone 7, as positive control, and the blot was probed for 
S100P and α-tubulin. Both HTR8/SVeo clone 7 and the EVTs showed S100P expression, with 
EVTs expressing 30 times higher than the clone (Figure 3.26). 
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Figure 3.26 S100P expression was detected in primary EVTs. EVT cells were collected, lysed 
and separated by 16% SDS-PAGE and S100P and α-tubulin were detected by western blot (A), 
and the expression levels of S100P were normalised to α-tubulin levels (B). N = 1. Sample size 
= 1 for each cell type. 
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3.3. Discussion  
Over-expression and ectopic expression of S100P protein has been well-documented in a variety 
of malignancies, making it a potential tumour marker (Parkkila et al. 2008). S100P has been 
shown to regulate cellular behaviours such as, proliferation (Arumugam et al. 2004; Guo et al. 
2014; Kim et al. 2009), motility (Austermann et al. 2008; Du et al. 2012; Hsu et al. 2015) and 
invasion (Mercado-Pimentel et al. 2015; Whiteman et al. 2007). In a more physiological context, 
its expression also has been associated with receptivity and decidualisation of the endometrium, 
an important contributor to successful embryo implantation (Zhang et al. 2012). However, there 
does not seem to be a clear definition for the role of S100P with regards to the organ of its origin, 
placenta, where it also shows the highest expression levels compared with any other organ 
(Becker et al. 1992; Emoto et al. 1992) and was therefore part of this section of the research 
project. 
Through our work, and making use of different human placental samples available such as 
embedded parafilm sections, we demonstrated that S100P protein expression is at its highest 
levels during the first trimester (Figure 3.2). At this stage, most trophoblast invasion and placenta 
development takes place (Caniggia et al. 2000), reducing gradually along the second and then the 
third trimesters, as demonstrated both by staining intensities of the DAB signal as well as 
following protein level determination with western blotting on samples from different stages of 
gestation (Tabrizi et al. 2018).  
In an effort to learn more about the localisation of the protein in cells, as well as further 
understanding about cell types that express it, in the context of placental samples, further analysis 
was carried out using IHC along with other trophoblast markers such as HLA-G and cytokeratin-
7 (Figure 3.3). Previously, S100P was shown to be localised within the trophoblast cytoplasm 
and nuclei (Zhu et al. 2015). Similarly, in this work, we detected the protein within the cytoplasm 
of the first trimester cyto- and syncytiotrophoblasts as well as EVTs, with occasional nuclear 
localisation in the last two (Figure 3.3). It has been suggested previously that trophoblasts might 
gain the ability to transport S100P into the nucleus, along their differentiation (Zhu et al. 2015). 
Interestingly, we also detected a strong signal in the apical membrane of the syncytiotrophoblasts 
and the EVTs, but not the cytotrophoblasts (Figure 3.3).  
Having demonstrated the high expression levels of S100P in trophoblast cells in human placental 
sections, we next wanted to establish cell culture models of trophoblast to further analyse the role 
of S100P. A number of cell lines were obtained (Jeg-3, BeWo, HTR8/SVneo, SW71, SGHPL-4 
and SGHPL-5) and the levels of S100P expression was determined using western blotting 
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techniques (Figure 3.4) and mRNA amplification (Tabrizi et al. 2018). We showed S100P 
expression in the choriocarcinoma cell lines Jeg-3 and BeWo. To our surprise, none of our first 
trimester trophoblast cell lines i.e. HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5, expressed 
detectable levels of the protein (Figure 3.4), whilst isolated primary first trimester EVTs 
demonstrated high levels of S100P expression (Figure 3.26). This brought us to the question of 
why none of our EVT cell lines showed detectable amounts of S100P. Changes in gene expression 
could happen at different stages and be due to protein stability, changes in mRNA levels, 
translation regulation or  epigenetic modifications (Arcondeguy et al. 2013), all of which are 
possible mechanisms that could be regulated in these cells to prevent/reduce S100P expression. 
For instance we know that trophoblast phenotypes are  associated with their microenvironment 
(Staun-Ram & Shalev 2005; Toro et al. 2014). As such, the presence of fibronectin in the 
trophoblast microenvironment has been shown to enhance their invasive capabilities, through 
interacting with integrin-α5 (Zeng et al. 2007). Matrigel, a gelatinous protein mixture secreted by 
mouse sarcoma cells, and mimics the ECM in the basement membrane, has been shown to have 
a similar effect on trophoblast invasiveness by modifying their protease expression pattern 
(Tarrade et al. 2002; Toro et al. 2014). Serum starvation has also been shown to affect the protein 
expression profile (both structural proteins and enzymes) in HTR8/SVneo cell lines (Novoa-
Herran et al. 2016) and hypoxia has been shown to affect trophoblast differentiation, metabolism 
and invasion (Esterman et al. 1997; Rosario, Konno & Soares 2008; Wakeland et al. 2017). It is 
unclear at this stage whether any of these regulations seen for other proteins may equally be linked 
to S100P expression. Further work was therefore carried out to establish whether cells incubated 
with different matrices would show changes in S100P expression. We showed that growing Jeg-
3 cells on fibronectin and gelatine increased S100P expression, while growing them on Matrigel 
reduced S100P expression. None of these changes induced S100P expression in non-S100P-
expressing EVT cell lines (Figure 3.5). However, we cannot rule out the possibility of S100P 
expression induction in these cells, provided that they are grown in an alternative 
microenvironment for a longer period of time. Likewise, a study reported the time-dependence 
of S100P expression levels in the presence of prostaglandin E2  (Chandramouli et al. 2010). 
Moreover, S100P expression been reported to be upregulated in response to stimulation with non-
steroidal anti-inflammatory drugs (Namba et al. 2009) and prostaglandin E₂ (Chandramouli et al. 
2010), but downregulated in response to androgen deprivation (Averboukh et al. 1996). 
Similar to other studies (L. Dong et al. 2016; Gong et al. 2017; C.-C. Wu et al. 2018; L. Wu et al. 
2018), this work showed that Jeg-3, BeWo and HTR8/SVneo cell lines are appropriate model 
systems to use to study trophoblast migration and invasion. We set about to see if modulating 
expression of S100P could be achieved in such cell systems. For the loss of function experiments, 
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siRNA delivery was found to be an effective method to knockdown S100P (Figure 3.6 and Figure 
3.16) with all cells tested and siRNA sequences used. It is interesting to note that although all 
siRNA sequences that we used were able to reduce S100P expression, there were cell-specific 
differences in their efficacies. SiRNA 4 and siRNA 6 were found to induce the highest level of 
expression downregulation in Jeg-3 and BeWo (Figure 3.6), while siRNA 4 and 5 were the most 
efficient in S100P-expressing HTR8/SVneo clones (Figure 3.16). SiRNA gene regulation was 
reported to be a reliable method at the concertation that was used in this study (5 nM), as its 
administration at <20 nM was reported to eliminate non-specific responses (Semizarov et al. 
2003). However, there is always a chance of unwanted siRNA interactions with proteins 
(aptameric effect), which could potentially reduce its availability and therefore result in silencing 
its effect (Brukner & Tremblay 2000). Therefore, varieties in the effectiveness of different siRNA 
sequences targeting different areas of the same gene might be a cell specific phenomenon, due to 
the complex nature of protein content in each cell type. 
We were able to significantly reduce both the motile (Figure 3.9) and invasive (Figure 3.10) 
properties of Jeg-3 and BeWo choriocarcinoma cell lines, by S100P knockdown, using siRNA 
delivery. Whilst this is the first time such an observation has been made in the context of 
trophoblast cells,  short-term (siRNA delivery) (Arumugam et al. 2005; Liu et al. 2017) and long-
term (lentiviral vector–mediated RNA interference) (Jiang et al. 2011) post-transcriptional S100P 
gene silencing methods have been reported to induce similar effects on tumour cell motility and 
invasion.  
Through gain of function experiments, we were successful in obtaining permanent transfection 
of HTR8/SVneo cells with a S100P expressing plasmid, and interestingly showed that S100P 
expression at levels similar to S100P levels in Jeg-3 cells correlated with an increase in the motile 
(Figure 1.12) and invasive (Figure 3.13) features of the cells. S100P expression levels lower than 
jeg-3 did not affect invasion and migration. Higher S100P expression levels than Jeg-3 did not 
affect migration but significantly reduced invasion in HTR8/SVneo clones. 
In an effort to further characterise the possible molecular pathways leading to such changes in 
migration, we investigated possible changes in cell adhesion to the ECM, through FA dynamics. 
FAs are multi-protein complexes that are recruited the cytoplasmic part of the clustered integrins 
(attaching the cell to the ECM) (Petit & Thiery 2000). FA-associated adaptor proteins such as 
paxillin and vinculin, link the protein complex to the actin cytoskeleton and provide the cell with 
the tension required for traction and morphological alterations necessary for cell movement, while 
signalling protein, recruited to FAs, such as focal adhesion kinase, transmit the signals from the 
ECM into the cell and regulate pathways such as cell migration and proliferation (Nagano et al. 
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2012). In general, during direction cell migration, rapid formation and turnover of the FAs, seen 
at the leading edge of the cells, pulls the cell body forward, while their rapid turnover at the rear 
end makes the detachment form the ECM possible. In contrast, stationary cells, which are strongly 
attached to the ECM, show a higher ratio of FA formation relative toturnover (Nagano et al. 
2012).  
We showed that the increase in HTR8/SVneo migration, upon S100P expression, was linked with 
a decrease in the number and the relative size of paxillin-containing, actin-terminating FAs 
(Figure 3.14). This could indicate the rapid turnover and formation of the FAs in the S100P-
expressing clones, while the larger and more mature FAs seen in non-S100P expressing control 
clone indicates their relative stationary state. This goes in line with the previously reported 
S100Pknockdown-induced increase in the size and number of FAs in trophoblasts (Tabrizi 2014) 
and cancer cells (Du et al. 2012).  
The S100P-induced increase in the migration and invasiveness of HTR8/SVneo clones was 
reversible upon S100P knockdown (Figure 3.18) and brought migration and invasion levels of 
the S100P-expressing HTR8/SVneo clones down to similar levels as the mock clone, confirming 
the role of S100P, alone, in the induction of such phenotypical changes, rather than another 
mutation that might have taken place during cloning. 
To rule out the possibility of increased cell proliferation affecting our migration  and invasion 
assays, cell viability assays were performed on HTR8/SVneo clones with and without S100P 
expression (Figure 3.15) and revealed the ineffectiveness of S100P expression on the viability of 
trophoblasts. Similarly, we showed the ineffectiveness of S100P knockdown on the viability of 
trophoblasts with both endogenous (Tabrizi et al. 2018) and exogenous S100P expression (Figure 
3.17). In cancer cells however, while many reports have shown the ineffectiveness of S100P 
expression on cell viability (Barry et al. 2013; Du et al. 2012; Hsu et al. 2015), others have 
indicated otherwise (Arumugam et al. 2004, 2005; Guo et al. 2014; Liu et al. 2017). 
Other than affecting trophoblast migration  and invasion, through regression analysis, we 
demonstrated that there is a strong correlation between S100P expression levels and trophoblast 
migration  and trophoblast invasion (Figure 3.19). The correlation was significant for migration 
and invasion in Jeg-3, and invasion in HTR8/SVneo clones. This new finding, which is to our 
knowledge, the first in its kind, not only in trophoblast cell lines but indeed in any other cells, 
highlights a proportionality between S100P levels and motile/invasive features.  
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Having demonstrated that S100P is an overall regulator of migration  and invasion in Jeg-3, 
BeWo and HTR8/SVneo cells, we next wanted to understand more about the mechanisms 
involved and how this protein regulates these behaviours. As stated earlier, a high percentage of 
S100P expression was detected within the apical membrane of syncytiotrophoblasts and the EVTs  
(Figure 3.3). However, there has been no direct evidence of S100P expression on the trophoblast 
cell surface. To this end, Jeg-3 cells with endogenous and HTR8/SVneo clones 5 and 7 with 
exogenous S100P expression were treated with S100P antibody. This resulted in a significant 
reduction in their migration  (Figure 3.21) and invasion (Figure 3.22), while no effect was seen 
on the motility (Figure 3.21) and invasion (Figure 3.22) of the control non-S100P-expressing 
HTR8/SVneo clone. This observation validates the importance of extracellularly-localised (either 
secretory or membrane-bound) S100P in regulating trophoblast motility and invasion, which is 
in line with the reported possibility of the extracellular localisation of S100P in cancer 
(Arumugam et al. 2004; Mercado-Pimentel et al. 2015). Furthermore, we equally showed that 
addition of ACA, which is an analogue of the amino acid lysine and an inhibitor of the 
plasmin/plasminogen cascade, equally resulted in a similar reduction in both trophoblast motility 
(Figure 3.21) and invasion (Figure 3.22) in S100P-expressing trophoblast cell lines (Jeg-3 and 
HTR8/SVneo clones 5 and 7), similar to the reduction levels seen with S100P antibody treatment. 
ACA also reduced the motility of our non-S100P expressing mock clone (Figure 3.21), while 
showed no effect on its invasion (Figure 3.22). The ACA-induced reduction in the motility of 
both S100P-expressing and non-S100P expressing HTR8/SVneo cells indicates that the 
plasmin/plasminogen cascade regulates trophoblast motility, at least partially, in a S100P-
indpendant manner, while the effectiveness of the drug on the invasion of S100P-expressing cells 
along with its ineffectiveness on non-S100P-expressing cell invasion, confirms the importance 
S100P in plasmin-induced trophoblast invasion. 
The interaction of plasmin with integrin α5β3 (vitronectin receptor) has been shown to promote 
stress fibre formation and migration (Tarui et al. 2002). Although no reports have shown the 
interaction between S100 proteins and these two integrin subunits so far, S100P has been shown 
to bind to integrin α7 (Hsu et al. 2015). Plasmin has been shown to promote invasion by degrading 
ECM components, directly and indirectly by activating the MMPs (Lijnen et al. 1998) and 
urokinase-type plasminogen activator (uPA) has been shown to regulate trophoblast motility and 
invasion (Liu et al. 2015). Annexin II, which induces plasminogen activation, binds to S100 
proteins, including S100P (Hajjar & Krishnan 1999; Liu, Myrvang & Dekker 2015). The S100P 
amino acid sequence includes a lysine residue at its C-terminus, which has the potential to bind 
to the lysine-binding site of the plasmin. Based on the mentioned reports, we propose a novel 
mechanism for S100P-induced invasiveness and possibility motility in trophoblasts, which 
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includes a potential interaction between surface S100P and plasmin/PAs. Indeed, S100P, similar 
to other S100 proteins (S100A4 and S100A1) was shown to induce invasion via activating the 
above stated pathway through interacting with plasminogen and tPA as well as stimulating tPA 
in cancer cells (Clarke et al. 2017; Kwon et al. 2005; Semov et al. 2005). 
Extracellular S100P, however, might not be regulating trophoblast motility and invasion via the 
same pathway as the total pool. Unlike the effect of changing expression in HTR8/SVneo, BeWo 
and Jeg-3 (Tabrizi et al. 2018), here S100P antibody treatment showed no effect on either the 
relative size or the number of FAs in Jeg-3 cells. Moreover, despite showing the role of 
extracellular and/or membrane-bound S100P in trophoblast motility and invasion, we still are not 
sure how this transport to the outside takes place. Submitting the S100P amino acid sequence 
(FASTA format) to the Phobius, a transmembrane topology and signal peptide predictor at 
http://phobius.sbc.su.se/ showed zero chance of the existence of a signal peptide in the protein. 
This however, does not rule out the possibility of S100P secretion by non-classical secretion 
pathways, which do not involve ER-to-Golgi transport, such as transport via membrane pores or 
ABC transporters, or the ability of transmembrane proteins to reach the membrane via by-passing 
the Golgi (Kim, Gee & Lee 2018).  
In conclusion, we report that due to its expression pattern in placental villi throughout the 
gestation period and its role in trophoblast motility and invasion, S100P might potentially play 
an important role in early placenta development and implantation. 
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Chapter 4.  
Ezrin regulates trophoblast motility 
and invasion 
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4.1. Introduction 
Ezrin is a member of the ERM protein family, mainly located at cellular protrusions such as 
microvilli and under the membrane. Ezrin links the plasma membrane to the cytoskeleton, and 
regulates cell morphology, polarity, cytokinesis and motility (Fehon, McClatchey & Bretscher 
2010; Tsukita, Yonemura & Tsukita 1997). The majority of the work done on ezrin relates to its 
function in pathological conditions; consequently, ezrin has been implicated in various human 
cancers as its over-expression in malignant melanoma and sarcomas has been linked with 
metastasis and poor survival (Ilmonen et al. 2005; Khanna et al. 2004) and its under-expression 
has been linked with poor survival in patients with ovarian cancer (Moilanen et al. 2003). In the 
physiological context, ezrin is highly expressed in the immune system (Pore & Gupta 2015), 
gastrointestinal (Casaletto et al. 2011) and urinary tract (Andersson et al. 2014). During the early 
stages of human embryonic and foetal development, ezrin shows tissue and time specificity in its 
expression: it is first detected in the neural tube at 4 weeks of gestation, and it is highly expressed 
in the nerve cells of the neural tube. In later stages of gestation, it is undetectable in the derivative 
tissues such as cerebral tissue as well as in adult nervous tissue (Woods, Perez-Garcia & 
Hemberger 2018). In the endometrium, ezrin expression has been reported in the glandular cells 
and microvilli of non-pregnant endometrium in both human and cow, mostly localised at apical 
cell poles and intercellular borders of the epithelium, and at lower levels in the epithelial cytosol 
as well as the stroma (Haeger et al. 2015; Tan et al. 2012), reaching at its highest levels during 
the secretary phase of the endometrium (around day 21 of a 28-day cycle, where it reaches the 
maximum thickness) (Tan et al. 2012). In bovine gestation, there is a reduction in endometrial 
ezrin in the early stages of the pregnancy, with minimal levels at around day 20 of the of the total 
283 gestation days and a complete depletion of cytosol and stromal ezrin, followed by a 
consequent increase back to normal levels after gestational day 35, when implantation occurs 
(Haeger et al. 2015). 
In human placenta, ezrin is highly concentrated at the plasma membrane of the microvilli of 
epithelial cells, especially in syncytiotrophoblasts (Berryman, Franck & Bretscher 1993; Pidoux 
et al. 2014). It has been suggested that the protein plays a role in the fusion of cytotrophoblasts 
into syncytiotrophoblast as well as formation of gap junctions (Firth, Farr & Bauman 1980; 
Pidoux et al. 2014). In rat placenta, ezrin is localized at the apical membrane of the trophoblasts 
and its expression increases during pregnancy, peaking at days 14-18 of the total of 21 gestational 
days, and then gradually decreases afterwards, thus correlating with the morphogenesis of the 
placental villi (Higuchi et al. 2010). In mouse, ezrin has been found in the trophoblasts of 
activated blastocysts at higher intensity in implantation-competent than in dormant blastocysts. 
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In dormant blastocysts the metabolism is naturally reduced, awaiting stimuli from the uterus for 
further development and subsequent implantation (Matsumoto et al. 2004). 
The true functions of ezrin in cellular behaviours are not clear, but its ability to interact with the 
membrane and the actin cytoskeleton have linked it to cellular motility. Ezrin has been found to 
localise at the leading edge of cells where it controls actin polymerisation (Arpin et al. 2011). 
Ezrin may also play a role in invasion, through regulating MMP expression (Jiang, Wang & Chen 
2014; Tang et al. 2019), and therefore can promote metastasis (Hunter 2004). The mechanism by 
which ezrin regulates cellular motility and invasion remains unclear and the possible functions of 
the protein in regulating these cellular processes in a non-pathological context are not known. As 
before, we set about to determine whether ezrin, a known metastasis inducing protein, has any 
roles in trophoblast motility and invasion, two of the main processes involved in embryo 
implantation, based on evidence that it is expressed during the early stages of placental formation 
(Berryman, Franck & Bretscher 1993; Pidoux et al. 2014). 
Aim 
To study the role of ezrin in trophoblast motility and invasion. 
Objectives 
• Establish ezrin expression in human placental samples at different stages of gestation 
• Establish ezrin expression in trophoblast cell lines 
• To regulate ezrin expression and activity by: 
1) Testing whether modulating ezrin expression affects trophoblast motility and 
invasion 
2) Testing whether ezrin inhibition affects trophoblast motility and invasion 
• To decipher the molecular mechanisms for the enhancement of motility and invasion by 
ezrin in trophoblasts 
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4.2. Results 
4.2.1. Immunohistochemical staining optimisation 
Having shown, in the previous chapter, that S100P expression is important for trophoblast 
motility/invasion and that its levels can be clearly seen to decrease in human placenta during 
gestation, we aimed to follow a similar approach in relation to ezrin, another known metastatic-
associated protein with no real physiological functions and establish its expression in human 
placenta.  We sought to first gain more information about both the localisation and expression 
levels of ezrin in samples of first, second and third trimester human placental villi.  
Optimisation for the use of the primary antibody against ezrin was first carried out, to find the 
lowest concentration of anti-ezrin antibody. For this aim, wax-embedded human placenta sections 
from first trimester human placenta villi were prepared and incubation with 10 µg/ml and 5 µg/ml 
anti-ezrin overnight, along with mouse IgG as negative control, followed by secondary antibody 
incubation and development using avidin-biotin complex and DAB chromogen. The sections 
were counter stained with haematoxylin before viewing. 
Both concentrations showed efficient staining for ezrin, which was localised within the 
trophoblasts, the cells that surround the villi, being highly detectable in the outer membrane of 
the syncytiotrophoblasts and to a lesser extent within the cytoplasm of cyto- and 
syncytiotrophoblasts, with weak staining detectable in some parts of the stroma, located at the 
core of the villi (Figure 4.1). 
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Figure 4.1 Primary ezrin antibody concentration optimisation for IHC. Wax-embedded 
human first trimester placental villi sections were prepared and incubated with two concentrations 
of primary anti-ezrin, before being incubated with secondary antibody, and finally staining using 
avidin-biotin complex and DAB chromogen and counter-staining using haematoxylin. 
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4.2.2. Placental ezrin expression decreases gradually during 
gestation 
Having optimised staining for ezrin, we then wanted to determine how ezrin levels were affected 
during gestation as well as its localisation during placental development. To this end, three 
samples from first trimester, three from second trimester and four from third trimester placenta 
samples were stained for ezrin as detailed earlier. Images were analysed by densitometry using 
Fiji-ImageJ software. The staining showed that during the first trimester, ezrin expression can be 
detected in the cytoplasm of cytotrophoblasts, very intensely in the apical membrane of 
syncytiotrophoblasts, and to a lesser extent in the cytoplasm of syncytiotrophoblasts (Figure 
4.2B). The expression of ezrin in the first and the second trimesters was not significantly different 
(P>0.05). Ezrin expression during the third trimester, however, was 50 lower than the first and 
second trimesters (P<0.001). (Figure 4.2 A and C). 
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Figure 4.2 Ezrin expression in human placenta is the highest during the first and second 
trimesters of gestation. Wax-embedded human first trimester placental villi sections were 
prepared and incubated with anti-ezrin antibody, before being incubated with secondary antibody, 
and finally staining using avidin-biotin complex and DAB chromogen and counter-staining using 
haematoxylin. Panel A shows representative images of human placental sections form first and 
second and third trimesters, panel B shows a magnified image of one of the first trimester placenta 
sections, and panel C shows the average ezrin expression (calculated by densitometry) in different 
samples. The error bars represent SD. (*** P<0.001). N = 2. Total sample size for each trimester: 
6 (1st), 6 (2nd) and 8 (3rd). 
4.2.3. Ezrin is expressed in human trophoblasts and EVTs 
Having shown that expression of ezrin in placenta is highest in the earlier stages of placental 
development, we wanted to learn more about its localisation and where it is expressed in first 
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trimester samples using markers for trophoblasts (cytokeratin 7) and more specifically to identify 
EVTs (HLA-G). Serial sections of wax-embedded first trimester human placental villi were 
prepared and incubation with the following primary antibodies: anti-ezrin, anti-S100P, anti-
cytokeratin 7, anti-HLA-G or mouse and rabbit IgGs (as negative control), prior to secondary 
antibody incubation and development using avidin-biotin complex and DAB chromogen. The 
sections were counter-stained with haematoxylin. Following staining, ezrin was shown to 
colocalise with cytokeratin-7 as well as S100P in cyto- and syncytiotrophoblasts as well as EVTs. 
It colocalised with HLA-G in the cytoplasm and the apical membrane of a sub-population of the 
trophoblasts (EVTs) located in trophoblastic columns (Figure 4.3). 
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Figure 4.3 Ezrin expression in human trophoblasts and EVTs. Serial sections of wax-
embedded human first trimester placental villi were prepared and incubated with primary anti-
ezrin, anti-cytokeratin 7, anti-HLA-G, and anti-S100P, as well as mouse and rabbit IgGs as 
negative controls, before being incubated with secondary antibodies, and finally staining using 
avidin-biotin complex and DAB chromogen and counters-staining using haematoxylin. The 
images were taken at 20x magnification.  
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4.2.4. Ezrin is expressed in human trophoblast cell lines 
Having demonstrated ezrin expression in human placenta and more specifically in trophoblast 
and EVTs, we aimed to investigate whether ezrin could also be detected in trophoblast cell lines. 
We sought to investigate the levels of ezrin expression in trophoblast cell lines, i.e. Jeg-3 and 
BeWo, as well as a series of human first trimester EVT cell lines SW71, HTR8/SVneo, SGHPL-
4 and SGHPL-5. Cell lysates were loaded on 10% polyacrylamide gel. Ezrin, phospho-ezrin (the 
active form of ezrin) and α-tubulin bands were detected by western blot and ezrin signals were 
normalised to the housekeeping gene expression. 
Ezrin was found to be highly expressed in the human trophoblast cell lines: Jeg-3, BeWo, 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5. Protein levels were seen to be relatively 
harmonious across all cells, with Jeg-3 cells expressing 50% higher levels (P >0.05) of the protein 
compared with the others (Figure 4.4). Phospho-ezrin showed a different expression pattern 
amongst the cell lines: BeWo, Jeg-3 and SGHPL-4 expressed relatively similar levels of phospho-
ezrin expression, while SW71 and SGHPL-4 showed about 50-70% lower levels of expression 
(P >0.05) n, and HTR8/SVneo showed the highest expression level (P >0.05) compared to other 
cells (Figure 4.4). 
156 
 
 
Figure 4.4 Ezrin and phospho-ezrin expression in human trophoblast cell lines. Human 
trophoblast cell lines BeWo, HTR8/SVneo, Jeg-3, SW71, SGHPL-4 and SGHPL-5, were 
collected in protease inhibitor cocktail and sonicated, prior to being separated by 10% SDS-
PAGE, prior to protein transfer and western blot against ezrin, phospho-ezrin and α-tubulin. 
Expression levels were quantified by Image Studio Lite software and ezrin and phospho-ezrin 
157 
 
expression levels were normalised to the housekeeping gene expression. Panel A shows the 
western blot bands for ezrin, phospho-ezrin and α-tubulin, and panel B shows the densitometry. 
The error bars represent SD. N = 2, therefore the differences are non-significant. Total sample 
size = 2 for each cell line. 
 
4.2.5. Ezrin localisation in trophoblast cell lines   
Having shown that ezrin is expressed in different trophoblast cell lines, we wanted to learn more 
about its cellular localisation.  To do this, trophoblast cells (HTR8/SVneo, SW71, SGHPL-4, 
SGHPL-5, Jeg-3 and BeWo) were seeded on to fibronectin-coated glass coverslips and left to 
attach for 24 hours. The coverslips were then fixed before permeabilisation, blocking and 
incubation with primary anti-ezrin antibody followed by secondary FITC-conjugated antibody 
and rhodamine phalloidin, prior to mounting and viewing. In the EVT cell lines HTR8/SVneo, 
SW71, SGHPL-5 and choriocarcinoma cell line BeWo, ezrin was highly detectable within the 
membrane protrusions, colocalising with actin at the leading edge of the cells, and in the 
cytoplasm to a lower extent, while showing a different pattern of localisation in EVT cell lines 
SGHPL-4 and choriocarcinoma cell lines Jeg-3, localising within the cytoplasm only. 
HTR8/SVneo and SW71 also showed nuclear localisation of the protein (Figure 4.5). 
 
 
158 
 
 
Figure 4.5 Ezrin expression and localisation in trophoblast cell lines. EVT cell lines 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5 along with choriocarcinoma cell lines Jeg-3 and 
BeWo were seeded on fibronectin-coated coverslips. The cells were stained for ezrin, F-actin and 
DNA by immunofluorescence. The images were taken at 63x magnification.  
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4.2.6. Ezrin expression knockdown 
Having confirmed the expression of ezrin in EVT and choriocarcinoma cells-lines, and in order 
to decipher the roles that might be associated with the expression of this protein in trophoblast 
cell lines, we aimed to manipulate its expression to further study some of the cellular changes 
induced by such regulation. For this purpose, HTR8/SVneo and SW71 EVT cell lines, which 
showed the highest amount of ezrin within their protrusions as well as Jeg-3 choriocarcinoma cell 
lines, which had been found to express the highest amount of ezrin compared to the rest of our 
trophoblast cell lines were chosen for the experiment, as follows. 
EVT cell lines HTR8/SVneo and SW71 as well as choriocarcinoma cell lines were treated with 
a panel of four different siRNA (5, 7, 8 and 9) targeting ezrin, along with a non-specific sequence 
of siRNA as negative control, for 72 hours. Then, the cells were collected and loaded on 10% 
polyacrylamide gel and was probed for ezrin and α-tubulin by western blot. Ezrin and α-tubulin 
expression in each condition were calculated by densitometry, ezrin expression was normalised 
to α-tubulin (housekeeping gene) expression.  
The treatment of the different cells with ezrin siRNA was found to reduce its expression in all 
cell lines tested. In HTR8/SVneo, siRNA 7 and 9 were the most effective and reduced ezrin 
expression significantly by 60% and 70%, respectively (P<0.01) compared with control, while 
siRNA 5 and 8 did not significantly affect ezrin expression. In SW71, once again siRNA 7 and 9 
were the most effective and reduced ezrin expression by 70% and 80%, respectively (P<0.001), 
and siRNA 8 by did so by 50% (P<0.01) compared with control, while siRNA 5 did not 
significantly affect ezrin expression. In Jeg-3, siRNA 7 and 8 brought ezrin expression down to 
10% and siRNA 9 reduced the expression of the protein by 50% compared with the control, 
however, none of these reductions were statistically significant. Ezrin expression levels in 
negative control samples remained similar to control samples in all three cell lines (Figure 4.6).  
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Figure 4.6 Ezrin siRNA treatment knocks down ezrin expression in trophoblast cell lines. 
HTR8/SVneo, SW71 and Jeg-3 cells, were treated with ezrin siRNA 5, 7, 8 and 9, along with 
mock treatment. The treated cells along with non-treated control cells were left to grow for 3 days 
prior to collection, lysing and sonication. The proteins were separated by 10% SDS-PAGE and 
ezrin and α-tubulin bands were detected by western blot. Expression levels were quantified by 
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Image Studio Lite software and ezrin expression levels were normalised to the housekeeping gene 
expression. Panels A1, B1 and C1 show ezrin and α-tubulin bands in HTR8/SVneo, SW71 and 
Jeg-3 cells, respectively, while panels A2, B2 and C2 show the densitometry in the mentioned 
cells in the same order. The error bars represent SD. (**P<0.01, ***P<0.001, ***P<0.0001). N 
= 3 for each cell line. Total sample size = 3 for each condition. 
 
4.2.7. Ezrin knockdown does not affect trophoblast viability  
Ezrin has been shown to promote proliferation in cancer (Jeong et al. 2019; Kong et al. 2016) and 
fibroblast-like cells (Huang et al. 2011). Having successfully knocked down ezrin expression in 
EVT cell lines HTR8/SVneo and SW71, we sought to find out whether this can affect the viability 
of these cells over time. To achieve this, HTR8/SVneo and SW71 cells were treated with ezrin 
siRNA 7 and 9, which were shown to be the most effective in reducing ezrin expression in these 
cells (Figure 4.6), as well as a non-specific siRNA sequence as negative control. 72 hours 
following the treatment, the viability of the cells as well as their metabolic activity were studied 
by trypan blue exclusion and MTT assays, respectively. Trypan blue assay indicated that 
HTR8/SVneo cells increased in cell number by 100% over the second 24 hours following the 
seeding and then by 50% over the third 24 hours, and SW71 increased by 50% over the second 
24 hours following the seeding and then by 50% over the third 24 hours in all four conditions. 
The MTT assay, showed that the HTR8/SVneo and SW71 increased in cell number by 50% over 
the second as well as the third 24 hours following the seeding, in all four conditions.  Ezrin 
knockdown, using either siRNA 7 or 9, did now show any significant effect on the growth rate of 
the cells, as their viability or the metabolic activity seemed to have followed a similar pattern as 
the control and the negative control cells (Figure 4.7).  
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Figure 4.7 Trophoblast viability with ezrin knockdown. HTR8/SVneo and SW71 cells were 
treated with ezrin siRNA 7 and 9, along with a non-specific siRNA sequence, as negative control, 
for 72 hours. The cells were then collected and reseeded and their viability and metabolic activity 
(MTT assay) was tested over the next 72 hours. N = 3 for each condition. Total sample size for 
each condition: 60 (viability) and 6 (for MTT). 
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4.2.8. Ezrin knockdown reduces trophoblast motility 
Ezrin over-expression has been reported to lead to increased cell motility and invasion in many 
tumours (Bruce et al. 2007; Geiger et al. 2000; Huang et al. 2010; Khanna et al. 2004; Yu et al. 
2004; Zhou et al. 2014). However, it is not clear whether ezrin plays a similar role in trophoblast 
cells or not. To investigate this, HTR8/SVneo and SW71 EVT and Jeg-3 choriocarcinoma cell 
lines were treated with ezrin siRNA 7 and 9, which were shown to be the most effective in 
reducing ezrin expression (Figure 4.6). The cells were collected after 72 hours and were seeded 
in transwells. After 24 hours of incubation, the migrated cells were fixed and stained using Quick 
Diff staining kit, the cells were counted on random fields at 20x magnification and the average 
number of migrated treated cells were compared with non-treated cells. While negative control 
cells showed similar migratory capabilities to control cells in all three cell lines, knocking down 
ezrin significantly reduced motility in HTR8/SVneo EVT cell lines by 20%, with siRNA 7 
(P<0.05) and 50% with siRNA 9 (P<0.0001) and in SW71 by 40% with siRNA 7 (P<0.0001) and 
50%  with siRNA 9 (P<0.0001) (Figure 4.8). In Jeg-3 cells however, the reduction was not 
significant (Figure 4.8). 
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Figure 4.8 The effect of ezrin knockdown on trophoblast migration. HTR8/SVneo, SW71 
and Jeg-3 cells were seeded in 24 well plates and treated with ezrin siRNA 5,7, 8 and 9, along 
with mock treatment and not treated control. They were left to grow for 48 hours before the 
medium was replaced with serum starvation medium. After another 24 hours of incubation, the 
cells were collected and were seeded in transwells. After 24 hours of incubation, the transwells 
were fixed and stained. The cells were counted in fields of 20x magnification. Panels A1, B1 and 
C1 show average cell count percentage compared with control in HTR8/SVneo, SW71 and Jeg-
3 cells, respectively and the error bars represent SEM (* P<0.05, **** p<0.0001). Panels A2, B2 
and C2 show representative fields of fixed and stained transwells for HTR8/SVneo, SW71 and 
Jeg-3 cells, respectively. N = 3 for each cell line. Total sample size = 18 for each condition. 
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4.2.9. Ezrin knockdown reduces trophoblast invasion 
Ezrin has been specifically linked with tumour cell invasion by enhancing MMP expression 
(Jiang, Wang & Chen 2014; Tang et al. 2019). Having shown the role of ezrin in trophoblast 
motility we next wanted to evaluate a possible role of ezrin in trophoblast invasion. HTR8/SVneo, 
SW71 (EVT) and Jeg-3 (choriocarcinoma) cell lines were treated with ezrin siRNA 7 and 9, 
which were shown to be the most effective in reducing ezrin expression (Figure 4.6), along with 
a non-specific sequence of siRNA as negative control. The cells were then seeded in transwells, 
coated with Matrigel. The cells were left to invade for 24 hours, before being fixed and stained. 
The cells were counted on random fields at 20x magnification and the average number of invaded 
treated cells were compared with non-treated control cells. Similar to motility, the negative 
control cells showed similar invasiveness to the control cells, but knocking down ezrin 
significantly reduced invasion in HTR8/SVneo EVT cell lines by 20%  with siRNA 7 (P<0.05) 
and 50%  with siRNA 9 (P<0.0001) compared with control, and in SW71 by 40% with siRNA 7 
(P<0.01) and 50% with siRNA 9 (P<0.001), while invasion in Jeg-3 choriocarcinoma cells was 
not reduced significantly upon ezrin knockdown (Figure 4.9).  
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Figure 4.9 The effect of ezrin knockdown on trophoblast invasion. HTR8/SVneo, SW71 and 
Jeg-3 cells were seeded in 24 well plates and treated with ezrin siRNA 5,7, 8 and 9, along with 
mock treatment and not treated control. They were left to grow for 48 hours before the medium 
was replaced with serum starvation medium. After another 24 hours of incubation, the cells were 
collected and were seeded in Matrigel-coated transwells. After 24 hours of incubation, the 
transwells were fixed and stained. The cells were counted in fields of 20x magnification. Graphs 
A1, B1 and C1 show average cell count percentage compared with control in HTR8/SVneo, 
SW71 and Jeg-3 cells, respectively and the error bars represent SEM (* P<0.05, ** P<P0.01, *** 
p<0.0001). Panels A2, B2 and C2 show representative fields of fixed and stained transwells for 
HTR8/SVneo, SW71 and Jeg-3 cells, respectively. N = 3 for each cell line. Total sample size = 
6 for each condition. 
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4.2.10. Regression analysis 
Having shown the effect of ezrin down regulation on trophoblast cell line motility and invasion, 
we next aimed to see whether there is a meaningful correlation between ezrin expression and 
migration/invasion in these cells, by regression analysis. To do this, ezrin expression levels in 
trophoblast cells HTR8/SVneo and SW71, with two sequences of ezrin siRNA (7 and 9), mock 
negative control, along with non-treated control (Figure 4.6) were correlated with their migration 
(Figure 4.8) and invasion (Figure 4.9). Pearson correlation coefficient, r was calculated, and 
Student's t-distribution was used to test the significance of the correlation. Regression analysis 
showed a positive correlation (r>0) between ezrin expression and cell migration/invasion for both 
trophoblast cells: ezrin expression and HTR8/SVneo migration r = 0.86 and invasion r = 0.86, 
ezrin expression and SW71 migration r = 0.94 and invasion r = 0.96. The correlation however, 
was only significant for SW71 motility (P<0.05) and invasion (P<0.01) (Figure 4.10).  
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Figure 4.10 Positive correlation between trophoblast migration/invasion and ezrin 
expression. Average ezrin expression levels in trophoblast cell lines HTR8/SVneo and SW71 
were correlated with motility and invasion and Pearson correlation coefficient, r, was calculated. 
Student's t-distribution was used to calculate the P-values. 
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4.2.11. Ezrin knockdown does not affect FAs 
Ezrin depletion in breast cancer cells has been shown to reduce the number and size of FAs as 
well as their invasion (Hoskin et al. 2015). Here, we hypothesised that the motility and invasion 
of trophoblast cells might also be regulated by ezrin through a similar mechanism. For this 
purpose, HTR8/SVneo and SW71 cells were treated with ezrin siRNA 7 and 9, which were shown 
to reduce both motility and invasion in these two cell lines along with a non-specific siRNA 
sequence as negative control. 72 hours after knocking down ezrin, the cells were seeded on 
fibronectin-coated coverslips and were left to attach for 24 hours. Following preparation, the 
coverslips were incubated with primary anti-paxillin (a component of the FA complex) antibody 
followed by secondary FITC-conjugated antibody and rhodamine phalloidin, before mounting 
and viewing. Control samples do not show a significant difference in the number (Table 4.1) or 
the relative size of FAs when compared with negative control and ezrin siRNA treated samples 
in either HTR8/SVneo or SW71 cells (Figure 4.11).  
 
Table 4.1 Average FA count per cell in HTR8/SVneo and SW71 cells. HTR8/SVneo and 
SW71 trophoblast cell lines were treated with ezrin siRNA 7 and 9 for 48 hours before collection. 
The cells were then seeded on fibronectin-coated coverslips, were left to attach for 24 hours, and 
finally, were stained for paxillin. The FAs were counted on all cells in each image. 
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Figure 4.11 Knocking down ezrin does not affect the FAs. HTR8/SVneo and SW71 
trophoblast cell lines were treated with ezrin siRNA 7 and 9 for 48 hours before collection and 
being seeded on fibronectin-coated coverslips and were left to attach for 24 hours. The cells were 
stained for paxillin, F-actin and DNA by immunofluorescence. The images were taken with 63x 
magnification. Panels A1 (previous page) and B1 show the staining on HTR8 and 9SW71 cells, 
respectively. Panels B2 (previous page) and B2 show average FA count (in percentage) in treated 
cells compared with the non-treated controls in HTR8/SVneo and SW71, respectively. The error 
bars represent SEM. Panel A3 on the first part of the image shows a zoomed-in part of control 
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HTR8/SVneo cells. N = 1 for each cell line. Total sample size for each condition: 10 
(HTR8/SVneo) and 20 (SW71). 
 
4.2.12. Ezrin phosphorylation inhibition  
Like other ERM protein family members, ezrin requires phosphorylation of a conserved threonine 
residue (Thr567), to switch to its open and active conformation (Fehon, McClatchey & Bretscher 
2010). Changes in ezrin phosphorylation have been reported to result in changes its sub-cellular 
localisation (Zhou et al. 2005). To assess the role of ezrin phosphorylation in trophoblasts, we 
aimed to measure the amount of phospho-ezrin as well as its localisation upon treatment with 
ezrin inhibitor, NSC668394, a chemical compound, which binds to ezrin (Kd = 12.59 µM), 
preventing its phosphorylation at Thr567 (Bulut et al. 2012). 
4.2.12.1. Ezrin inhibitor reduces phospho-ezrin in HTR8/SVneo  
To evaluate phospho-ezrin levels in ezrin inhibited trophoblasts, 100,000 HTR8/SVneo and 
50,000 SW71 cells were seeded in 24-well plates, while being treated with 5µM ezrin inhibitor 
NSC668394 (dissolved in DMSO), or with 0.1% DMSO (same volume as NSC668394), as 
negative control for 24 hours. After treatment, HTR8/SVneo and SW71 EVT cells were collected 
and loaded on 10% SDS-PAGE. Phospho-ezrin and α-tubulin bands were detected by western 
blot. The expression levels were measured by densitometry and phospho-ezrin expression was 
normalised to α-tubulin expression levels. In HTR8/SVneo cells, NSC668394 significantly 
reduced phospho-ezrin expression by 70% (P<0.001) compared with non-treated control cells, 
while in SW71, phospho-ezrin levels remained unchanged upon treatment with the inhibitor 
(Figure 4.12). In both cell lines, DMSO treated samples expressed the same amount of ezrin as 
the controls. 
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Figure 4.12 The effect of ezrin inhibition on phospho-ezrin levels. HTR8/SVneo and SW71 
cells were treated with NSC668394 or DMSO (as negative control) for 24 hours prior to being 
collected in protease inhibitor cocktail and sonication. The cell lysates were then loaded on 10% 
SDS-PAGE and then phospho-ezrin and α-tubulin bands were detected by western blot. A1 and 
B1 show the bands for phospho-ezrin in HTR8/SVneo and SW71 cells, respectively, while A2 
and B2 show phospho-ezrin expression levels normalised to α-tubulin in these cells. The error 
bars represent SD (*** P<0.001). N = 3 for each cell line. Total sample size = 3 for each condition. 
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4.2.13. Ezrin inhibition modifies the localisation of ezrin and 
phospho-ezrin in HTR8/SVneo  
Having shown the effectiveness of the ezrin inhibitor drug NSC668394 in reducing phospho-
ezrin in HTR8/SVneo EVT cell lines, here we aimed to see whether the drug can cause a change 
in the localisation of ezrin and/or phospho-ezrin in HTR8/SVneo and SW71 cell lines. For this 
purpose, the cells were seeded on fibronectin-coated glass coverslips, while being treated with 5 
µM NSC668394, or without treatment. The cells were left to attach or 24 hours. The coverslips 
were then prepared and incubated with primary anti-phospho-ezrin and anti-ezrin antibodies 
followed by incubation with secondary TRITC (for ezrin) and FITC-conjugated (for phospho-
ezrin) antibodies, before mounting and viewing. Both ezrin (red) and phospho-ezrin (green) were 
shown to be mainly localised within the protrusions in control HTR8/SVneo and SW71 cells. 
Both ezrin and phospho-ezrin show reduced membrane localisation upon treatment with 
NSC668394 in HTR8/SVneo cells. In SW71 however, there are no distinctive changes in the 
localisation of ezrin and phospho-ezrin following the treatment. Ezrin and phospho-ezrin also 
showed nuclear localisation, which was reduced in HTR8/SVneo cells upon ezrin inhibition 
(Figure 4.13). 
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Figure 4.13 The effect of ezrin inhibition on ezrin and phospho-ezrin localisation in EVT 
cell lines. EVT cell lines HTR8 and SW71 were seeded on fibronectin-coated coverslips, while 
being treated with NSC668394 along with non-treated control. After 24 hours of incubation, ezrin 
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was visualised with TRITC, phospho-ezrin with FITC, and DNA with DAPI. The images were 
taken at 63x magnification.  
 
4.2.14. Ezrin inhibition does not affect trophoblast viability  
The ezrin inhibitor NSC668394 has been shown to affect cell proliferation in different ways. 
While it was shown to reduce the viability of human glioblastoma cells (Hilliard et al. 2017), it 
was not shown to affect the viability of osteosarcoma cells (Bulut et al. 2012). Here, we aimed to 
find out if ezrin inhibition affects trophoblast cell lines’ viability. For this purpose, HTR8/SVneo 
and SW71 cells were treated with 5 µM NSC668394, or with 0.1% (v/v) DMSO as negative 
control. Over the next 72 hours, the viability of the cells was assessed by trypan blue exclusion 
assay and the metabolic activity of the cells was assessed by MTT assay. Trypan blue assay 
indicated that HTR8/SVneo cells increased in cell number by 100% over the second 24 hours 
following the seeding then by 50% over the third 24 hours, and SW71 increased by 50% over the 
second 24 hours following the seeding and then by 50% over the third 24 hours in all four 
conditions. The MTT assay showed that the HTR8/SVneo increased in cell number by 20% over 
the second and then by 30% over the third 24 hours following the seeding, while SW71 increased 
in cell number by 50% over the second as well as the third 24 hours following the seeding in all 
four conditions. Ezrin inhibition was not shown to significantly affect the viability or the 
metabolic activity of neither the HTR8/SVneo nor the SW71 cells (Figure 4.14).   
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Figure 4.14 Trophoblast viability with ezrin inhibition. HTR8/SVneo and SW71 cells were 
seeded and treated with ezrin inhibitor NSC668394 or DMSO for 24 hours. Their viability and 
metabolic activity were tested during the next 3 days, by trypan blue exclusion and MTT assays, 
respectively. The error bars represent SD. The numbers have been reported as percentages. N = 
3 for each condition. Total sample size for each condition: 60 (viability) and 6 (for MTT). 
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4.2.15. The effect of ezrin inhibition on trophoblast motility 
Ezrin inhibitor, NSC668394, has been shown to inhibit motility and invasion of osteosarcoma 
cells (Bulut et al. 2012). Here we aimed to study the effect of ezrin phosphorylation inhibition on 
trophoblasts. For this purpose, HTR8/SVneo and SW71 cells were serum starved for 24 hours, 
and then were seeded into transwells without treatment (control), with 0.1% (v/v) DMSO (as 
negative control), or with 5 µM NSC668394, followed by 24 hours incubation. The transwells 
were then fixed and stained and the cells were counted on random fields at 20x magnification. 
NSC668394 significantly reduced HTR8 migration by 80% (P<0.0001), while it did not 
significantly affect SW71, indicating a proportionality between phospho-ezrin levels (Figure 
4.15) and EVT migration.  
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Figure 4.15 Ezrin phosphorylation inhibition reduces trophoblast motility. HTR8/SVneo 
and SW71 EVT cell lines were serum starved for 24 hours prior to being collected and 
resuspended in serum starvation medium. The cells were seeded in transwells while being treated 
with NSC668394, DMSO (as negative control) or without any treatment. After 24 hours, the 
transwells were fixed, stained and the stained cells were counted on random fields at 20x 
magnification. The graphs show average cell count percentage compared with control in 
HTR8/SVneo (A1) and SW71 (B1) and the error bars represent SEM (**** p<0.0001). Panels 
A2 and B2 and show representative fields of fixed and stained transwells. N = 3 for each cell line. 
Total sample size = 18 for each condition. 
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4.2.16. The effect of ezrin inhibition on trophoblast invasion  
Having shown the effect of ezrin inhibition on trophoblast motility, here we sought investigate 
the effect of ezrin inhibition on trophoblast invasion. For this aim, HTR8/SVneo and SW71 cells 
were seeded into Matrigel-coated transwells without treatment (control), with 0.1% (v/v) DMSO 
(as negative control), or with 5 µM NSC668394, followed by 24 hours of incubation. The 
transwells were then fixed and stained and the cells were counted on random fields at 20x 
magnification. NSC668394 significantly reduced HTR8 invasion by 70% (P<0.0001), while it 
did not significantly affect SW71 (Figure 4.16).  
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Figure 4.16 Ezrin phosphorylation inhibition reduces trophoblast invasion. HTR8/SVneo 
and SW71 EVT cell lines were serum starved for 24 hours prior to being collected and 
resuspended in serum starvation medium. The cells were seeded in Matrigel-coated transwells 
while being treated with NSC668394, DMSO (as negative control) or without any treatment. 
After 24 hours, the transwells were fixed, stained and the stained cells were counted at 20x 
magnification. The graphs show average cell count percentage compared with control in 
HTR8/SVneo (A1) and SW71 (B1) and the error bars represent SEM (*** p<0.001). Panels A2 
and B2 show representative fields of fixed and stained transwells. N = 3 for each cell line. Total 
sample size = 6 for each condition. 
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4.2.17. Ezrin inhibition affects FA number and size in 
HTR8/SVneo 
Knocking down ezrin in the previous section (4.2.11) was not shown to affect the size or the 
number of FAs. In this section, we aimed to study the effect of ezrin inhibition on FAs in 
HTR8/SVneo, which was shown to reduce motility and invasion in the mentioned cells. For this 
purpose, HTR8/SVneo cell lines were seeded on fibronectin-coated glass coverslips, while they 
were treated with 5 µM NSC668394, along with non-treated control cells. After 24 hours, the 
coverslips were prepared and incubated with primary anti-paxillin antibody followed by 
incubation with secondary FITC-conjugated antibody and rhodamine phalloidin, before mounting 
and viewing. Control samples were shown to have significantly (P<0.0001) 60% lower numbers 
of FAs (Table 1.1), which looked relatively smaller as well, compared with the treated cells 
(Figure 4.17). 
 
Table 4.2 Average FA count per cell in HTR8/SVneo cells, following ezrin inhibition. 
HTR8/SVneo trophoblast cell lines were seeded on fibronectin-coated coverslips, while being 
treated with NSC668394 ezrin-inhibitor and were left to attach for 24 hours. The cells were then 
fixed and stained for paxillin. The FAs were counted on all cells in each image.  
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Figure 4.17 Ezrin inhibition affects the FAs in HTR8/SVneo. HTR8/SVneo cells were seeded 
on fibronectin-coated coverslips while being treated with the ezrin inhibitor NSC668394 along 
with non-treated control and were left to attach for 24 hours. Paxillin was visualised with FITC, 
F-actin with rhodamine phalloidin and DNA with DAPI. The images were taken at 63x 
magnification. Panel A shows staining on paxillin, F-actin and DNA. Panel B shows average FA 
count in NSC668394-treated HTR8 cells compared with the non-treated control. The error bars 
represent SEM (**** P<0.0001). N = 2. Total sample size = 20 for each condition. 
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4.2.18. Ezrin expression and localisation in primary EVTs 
Having shown ezrin expression in all trophoblast cell lines, here we aimed to look for the 
expression of the protein in primary EVT cells, which were isolated from first trimester human 
placenta. For this purpose, the cells were collected, a day following the isolation of EVTs and 
cell lysate was prepared in 10% protease inhibitor cocktail and sonicated.  The lysate was separate 
by 10% SDS-PAGE and was probed for ezrin, phospho-ezrin and α-tubulin by western blot. Ezrin 
signal and a strong phospho-ezrin signal were obtained when expression was measured by 
western blotting (Figure 4.18 A).  
To find out more about the localisation of ezrin in primary EVTs, the cells were fixed on 
fibronectin-coated glass coverslips and incubated with primary anti-ezrin antibody followed by 
incubation with secondary FITC-conjugated antibody, as well as rhodamine phalloidin, before 
mounting and viewing. The immunofluorescence staining showed the localisation of the protein 
in the EVT cytoplasm as well as the cell membrane and membrane projections (Figure 4.18 B). 
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Figure 4.18 Ezrin expression and localisation in primary EVTs. For expression analysis 
(panel A) EVT cells were collected, lysed and separated by 10% SDS-PAGE, and probed for 
ezrin, phospho-ezrin and α-tubulin by western blotting. For the localisation experiment, (panel 
B) the EVTs were seeded on fibronectin-coated coverslips and incubated for 24 hours. Ezrin was 
visualised by immunofluorescence with FITC and actin with rhodamine phalloidin and DNA with 
DAPI. The images were taken at 63x magnification. 
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4.2.19. Phospho-ezrin localisation in first and second trimester 
EVTs 
Having shown the differential expression of ezrin proteins over the course of gestation, with 
higher levels being seen in first and second trimesters compared with the third, but no significant 
difference between the first two, we sought to determine whether changes could be seen in the 
levels of ezrin activation, such as its phosphorylated state over the early stages of implantations. 
Consequently, we aimed to compare at the localisation of phospho-ezrin (active form) in primary 
EVTs isolated from first (weeks 9) and second trimester (16 weeks) placenta samples. The cells 
were seeded on fibronectin-coated glass coverslips and incubated with anti-phospho-ezrin and 
then secondary FITC-conjugated secondary antibody as well as phalloidin. The staining showed 
strong phospho-ezrin localisation within membrane protrusions of both the first trimester and 
second trimester EVTs, while the cells form earlier gestational age showed a stronger nuclear 
localisation. EVT morphology also looked different between these two gestational ages, as there 
were 40% more (Table 4.3) membrane protrusions in the first trimester EVTs (P<0.05) and they 
looked more elongated compared with the older cells (Figure 4.19).  
 
Table 4.3 Average membrane projection count per cell in primary first and second 
trimester EVTs. Primary EVTs from first and second trimesters were seeded on fibronectin-
coated coverslips and were left to attach for 24 hours. The cells were then fixed and stained for 
phospho-ezrin. The membrane projections were counted on all cells in each image. 
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Figure 4.19 Phospho-ezrin localisation in EVTs from first and second trimester. The primary 
EVTs from week 9 (first trimester) and week 16 (second trimester) of gestation were seeded on 
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fibronectin-coated coverslips and incubated for 24 hours. Panel A shows phospho-ezrin 
visualised with FITC, F-actin with rhodamine phalloidin and DNA with DAPI. The images were 
taken at 63x magnification. Panel B shows the average memorable projection count per cell, 
represented as percentage. The error bars represent SEM (* P<0.05). N = 1. Total sample size = 
12 for each condition. 
 
4.2.20. Ezrin inhibition in primary EVTs 
Having shown the effect of ezrin inhibition in EVT cell lines and the subsequent effects on their 
motility and invasion, we next aimed to carry out loss of function experiments in primary EVTs. 
To facilitate this, and in view of the key requirement for ezrin to be phosphorylated at reside 
Thr567, a step that is necessary for its association with the membrane and actin cytoskeleton, we 
set about to inhibit this through the use of the ezrin inhibitor NSC668394 as previously explained. 
For this aim, primary EVTs, isolated from first trimester human placenta, were seeded on 
fibronectin-coated glass coverslips while being treated with 5 µM ezrin inhibitor NSC668394, or 
with no treatment as control. 24 hours following seeding, the cells were incubated with anti-
phospho-ezrin and then secondary FITC-conjugated secondary antibody as well as phalloidin. 
The inhibitor altered the localisation pattern of the protein by significantly (P<0.001) reducing 
the microvillous structures, by 60% (Table 4.4) and by making it relatively more abundant within 
the cytoplasm, rather than the membrane (Figure 4.20). 
 
Table 4.4 Average membrane projection count per cell in primary EVTs. Primary first 
trimester EVTs were seeded on fibronectin-coated coverslips, while being treated with 
NSC668394 ezrin-inhibitor and were left to attach for 24 hours. The cells were then fixed and 
stained for phospho-ezrin. The microvillous projections were counted on all cells in each image. 
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Figure 4.20 The effect of ezrin inhibition on primary EVT morphology. The primary EVTs 
were seeded on fibronectin-coated coverslips while being treated with NSC668394, or with no 
treatment as control, and incubated for 24 hours. Phospho-ezrin was visualised with FITC, F-
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actin with rhodamine phalloidin and DNA with DAPI. The images were taken at 63x 
magnification. The error bars represent SEM (*** P<0.001). N = 1. Sample size for each 
condition = 12. 
 
4.2.21. The effect of ezrin inhibition on the motility of primary 
EVTs 
Having shown the effect of ezrin inhibition on the motility of our EVT cell lines, and further 
demonstrated the effect of NSC668394 on phospho-ezrin localisation in primary EVTs, we then 
looked to determine whether the same inhibition would affect the motility of primary EVTs. To 
do this, primary EVTs from first trimester human placenta were seeded in transwells, while being 
treated with 5 µM ezrin inhibitor NSC668394, or with no treatment as control. After 24 hours, 
the migrated cells were fixed, stained  and counted on random fields at 20x magnification and the 
average number of migrated cells were compared in the treated and the non-treated cells. The 
inhibition of ezrin in primary EVTs significantly (P<0.0001) reduced their migration by 30% 
(Figure 4.21). 
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Figure 4.21 Ezrin inhibition leads to motility reduction in primary EVT. Primary EVT cells 
were seeded in transwells without treatment or while being treated with NSC668394. After 24 
hours, the transwells were fixed, stained and the stained cells were counted at 20x magnification. 
The graph (panel A) shows the average cell count percentage compared with control and the error 
bars represent SEM (**** p<0.0001). Panels B shows representative fields of fixed and stained 
transwells. N = 3. Sample size = 18 for each condition.  
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4.2.22. The effect of ezrin inhibition on the invasion of primary 
EVTs 
We showed that the inhibition of ezrin significantly reduces migration in primate EVTs. Here, 
we aimed to find out if this inhibition also affects EVT invasion. For this purpose, 35,0000 
primary EVTs form first trimester human placenta were seeded on Matrigel-coated transwells, 
while being treated with 5 µM ezrin inhibitor NSC668394, or with no treatment as control. The 
cells were left to invade for 24 hours, prior to fixation and staining. The cells were counted on 
random fields at 20x magnification and the average number of migrated cells were compared in 
the treated and the non-treated cells. The inhibition of ezrin in the primary EVTs significantly 
reduced invasion by 20% (P<0.0001) (Figure 4.22). N = 3. 
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Figure 4.22 Ezrin inhibition leads to invasion reduction in primary EVT. Primary EVT cells 
were seeded in Matrigel-coated transwells without treatment or while being treated with 
NSC668394. After 24 hours, the transwells were fixed, stained and the stained cells were counted 
at 20x magnification. The graph (panel A) shows average cell count percentage compared with 
control and the error bars represent SEM (**** p<0.0001). Panels B shows representative fields 
of fixed and stained transwells. N = 3. Sample size = 6 for each condition. 
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4.2.23. Ezrin inhibition does not affect FAs in primary first 
trimester EVTs 
Having shown the reduction in in the relative size and the number of FAs in HTR8/SVneo cell 
line, upon ezrin phosphorylation inhibition (4.2.17), here we aimed to study the effect of ezrin 
inhibition on FAs in primary first trimester EVTs. For this purpose, primary EVTs were seeded 
on fibronectin-coated glass coverslips, while they were treated with 5 µM NSC668394, along 
with non-treated control cells. The cells were left to attach for 24. The coverslips were prepared 
and incubated with primary anti-paxillin antibody, followed by incubation with secondary FITC-
conjugated antibody and rhodamine phalloidin, before mounting and viewing. The cells treated 
with NSC668394 showed no significant difference in their FA count (P = 0.277) (Table 4.5), 
when compared with the control cells (Figure 4.23). 
 
Table 4.5 Average FA count per cell in primary EVTs. Primary first trimester EVTs were 
seeded on fibronectin-coated coverslips, while being treated with NSC668394 ezrin inhibitor and 
were left to attach for 24 hours. The cells were then fixed and stained for paxillin. The FAs were 
counted on all cells in each image. 
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Figure 4.23 Ezrin inhibition does not affect the FAs in HTR8/SVneo. Primary EVTs were 
seeded on fibronectin-coated coverslips while being treated with NSC668394 ezrin inhibitor, 
along with non-treated control and were left to attach for 24 hours. Paxillin was visualised with 
FITC, F-actin with rhodamine phalloidin and DNA with DAPI. The images were taken at 63x 
magnification. Panel A shows staining on paxillin, F-actin and DNA. Panel B shows average FA 
count in NSC668394 treated EVTs compared with the non-treated controls. The error bars 
represent SEM. N = 2. Sample size = 20 for each condition. 
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4.3. Discussion 
In this chapter, we have studied how ezrin, a protein that plays a key role in tumour invasion and 
metastasis (Fehon, McClatchey & Bretscher 2010; McClatchey 2003, 2014), also regulates 
motility and invasion in trophoblasts cells, using cell lines or primary cells, along with ex vivo 
work carried out on human placental sections. 
By staining the human placental samples available, through specific IHC, we showed that the 
highest level of ezrin was seen during the first and second trimesters of gestation, while its 
expression was significantly reduced in third trimester placenta samples (Figure 4.2). Indicating 
the potential involvement of the protein in earlier stages of gestation. Similarly, placental ezrin 
expression was shown to decrease in late pregnancy in rats (Higuchi et al. 2010). Moreover, 
another study showed higher expression levels of ERM proteins in implantation-competent 
blastocyst compared with dormant blastocyst in mice (Matsumoto et al. 2004). Although IHC did 
not show a significant difference between ezrin levels in placenta villi sections from first and 
second trimesters (Figure 4.2), there was a significant difference between the localisation of the 
active form of ezrin (phospho-ezrin Thr567) in the primary EVTs isolated form these two time-
points (Figure 4.19), as phospho-ezrin in the younger EVTs showed more localisation within the 
nucleus as well as the membrane protrusions, which looked relatively longer as well. 
Next, to find out more about the localisation and cell-specific expression of ezrin in human 
placenta villi, we stained serial sections of first trimester human placenta for ezrin, cytokeratin-7 
and HLA-G by IHC. The sections showed ezrin localisation in the cytoplasm of cytotrophoblasts 
and syncytiotrophoblasts, with the highest levels seen in the apical membrane of the 
syncytiotrophoblasts (Figure 4.3), similar to what was reported previously (Berryman, Franck & 
Bretscher 1993; Pidoux et al. 2014). Ezrin has been suggested to play a role in trophoblast fusion 
and the formation of the syncytium (Pidoux et al. 2014). We also detected ezrin in the invasive 
trophoblast columns, localised within the cytoplasmic and apical membrane the EVTs (Figure 
4.3). 
Having shown ezrin expression in placenta sections, we next aimed to find out about its 
expression in the trophoblast cell lines available to us and have been described in earlier chapters 
(Jeg-3, BeWo, HTR8/SVneo, SW71, SHGPL4 and -5) as well as primary EVTs isolated from 
first trimester human placenta. We showed that ezrin is ubiquitously expressed in all of our 
trophoblast cell lines (Figure 4.4), while Jeg-3 cells expressed the highest amounts relative to the 
other cells. Ezrin expression was also detected in the primary first trimester EVTs (Figure 4.18). 
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Having shown that ezrin is expressed in our trophoblast cell lines and primary EVTs, we set about 
to learn about its localisation. Immunofluorescence staining showed that ezrin was localised in 
the cytoplasm of all cells (Figure 4.5). Ezrin was also detectable in the plasma membrane and the 
membrane projections of primary first trimester EVTs (Figure 4.18) and HTR8/SVneo, SW71, 
SGHPL-5 and BeWo cells, while the other two cell lines (Jeg-3 and SGHPL-4) showed a different 
localisation pattern, showing ezrin localisation within their cytoplasm only (Figure 4.5). Different 
localisation of the proteins might indicate the level of the protein activation, as the active (open) 
ezrin, similar to other ERM family members, links the cytoskeleton to the plasma membrane via 
PIP2, and therefore is localised within the cell cortex, while the inactive (closed) ezrin is located 
in the cytoplasm (Fehon, McClatchey & Bretscher 2010).  
Unfolding and activation of ezrin happens by the interaction between plasma membrane PIP2 and 
the N-terminal side of ezrin, followed by its phosphorylation at a conserved Thr567 residue at the 
C-terminal side of the protein (Fievet et al. 2004). Here, to find out about the levels of the active 
form of the protein in our trophoblast cell lines, we probed the cell-lysates for phospho-ezrin 
(Thr567), by western blot. showed that our trophoblast cell lines expressed different amounts of 
phospho-ezrin (Figure 4.4). The highest levels of phospho-ezrin were seen in HTR8/SVneo cells. 
This was in line with the immunofluorescence staining, which showed the HTR8/SVneo cells 
have the highest levels of cortical ezrin compared with our other trophoblast cell lines (Figure 
4.5). In contrast, moderate levels of phospho-ezrin expression in Jeg-3 (measured by western 
blot) (Figure 4.4) was not in line with ezrin’s non-detectable membrane localisation (visualised 
by immunofluorescence staining) in these cells (Figure 4.5). One possible explanation for this 
could be that, as explained earlier, for ezrin activation, the phosphorylation of the protein at 
Thr567, happens after the protein interaction with the membrane-bound PIP2, a process that leads 
to ezrin’s conformational change (Fievet et al. 2004). Therefore, high amount of phospho-Thr567 
ezrin alone, does not guarantee high ezrin activation, similar to another study, which reported that 
Thr567 phosphorylation is required for cell spreading, but is not sufficient (Parnell et al. 2015).  
Ezrin over-expression has been associated with enhanced cellular motility and invasion, as well 
as metastasis and poor prognosis for cancer patients (Makitie et al. 2001; Meng et al. 2010; Weng 
et al. 2005). Here, we aimed to see how this protein regulates motility and invasion in trophoblasts 
through loss of functions experiments. We used four different sequences of siRNA against ezrin 
and showed that two of them (siRNA 7 and 9) were the most effective in knocking down ezrin in 
HTR8/SVneo and SW71 cells (Figure 4.6). None of the ezrin siRNA sequences significantly 
reduced protein expression, in Jeg-3 (Figure 4.6). We then showed that the reduction in ezrin 
expression significantly reduced both motility (Figure 4.8) and invasion (Figure 4.9) in 
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HTR8/SVneo and SW71 cells, while not affecting the Jeg-3 cells. The ineffectiveness of ezrin 
knockdown in Jeg-3 motility and invasion cells might have been due to the different localisation 
pattern of the protein, which was shown with immunofluorescence staining, and suggested lower 
membrane-bound ezrin in these cells (Figure 4.5). However, this also might have been due to the 
ineffectiveness of our specific siRNA sequences in Jeg-3 cells, since successful ezrin knockdown 
in these cells has been reported previously with a different sequence of ezrin siRNA, when used 
at a higher concentration (30 nM) (Viswanatha et al. 2012). In line with our findings, another 
study showed that ezrin could partially restore invasion in HTR8/SVneo cells with titanium 
dioxide nanoparticles-induced invasion impairment (Mao et al. 2019). In cancer cells, ezrin 
knockdown also has been shown to reduce motility and invasion (Fan et al. 2011; Meng et al. 
2010; Tang et al. 2019; Zhang et al. 2014). However, despite being a key metastasis regulator 
(Briggs et al. 2012; Lin & Chen 2013), the over-expression of this protein does not always 
enhance motility, invasion and metastasis (Elliott et al. 2005).  
Through regression analysis, it was shown that there was a positive correlation between the ezrin 
expression levels, in control, negative control and siRNA 7 and 9 treated HTR8/SVneo and SW71 
cells. This correlation was relatively stronger in SW71 cell (r = 0.94 for motility, r = 0.96 for 
invasion in SW71 compared with r = 0.86 for motility, r = 0.86 for invasion in Jeg-3 cells) and 
was only significant in SW71 cells (Figure 4.10). The correlation between ezrin expression and 
motility/invasion has not been previously shown in any cells. 
The role of ezrin in trophoblast motility and invasion was validated by showing the 
ineffectiveness of ezrin knockdown on the viability and the metabolic activity of HTR8/SVneo 
and SW71 cells (Figure 4.7). This suggests that ezrin does not regulate cell proliferation in 
trophoblasts, similar to what was shown in some types of tumour cell (Horwitz et al. 2016), where 
other studies have reported otherwise (Kishore et al. 2005; Quan et al. 2019). 
As mentioned in the previous chapter, rapid formation and turnover of the FAs during directional 
cell movement pulls the cell body forward, while their rapid turnover at the rear end detaches 
them from the ECM. Here, we aimed to find out if the ezrin-induced cell motility involves 
observable FA changes, by analysing the localisation pattern of paxillin, an FA component, upon 
ezrin knockdown. Ezrin has previously been shown to regulate FA dynamics in breast cancer 
(Hoskin et al. 2015). In our trophoblast cell lines HTR8/SVneo and SW71 however, ezrin 
knockdown did not result in detectable changes in the overall size or the number of the FAs 
(Figure 4.11). Although, we cannot rule out the possible changes in the phosphorylation state of 
the FA components, which have been reported to take place as response to changes in cellular 
dynamics (Katz et al. 2000; Zamir et al. 2000). Despite the usual association of FA and cell 
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adhesion dynamics with cell migration (Nagano et al. 2012), not all cells show similar changes 
in their FAs, due to the difference in their adhesive structures. For example, fast-moving  cells 
seem to have highly dynamic and smaller FAs, while slower-moving cells seem to have larger 
and more stable FAs (Parsons, Horwitz & Schwartz 2010). This, however, might not necessarily 
be the case in here, since HTR8/SVneo cells did in fact show a significant reduction in the relative 
size and the number of FAs, due to S100P expression, in the previous chapter (Figure 3.14). 
Additionally, cell adhesion does not always correlate with FA size and number. In fact, FA 
assembly has been shown to contribute to only a small percentage of adhesive strength (Gallant, 
Michael & García 2005). Furthered more, our FA analysis in fixed cells, is a limited process, 
which resents only a “snapshot” in a timeframe of a highly dynamic process, and therefore cannot 
guarantee to provide a holistic view.  
Ezrin phosphorylation results in its activation and promotes phenotype changes such as the 
promotion of apical microvilli formation (Bonilha, Finnemann & Rodriguez-Boulan 1999; Dard 
et al. 2004) and enhanced migration and invasion (Mak et al. 2012; Zhan et al. 2019). Ezrin 
phosphorylation at Thr567 by members of the PKC family (Ng et al. 2001; Pietromonaco et al. 
1998; Wald et al. 2008), which was shown to be dependent on the p38 MAP-kinase activity (Zhao 
et al. 2004), has been reported to be crucial for the ezrin-mediated membrane-cytoskeleton 
anchorage (Zhu et al. 2007) and was suggested to play an important role in metastasis (Jin et al. 
2014; Krishnan et al. 2006). Having shown that ezrin knockdown reduces motility (Figure 4.8) 
and invasion (Figure 4.9) in our EVT cell lines, and that the expression of the phosphorylated 
form of the protein does not follow a similar pattern as the expression of the total pool of the 
protein amongst our trophoblast cell lines (Figure 4.4), we were interested to see how the 
inhibition of ezrin phosphorylation affects our trophoblast cells. For this purpose, HTR8/SVneo 
and SW71 cells were treated with NSC668394, a compound that prevents ezrin phosphorylation 
at Thr567, without affecting PKC activity and has been shown to reduce tumour cell motility and 
causing developmental defects in zebrafish (Bulut et al. 2012) as well as up-regulation of the 
expression of stress response genes (Celik et al. 2016). Following 24 hours of treatment, through 
western blot analysis, we showed that the drug has significantly reduced the expression level of 
the phospho-ezrin in HTR8/SVneo cells, but did not show the same effect in SW71 cells (Figure 
4.12). The drug also reduced membrane-bound and nuclear ezrin as well as its active form in 
HTR8/SVneo cells, without affecting the localisation of either in SW71 cells (Figure 4.13). 
Ezrin inhibition reduced both motility (Figure 4.15) and invasion (Figure 4.16) of HTR8/SVneo 
cells (by 80% and 70% respectively), to a greater extent than the effect seen by protein 
knockdown (20% for motility and invasion with siRNA 7 and 50% for motility and invasion with 
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siRNA 9) (Figure 4.8 and Figure 4.9), without affecting the viability of either HTR8/SVneo or 
SW71 cells (Figure 4.14). Ezrin inhibition also reduced membrane protrusions (Figure 4.19) and 
significantly decreased both migration (Figure 4.20) and invasion (Figure 4.21) of primary first 
trimester EVTs by 30%  and 20%, respectively. One possible explanation for the lower 
effectiveness of ezrin inhibition on the motility and invasion of primary EVTs compared to 
HTR8/SVneo cells (30 and 20% compared with 80 and 70%, respectively) might have been due 
to not using a serum attractant. Serum starving the cells and using a serum attractant has been 
shown to significantly enhance cell migration in transwell assays (Justus et al. 2014). 
Additionally, we showed that the changes due to S100P knockdown were more significant in Jeg-
3 cells, when they were seeded at higher numbers (Figure 3.7), and this might also, at least 
partially, explain our relatively lower effect of ezrin inhibition on EVT motility/invasion, 
compared with the HTR8/Svneo cells, indicating a requirement for EVT cell number optimisation 
for motility and invasion assays. 
Similarly, redistribution of ezrin in membrane and microvilli has been associated with enhanced 
motility, invasion and proliferation in cancer cells (Curto & McClatchey 2004). Membrane and 
nuclear localisation of the phosphorylated form of the protein has been  linked with metastasis  
(Di Cristofano et al. 2010), while others have shown the loss of ezrin from the membrane and 
elevated levels of ezrin in the cytoplasm to be linked with metastasis in different cancers (Arslan 
et al. 2012; Di Cristofano et al. 2010; Elzagheid et al. 2008; Sarrio et al. 2006; Schlecht et al. 
2012). 
Interestingly, in contrast to our results with ezrin knockdown, ezrin inhibition also resulted in an 
increase in both the number and the relative size of FAs in HTR8/SVneo cells (Figure 4.17). This 
contradictory observation might possibly be due to the greater effect of the inhibition compared 
with the protein knockdown, although we do not currently have further evidence to support this 
hypothesis. 
Since the effectiveness of ezrin phosphorylation inhibition was more prominent on both 
motility/invasion (80% and 70% reduction in motility and invasion, respectively, in HTR8/SVneo 
cells) and FA dynamics, compared with the effect seen with ezrin downregulation (20% by 
siRNA 7 and 50% by siRNA 9) on both motility and invasion of HTR8/SVeo cells, we suggest 
the possibility that the availability of active ezrin might play a more crucial role in cytoskeleton 
regulation in trophoblasts, compared with the total protein availability. In contrast to this, a study 
has reported i the significance of total ezrin levels in the prediction of metastasis and prognosis 
in osteosarcoma, while the phospho-ezrin levels were not as relevant (Di Cristofano et al. 2010).  
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Unlike in HTR8/Svneo cells, ezrin inhibition did not affect the number or the relative size of the 
FAs in primary EVTs (Figure 4.23). Other than the earlier possible explanations for our similar 
observation on the ineffectiveness of ezrin knockdown on the FAs, another explanation for this 
could be that, although the term “phospho-ezrin”, generally refers to phosphorylated Thr567 
residue on the protein, the most well-known region in protein activation, other phosphorylated 
residues of ezrin, such as tyrosine 477 (Mak et al. 2012; Naba et al. 2008), serine 66 (Zhou et al. 
2003), threonine 235 (Yang & Hinds 2003) and tyrosine 145 (Srivastava et al. 2005) also have 
been associated with its activation. Perhaps studying the role of these less-studied regions, and 
potentially other unknown regions, would give us a better understanding of how ezrin regulates 
the cytoskeletal changes in trophoblasts. Moreover, comparing the level and the localisation 
pattern of the active from of the ezrin in placental villi and the isolated EVTs from different 
gestational ages, as well as its proportional levels compared with total ezrin might give us a better 
insight about how this protein regulates trophoblasts and implantation. Additionally, we used 24 
hours of treatment with the ezrin inhibitor-drug for our western blot, immunofluorescence and 
motility/invasion assays, while the half-life of active ezrin is in fact rather long (> 1 day) (Grune 
et al. 2002), and this might have affected our results. Perhaps longer treatment of cells with 
NSC668394 might have increased the effects we observed in HTR8/SVneo and primary EVTs, 
and even the SW71 cells.  
In conclusion, we report that, due to its expression pattern in placental villi throughout the 
gestation period, and its role in trophoblast motility and invasion, ezrin might potentially play an 
important role in early placenta development and implantation. 
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Chapter 5.  
IQGAP1 regulates trophoblast 
motility and invasion 
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5.1. Introduction 
IQGAP1 is a member of the eukaryotic IQGAP family of scaffold proteins, which have three 
members in mammals: IQGAP1, IQGAP2, and IQGAP3 (Brown & Sacks 2006). Although 
IQGAP1 shows ubiquitous expression in all mammals, it is not essential for murine development, 
as IQGAP1 null mutants were shown to develop normally, except for showing significantly 
higher late-onset gastric hyperplasia (Li et al. 2000) and heart malfunction compared with wild-
type animals (Sbroggiò et al. 2011). IQGAP1 is a regulator of the MAPK (Roy, Li and Sacks, 
2004 and 2005) and Wnt signalling pathways (Carmon et al. 2014), F-actin polymerisation 
(Mateer et al. 2002), cell proliferation (Wang et al. 2009), adhesion (Noritake et al. 2005), motility 
and invasion (Dong et al. 2008; Hayashi et al. 2010; Mataraza et al. 2003). In physiological 
conditions, IQGAP1 has been associated with cell adhesion in the kidneys (Rigothier et al. 2012), 
neuronal proliferation and migration (Li et al. 2005), endothelial cell proliferation and migration 
in the cardiovascular system (Kohno et al. 2013; Yamaoka-Tojo et al. 2004), smooth muscle cell 
contraction in the lungs (Bhattacharya et al. 2014) and facilitating insulin secretion through 
regulating vesicle trafficking (Rittmeyer et al. 2008), while its over-expression and modified 
localisation within the cells  has been associated with carcinogenesis (McDonald et al. 2007; 
Nabeshima et al. 2002). IQGAP1 expression has been detected in placental microvilli (Berryman 
& Bretscher 2000; Weissbach et al. 1994) and the syncytiotrophoblast membrane (Paradela et al. 
2005), but, to this date, no roles have been reported to be associated with this protein in 
trophoblasts or the placenta. 
Aim 
The role of IQGAP1 is clearly established as a marker of metastasis through its role in 
promoting cancer cell motility and invasion (White, Brown & Sacks 2009). However, a 
function for this protein in the context of trophoblast physiology is unknown. We propose to 
study whether there are changes in trophoblastic IQGAP1 expression levels during gestation 
and whether its presence regulates trophoblast motility and invasion. 
Objectives 
• Establish IQGAP1 expression in placenta 
• Establish IQGAP1 expression in trophoblast cell lines 
• Test whether modulating IQGAP1 expression affects trophoblast motility and invasion 
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• Decipher the molecular mechanisms of IQGAP1-promoted motility and invasion in 
trophoblasts 
5.2. Results 
5.2.1. Immunohistochemical staining optimisation  
Over the course of the study so far, we have aimed to focus our work on determining whether 
metastasis-associated proteins, namely S100P and ezrin, are expressed during placental 
development and whether their expression affects trophoblast motility/invasion. 
In this chapter, we sought to follow a similar approach in relation to IQGAP1 by looking at its 
localisation and expression levels in samples of first, second and third trimester human placental 
villi. First, the optimal concentration of the primary antibody against IQGAP1 was optimised as 
below. 
In order to find the lowest concentration of primary anti-IQGAP1 antibody applicable for the IHC 
in this part, two dilutions of the antibody (1 and 0.5 µg/ml anti-IQGAP1) were tested for the 
staining of first trimester samples.  
Concentrations of IQGAP antibody at either 1 or 0.5 µg/ml showed efficient staining for 
IQGAP1, highlighting IQGAP1 localisation within the trophoblasts surrounding placental villi, 
with weak staining detectable in some parts of the stroma, located in the core of the villi (Figure 
5.1). 
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Figure 5.1 IQGAP1 antibody concentration optimisation for IHC. Wax-embedded human 
first trimester placental villi sections were prepared and incubated with two concentrations of 
primary anti-IQGAP1, along with rabbit IgG as negative control, before being incubated with 
secondary antibody, and finally were stained using avidin-biotin complex and DAB chromogen 
and counter-stained using haematoxylin. 
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5.2.2. Placental IQGAP1 expression decreases gradually during 
gestation 
Having optimised staining for IQGAP1, we now wanted to determine how IQGAP1 levels were 
affected during gestation as well as its localisation during placental development. To this end, 
three samples from first trimester, three from second trimester and four third trimester placenta 
samples were stained for IQGAP1 as detailed earlier. Images were analysed by densitometry 
using Fiji-ImageJ software. During the first trimester, IQGAP1 expression was detected very 
strongly in the apical membrane of syncytiotrophoblasts and to a lesser extent in the cytoplasm 
of syncytiotrophoblasts, as well as in the cytoplasm of cytotrophoblasts (Figure 5.2 5.2 B). The 
expression of IQGAP1 in the second trimester was reduced by 20% when compared to the first 
trimester (P<0.05), while the third trimester samples expressed very small amounts of IQGAP1 
compared with the first trimester (50% lower) (P<0.001) and 30% lower compared with the 
second trimester (Figure 5.2 A and C).  
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Figure 5.2 IQGAP1 expression in human placenta is the highest during the first trimester 
of gestation. Wax-embedded human first trimester placental villi sections were prepared and 
incubated with anti-IQGAP1 antibody as well as rabbit IgG as negative control, before being 
incubated with secondary antibody, and finally staining using avidin-biotin complex and DAB 
chromogen and counter-staining using haematoxylin. Panel A shows representative images of 
human placental sections form first, second and third trimesters. Panel B shows a magnified 
image of one of the first trimester placenta sections, and panel C shows average IQGAP1 
expression (calculated by densitometry) in different gestational ages. The error bars represent SD 
(* P<0.05, **<0.01, *** P<0.001). N = 2. Total sample size for each trimester: 6 (1st), 6 (2nd) 
and 8 (3rd). 
  
209 
 
5.2.3. IQGAP1 is expressed in human trophoblasts and EVTs 
Having shown that expression of IQGAP1 in placenta is highest in the early stages of placental 
development, we now wanted to learn more about its localisation and where it was expressed in 
first trimester samples using markers for trophoblast (cytokeratin 7) and more specifically EVTs 
(HLA-G). Serial sections of wax-embedded first trimester human placental villi were prepared 
and incubated anti-IQGAP1, anti-cytokeratin 7, anti-HLA-G, anti-S100P or anti-ezrin as well as 
mouse and rabbit IgGs (as negative control) overnight, followed by secondary antibody 
incubation and development using avidin-biotin complex and DAB chromogen. The sections 
were counter stained with haematoxylin. IQGAP1 was shown to be expressed in the anchoring 
villi, colocalised with cytokeratin 7 in cyto- and syncytiotrophoblasts, with HLA-G in EVTs, and 
with S100P and ezrin in cyto- and syncytiotrophoblasts as well as the EVTs (Figure 5.3). 
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Figure 5.3 IQGAP1 expression in human trophoblasts and EVTs. Serial sections of wax-
embedded human first trimester placental villi were prepared and incubated with primary anti-
211 
 
IQGAP1, anti-cytokeratin 7, anti-HLA-G, anti-S100P and anti-ezrin as well as mouse and rabbit 
IgGs as negative control, before being incubated with secondary antibodies, and finally were 
stained using avidin-biotin complex and DAB chromogen and counter-stained using 
haematoxylin. The images were taken at 20x magnification. 
 
5.2.4. IQGAP1 is expressed in human trophoblast cell lines 
Having demonstrated IQGAP1 expression in human placenta and more specifically in, 
trophoblast and EVTs, we aimed to investigate whether IQGAP1 could also be detected in 
trophoblast cell lines. We sought to investigate IQGAP1 expression in the trophoblast cell lines 
Jeg-3 and BeWo as well as human first trimester EVT cell lines SW71, HTR8/SVneo, SGHPL-4 
and SGHPL-5 by western blot. 
IQGAP1 was found to be highly expressed in all human trophoblast cell lines used: Jeg-3, BeWo, 
SW71, HTR8/SVneo, SGHPL-4 and SGHPL-5. Compared with BeWo cells, HTR8/Svneo cells 
expressed 10% more, Jeg-3 cell expressed 30% more, SW71 expressed 20% less, SGHPL-4 
expressed 50% less and SGHPL-5 expressed almost the same level of IQGAP1 protein (Figure 
5.4). 
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Figure 5.4 IQGAP1 expression in human trophoblast cell lines. Human trophoblast cell lines 
BeWo, HTR8/SVneo, Jeg-3, SW71, SGHPL-4 and SGHPL-5, were collected in protease 
inhibitor cocktail and sonicated, prior to being separated by 10% SDS-PAGE. The samples were 
probed for IQGAP1 and α-tubulin by western blot. Expression levels were quantified by Image 
Studio Lite software and IQGAP1 expression levels were normalised to the housekeeping gene 
expression. Panel A shows the western blot bands for IQGAP1 and α-tubulin, and panel B shows 
the densitometry. The error bars represent SD. N=3. All differences are non-significant (P>0.05). 
Sample size = 3 for each cell line. 
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5.2.5. IQGAP1 localisation in human trophoblast cell lines 
Having shown that IQGAP1 is expressed in different trophoblast cell lines, we now aimed to 
study its cellular localisation. To do this, trophoblast cells BeWo, HTR8/SVneo, Jeg-3, SW71, 
SGHPL-4 and SGHPL-5 were incubated with primary anti-IQGAP1 antibody followed by 
secondary FITC-conjugated antibody and rhodamine phalloidin, before mounting and viewing. 
In HTR8/SVneo and SW71, IQGAP1 was localised within the nucleus, cytoplasm, and the 
membrane, being strongly detectable in the cell protrusions of HTR8/SVneo cells. In the rest of 
the trophoblasts (SGHPL-4, SGHPL-5, Jeg-3 and BeWo) however, IQGAP1 was detected within 
the membrane, the cytoplasm and around the nucleus, with the strongest peri-nuclear localisation 
seen in SGHPL-4 and -5 (Figure 5.5). 
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Figure 5.5 IQGAP1 expression and localisation in trophoblast cell lines. EVT cell lines 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5 along with choriocarcinoma cell lines Jeg-3 and 
BeWo were seeded on fibronectin-coated coverslips. The cells were stained for IQGAP1, F-actin 
and DNA by immunofluorescence. The images were taken at 63x magnification.  
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5.2.6. IQGAP1 expression knockdown 
Having confirmed the expression of IQGAP1 in EVT and choriocarcinoma cells-lines, we now 
wanted to learn more about its potential through loss of function studies, by regulating its 
expression using siRNA delivery. 
For this purpose, HTR8/SVneo and SW71 human EVT cell lines, as well as Jeg-3 
choriocarcinoma cell lines were treated with a panel of different siRNA (1, 2, 3 and 5) targeting 
IQGAP1, along with a non-specific sequence of siRNA as negative control. The treated cells 
were loaded on 10% SDS-PAGE and were probed for IQGAP1 and α-tubulin by western blot. 
IQGAP1 expression was calculated by densitometry normalised to α-tubulin (housekeeping gene) 
expression, and the values were compared with each other (Figure 5.6). 
IQGAP1 expression was found to be reduced following targeted siRNA delivery in all cell lines 
used but with different degrees of variation depending on the cells and siRNAs used (Figure 5.6): 
In HTR8/SVneo, siRNA 2 and 5 were the most effective and reduced IQGAP1 expression 
significantly by 60% (P<0.01) compared to their control counterparts, while at the same 
concentration, siRNA 1 and 3 did not significantly affect IQGAP1 expression (Figure 5.6 A1 and 
5.6 A2). When the same experiment was conducted in SW71 cells (Figure 5.6 B1 and B2), siRNA 
1 and siRNA 3 reduced IQGAP1 expression by 70% and 80% respectively (P<0.001), whilst 
siRNA 2 and siRNA 5 were the most effective and reduced expression by 90% (P<0.001 and 
P<0.0001, respectively). Knock-down experiments performed in Jeg-3 resulted in siRNA 1 and 
siRNA 2 bringing IQGAP1 expression down to 40 and 50%, respectively (although not 
significantly), while siRNA 3 and 5 did not show any effect on IQGAP1 expression (Figure 5.6 
C1 and C2). Therefore, IQGAP1 siRNA 2 and 5 and the cell lines HTR8/SVneo and SW71 were 
chosen for further experiments on studying the role of IQGAP1 on trophoblast phenotype. 
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Figure 5.6 IQGAP1 siRNA treatment knocks down IQGAP1 expression in trophoblast cell 
lines. HTR8/SVneo, SW71 and Jeg-3 cells, were treated with IQGAP1 siRNA 1, 2, 3 and 5, along 
with mock treatment. The treated cells along with non-treated control cells were left to grow for 
3 days prior to collection, lysing and sonication. The proteins were separated by 10% SDS-PAGE 
and IQGAP1 and α-tubulin bands were detected by western blot. Expression levels were 
quantified by Image Studio Lite software and IQGAP1 expression levels were normalised to the 
housekeeping gene expression. Panels A1, B1 and C1 show IQGAP1 and α-tubulin bands in 
HTR8/SVneo, SW71 and Jeg-3 cells, respectively, while panels A2, B2 and C2 show the 
densitometry in the mentioned cells in the same order. The error bars represent SD. (**P<0.01, 
***P<0.001, ***P<0.0001). N = 3 for each cell line. Sample size = 3 for each condition.  
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5.2.7. IQGAP1 knockdown does not affect trophoblast viability 
Having successfully knocked down IQGAP1 expression in trophoblast cell lines, we sought to 
find out whether this reduction can affect the viability of our EVT cell lines HTR8/SVneo and 
SW71, as increased levels of IQGAP1 have been associated with enhanced cell growth in cancer 
cell lines (Wang t a., 2009). To achieve this, cells were treated with IQGAP1 siRNA 2 and 5, 
which were shown to be the most efficient in reducing IQGAP1 expression in the previous 
experiment, as well as non-specific siRNA sequence as negative control. Then, the treatment, the 
viability of the cells as well as their metabolic activity were studied using trypan blue exclusion 
and MTT assays, respectively, over the course of the next 72 hours.  
The untreated HTR8/SVneo cells were increased in number by 50% at 48 hours compared with 
24 hours following the seeding and by another 50% at 72 hours compared with 48 hours following 
the seeding, while SW71 cells increased in cell number by 100% at 48 hours compared with 24 
hours following the seeding and 50% at 72 hours compared with 48 hours following the seeding 
(Figure 5.7). Addition of the IQGAP1 siRNA or the negative control siRNA did not affect the 
proliferation of HTR8/SVneo cells, while both of the treatments in SW71 cells, at 72 hours, 
resulted in 20% decrease, with overlapping SDs, compared with the control (Figure 5.7).  
Metabolic activity of untreated HTR8/SVneo and SW71 cells increased by 60 and 20% 
respectively, at 48 hours compared with 24 hours following the seeding and then by 100 and 
200%, respectively at 72 hours compared with 48 hours following the seeding (Figure 5.7). 
Addition of IQGAP1 siRNA or the negative control siRNA did not affect the metabolic activity 
of either HTR8/SVneo or SW71 cells (Figure 5.7). 
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Figure 5.7 Trophoblast viability with IQGAP1 knockdown. HTR8/SVneo and SW71 cells 
were treated with IQGAP1 siRNA 2 and 5, along with a non-specific siRNA sequence, as 
negative control, for 72 hours. The cells were then collected and reseeded and their viability and 
metabolic activity (MTT assay) were recorded over the next 72 hours. N = 3 for each condition. 
Total sample size for each condition: 60 (viability) and 6 (for MTT). 
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5.2.8. IQGAP1 knockdown reduces trophoblast motility 
IQGAP1 has been suggested to be a key regulator of cell motility (Brown & Sacks 2006; Noritake 
et al. 2005; Watanabe et al. 2004). However, it is not clear whether it plays a similar role in 
trophoblast cells. Having shown that IQGAP levels can be specifically and significantlyreduced 
in HTR8/SVneo and SW71 EVT cells, the cell lines were treated with IQGAP1 siRNA 2 and 5 
and then were seeded in transwells to assess their migration. The cells were counted on random 
fields at 20x magnification and the average number of migrated treated cells were compared with 
non-treated cells. Knocking down IQGAP1 significantly reduced migration in HTR8/SVneo EVT 
cell lines by 50% (siRNA 2, P<0.0001) and 40% (siRNA 5, P<0.001) compared with control. The 
effect on migration in SW71 was slightly higher, reducing it by 70% (siRNA 2, P<0.0001) and 
50% (siRNA 5, P<0.0001) compared with control (Figure 5.8). 
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Figure 5.8 The effect of IQGAP1 knockdown on trophoblast motility. HTR8/SVneo and 
SW71 cells were seeded in 24-well plates and were treated with IQGAP1 siRNA 1, 2, 3 and 5, 
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along with mock treatment and non-treated control. They were left to grow for 48 hours before 
the medium was replaced with serum starvation medium. After another 24 hours of incubation, 
the cells were collected and were seeded in transwells, while the lower wells contained complete 
medium. After 24 hours of incubation, the transwells were fixed and stained. The cells were 
counted in fields with 20x magnification. Panels A1 and B1 show average cell count percentage 
compared with control in HTR8/SVneo and SW71 cells, respectively and the bars represent SEM 
(*** P<0.001, **** p<0.0001). Panels A2 and B2 show representative fields of fixed and stained 
transwells for HTR8/SVneo and SW71 cells, respectively. N = 3 for each cell line. Total sample 
size = 18 for each condition. 
 
5.2.9. IQGAP1 knockdown reduces trophoblast invasion 
IQGAP1 has been linked with enhanced cellular invasion (Chellini et al. 2019; Sakurai-Yageta 
et al. 2008). Having shown the role of IQGAP1 in trophoblast motility, here we aimed to test the 
possible role of the protein in trophoblast invasion. 
HTR8/SVneo and SW71 EVT cell lines were treated with IQGAP1 siRNA 2 and 5 along with a 
non-specific sequence of siRNA as negative control for 72 hours prior to being seeded in 
Matrigel-coated transwells. The invaded cells fixed, stained and counted on random fields at 20x 
magnification. Knocking down IQGAP1 significantly reduced invasion in HTR8/SVneo EVT 
cell lines by 40% (siRNA 2, P<0.0001) and 50% (siRNA 5, P<0.001), and in SW71, by 80% 
(siRNA 7, P<0.0001) and 70% (siRNA 9, P<0.0001) (Figure 5.9) compared with their control 
counterparts.  
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Figure 5.9 The effect of IQGAP1 knockdown on trophoblast invasion. HTR8/SVneo and 
SW71 cells were seeded in 24-well plates and were treated with IQGAP1 siRNA 1, 2, 3 and 5, 
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along with mock treatment and non-treated control. They were left to grow for 48 hours before 
the medium was replaced with serum starvation medium. After another 24 hours of incubation, 
the cells were collected and were seeded on Matrigel-coated transwells, while the lower wells 
contained complete medium. After 24 hours of incubation, the transwells were fixed and stained. 
The cells were counted in fields at 20x magnification. Panels A1 and B1 show average cell count 
percentage compared with control in HTR8/SVneo and SW71 cells, respectively and the bars 
represent SEM (*** P<0.001, **** p<0.0001). Panels A2 and B2 show representative fields of 
fixed and stained transwells for HTR8/SVneo and SW71 cells, respectively. N = 3 for each cell 
line. Total sample size = 6 for each condition. 
 
5.2.10. Regression analysis 
Having shown the effect of IQGAP1 down regulation on trophoblast cell line migration and 
invasion, we next aimed to see whether there is a meaningful correlation between IQGAP1 
expression and migration/invasion in these cells, by regression analysis. To do this, IQGAP1 
expression levels in trophoblast cells HTR8/SVneo and SW71, with two sequences of IQGAP1 
siRNA (2 and 5), mock negative control, along with non-treated control (Figure 5.6) were 
correlated with their migration (Figure 5.8) and invasion (Figure 5.9). The Pearson correlation 
coefficient, r was calculated, and Student's t-distribution was used to test the significance of the 
correlation. Regression analysis showed a significant positive correlation (r>0) between IQGAP1 
expression and cell migration/invasion for both trophoblast cells (Figure 5.10): IQGAP1 
expression and HTR8/SVneo migration r = 0.95 (P<0.05) and invasion r = 0.96 (P<0.01), 
IQGAP1 expression and SW71 motility r = 0.98 (P<0.01) and invasion r = 0.99 (P<0.01).  
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Figure 5.10 Positive correlation between trophoblast migration/invasion and IQGAP1 
expression. Average IQGAP1 expression levels in trophoblast cell lines HTR8/SVneo and SW71 
were correlated with their migration and invasion and Pearson correlation coefficient, r, was 
calculated. Student's t-distribution was used to measure the P-values. 
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5.2.11. The effect of IQGAP1 knockdown on trophoblast FAs 
IQGAP1 knockdown in endothelial cells has been shown to reduce the turnover of FAs at the 
leading edge of the cells as well as their migration (Kohno et al. 2013). Here, we hypothesised 
that the motility and invasion of trophoblast cells might also be regulated by IQGAP1 through a 
similar mechanism. For this purpose, IQGAP1 was knocked down in HTR8/SVneo and SW71 
cells, through treatment with IQGAP1 siRNA 2 and 5. The cells were seeded on fibronectin-
coated coverslips. The coverslips were fixed and incubated with primary anti-paxillin antibody 
followed by secondary FITC-conjugated antibody and rhodamine phalloidin, before mounting 
and viewing. Treating HTR8/SVneo cells with IQGAP1 siRNA5 significantly increased FA 
count by 20% (P<0.05) compared with control cells, while siRNA 2 did not affect FA count(Table 
5.1).In SW71 cells,IQGAP1 knockdown resulted in an increase in the relative size (Figure 5.11) 
of the FAs as well as a significant 30% (siRNA 2) and 60% (siRNA 5) increase in their number 
(Table 5.1) compared with control cells (P<0.05 and P<0.0001. respectively) (Figure 5.11). 
 
Table 5.1 Average FA count per cell in HTR8/SVneo and SW71 cells. HTR8/SVneo cells and 
SW71 trophoblast cell lines were treated with IQGAP1 siRNA 2 and 5 for 48 hours before 
collection. The cells were then seeded on fibronectin-coated coverslips, were left to attach for 24 
hours, and stained for paxillin. The FAs were counted on all cells in each image. 
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Figure 5.11 The effect of IQGAP1 knockdown on FAs. HTR8/SVneo cells and SW71 
trophoblast cell lines were treated with IQGAP1 siRNA 2 and 5 as well as non-specific siRNA 
(negative control) for 48 hours before collection and being seeded on fibronectin-coated 
coverslips. They were left attach for 24 hours. The cells were then stained for paxillin, F-actin 
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and DNA by immunofluorescence. The images were taken at 63x magnification. Panels A1 and 
B1 show the staining on HTR8/SVneo and SW71 cells, respectively. Panels B1 and B2 show the 
average FA count (in percentage) in treated cells compared with the non-treated controls in 
HTR8/SVneo and SW71, respectively. The error bars represent SEM (*<0.05, **<0.001). N = 1 
for each cell line. Total sample size = 20 for each condition. 
 
5.2.12. IQGAP1 is expressed in primary EVTs 
Having shown IQGAP1 expression in all trophoblast cell lines, here we aimed to look for the 
expression of the protein in primary EVT cells, which were isolated from first trimester human 
placenta by western blot. IQGAP1 signal was obtained (Figure 5.12A).  
To find out more about the localisation of the protein in primary EVTs, the same cells were fixed 
and stained with primary anti-IQGAP1 antibody followed by incubation with secondary FITC-
conjugated antibody, as well as rhodamine phalloidin, before mounting and viewing. The 
immunofluorescence staining showed strong localisation of the protein in the EVT membrane 
and nucleus as well as lower levels of localisation in their cytoplasm (Figure 5.12B). 
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Figure 5.12 IQGAP1 expression and localisation in primary EVTs. For expression analysis 
(panel A) EVT cells were collected, lysed and separated by 10% SDS-PAGE, and probed for 
IQGAP1 and α-tubulin by western blotting. For the localisation experiment, (panel B) the EVTs 
were seeded on fibronectin-coated coverslips and were incubated for 24 hours. IQGAP1 was 
visualised by immunofluorescence with FITC and counterstained, F-actin with rhodamine 
phalloidin and DNA with DAPI. The images were taken at 63x magnification.  
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5.3. Discussion 
Having shown the role of two metastasis-associated proteins in trophoblast motility and invasion 
in previous chapters, in this chapter we aimed to find out about the role of IQGAP1, another 
metastasis-associated protein, in these cells.  
IQGAP1 is ubiquitously expressed and has been shown to regulate cell morphology, motility, 
invasion and cell cycle by interacting with cytoskeletal components and signalling molecules 
(Johnson, Sharma & Henderson 2009; White, Brown & Sacks 2009). The over-expression of the 
protein has been associated with metastasis and poor prognosis in cancers of different origins (Hu 
et al. 2019; Jin et al. 2015; Li et al. 2017; C.-C. Wu et al. 2018; Zeng et al. 2018). Moreover, 
around 10% of all metastasis-associated proteins have been reported to be binding partners of 
IQGAP1 (White, Brown, and Sacks 2009).  
IQGAP1 expression has previously been reported to be present in placental microvilli (Berryman 
& Bretscher 2000) and the syncytiotrophoblast microvillous membrane (Paradela et al. 2005). 
Here, through staining human placental sections by IHC, we also showed IQGAP1 expression in 
the placental villi.  The highest expression level of the protein was detected in first trimester 
placenta with a gradual reduction in IQGAP expression throughout gestation. (Figure 5.2). IHC 
showed IQGAP expression in the trophoblasts forming the anchoring villi, and in the invasive 
trophoblast columns. The protein was localised within the cytoplasm of all trophoblasts, but its 
highest expression levels were seen in the apical membrane of syncytiotrophoblasts and EVTs 
(Figure 5.2 and Figure 5.3). IQGAP1 was shown to colocalise with cytokeratin 7, ezrin and S100P 
in trophoblasts (Figure 5.3). This colocalisation is in line with other studies, which have reported 
the interaction of these three proteins (S100P, ezrin and IQGAP1) with one another (Heil et al. 
2011; Koltzscher et al. 2003; Nammalwar, Heil & Gerke 2015). This pattern of expression in the 
early stages of implantation is suggestive of a potential role of the protein in  trophoblast invasion 
and implantation, due to the highest invasive capabilities of the EVTs during the first trimester, 
peaking at around weeks 10-12 of gestation (Caniggia et al. 2000), and in line with our 
observation regarding the other metastasis-associated proteins in this study. 
Western blot analysis confirmed IQGAP1 expression in all our trophoblast cell lines: BeWo, 
HTR8/SVneo, Jeg-3, SW71, SGHPL-4 and SGHPL-5 (Figure 5.4) as well as first trimester EVTs 
(Figure 5.12), with Jeg-3 expressing the highest and SGHPL-4 expressing the lowest amount of 
the protein amongst all cell lines. Furthermore, immunofluorescence staining showed IQGAP1 
localisation in the membrane, the cytoplasm as well as the nuclear envelope in all trophoblast cell 
lines (Figure 5.5) and primary EVTs (Figure 5.12). IQGAP1 has been reported to show strong 
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localisation within the membrane at the invasive front of metastatic cancer cells (McDonald et al. 
2007; Nabeshima et al. 2002). In the HTR8/SVneo and SW71 cell lines and primary EVTs, the 
protein also seemed to be localised within the nucleus (Figure 5.5 and Figure 5.11). Nuclear 
IQGAP1 has been reported to make up only a very small portion of the total pool of IQGAP1 and 
is involved in DNA replication (Bielak-Zmijewska et al. 2008; Johnson et al. 2011). This again 
is the first evidence of IQGAP1 expression in trophoblast cell lines and suggest that all our model 
systems are suitable for further studies to decipher the role of the protein in cell behaviours.  
To further study the role of IQGAP1 in trophoblast cell lines, we sought to modulate its 
expression levels. HTR8/SVneo and SW71 EVT cell lines and Jeg-3 choriocarcinoma cell lines 
were treated with four sequences of siRNA targeting IQGAP1. We showed that two of our siRNA 
sequences (siRNA 2 and 5) successfully knocked down IQGAP1 expression in HTR8/SVneo and 
SW71 cells, while none of the sequences showed a significant effect on Jeg-3 cells (Figure 5.6). 
Through transwell assays, it was shown that downregulation of IQGAP1 reduced the migration 
(Figure 5.8) and invasion (Figure 5.9) of EVT cell lines HTR8/SVneo and SW71. Regression 
analysis revealed that the expression level of the protein positively and significantly correlated 
with both migration and invasion in HTR8/SVneo and SW71 cells (Figure 5.10). IQGAP1 
downregulation was not shown to affect the viability of neither of our two trophoblast cells 
(Figure 5.7), and this ruled out the possibility of a difference in cell viability affecting our 
transwell results. In cancer cells, IQGAP1 downregulation has been shown to reduce migration 
and invasion as well as proliferation (Diao et al. 2017; Hu et al. 2019), or, similar to our results,  
invasion and migration only, without affecting their proliferation (Dong et al. 2008).   
FA formation and turnover have been shown to regulate directional cell motility by modulating 
the linkage between the intracellular cytoskeleton and the ECM (Nagano et al. 2012). Here, in 
order to find out about the mechanisms involved in IQGAP1-induced motility, HTR8/SVneo and 
SW71 cells with reduced IQGAP1 expression were stained for paxillin, one of the components 
of the FA complex. We showed that IQGAP1 downregulation using both siRNAs 2 and 5 
significantly increased the number as well as the relative size of FAs in SW71 cells (Figure 5.11). 
In HTR8/SVneo cells however, only IQGAP1 siRNA5 significantly increased the number of FAs 
(Figure 5.11). In line with this, the regression analysis also had revealed a slightly stronger 
correlation between IQGAP expression with both migration and invasion in SW71 (r = 0.98 for 
migration, r = 0.99 for invasion), compared with HTR8/SVneo (r = 0.95 for migration and r = 
0.96), which was also more significant in SW71(P-value = 0.003 for migration, P-value = 0.001 
for invasion) compared with HTR8/SVneo (P-value = 0.011 for migration and P-value = 0.006) 
(Figure 5.10). One explanation for this observation could be the higher IQGAP1 expression levels 
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of IQGAP1 in HTR8/SVneo cells compared with SW71 (Figure 5.4), which might have resulted 
in a relatively lower efficiency of siRNA treatment in reducing protein levels in HTR8/SVneo. 
IQGAP1 was previously shown to colocalise with FAs (Kuo et al. 2011; Schiller et al. 2011) to 
and to directly interact with FA components (Schiefermeier et al. 2014). The down regulation of 
the protein was shown to result in the elongation of FAs, without affecting cell migration in 
fibroblasts (Schiefermeier et al. 2014). While the upregulation of the protein was shown to impair 
FA formation, as well as the migration of fibroblasts (Shen et al. 2017). Moreover, paxillin is 
only one of the many adapter proteins involved in multiprotein FA structures, and therefore might 
not always show a true representation of the changes in FA dynamics, while being studied alone. 
Likewise, different FA proteins show different levels of stability and are recruited to the FA at 
different timepoints. For example, a study reported that paxillin and vinculin are more stably 
associated with FAs, while zyxin and vasodilator-stimulated phosphoprotein (VASP) are 
associated them in a more transient manner. Moreover, paxillin, zyxin and VASP were more 
dynamic than vinculin in FAs closer to the edge of the cell membrane (Legerstee et al. 2019). 
Zyxin and VASP have been reported to be more closely linked with actin compared with paxillin 
and vinculin, while being recruited to FAs at a later stage compared with paxillin and vinculin 
(Choi et al. 2008). Therefore, studying FA dynamics using other makers, might perhaps give a 
better view of how IQGAP1 regulates their dynamics. In line with this, other FA markers such as 
vinculin and VASP have already been suggested to play a role in trophoblast migration and 
invasion (Kayisli et al. 2002; Lang et al. 2004). Additionally, VASP was shown to be a binding 
partner for IQGAP1 (Routray et al. 2011), while IQGAP-rich areas in the adhesion sites of cells 
were shown to have reduced vinculin expression (Foroutannejad et al. 2014), 
To conclude, IQGAP1 expression was shown in cyto- and syncytiotrophoblasts as well as EVTs, 
and there was a gradual reduction in its expression throughout gestation. IQGAP1 was shown to 
regulate trophoblast migration as well as invasion. Based on these findings, we propose a 
potential role for IQGAP1in early placenta development and implantation. 
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Chapter 6.  
Conclusions 
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6.1. General discussion   
Miscarriage and preeclampsia are the most common pregnancy-related issues in humans 
(Jauniaux, Poston & Burton 2006). As much as 30% of all pregnancy cases have been estimated 
to end with spontaneous abortion or miscarriage before 20 weeks of gestation, with about 80% 
of these cases happen during the first trimester (Wilcox et al. 1988; Zinaman et al. 1996). 
Preeclampsia, which also occurs in about 10% of otherwise normal pregnancies (Roberts & Lain 
2002) can also be detected during the first trimester (Roberts & Hubel 2009). Preeclampsia, 
miscarriage and foetal growth restriction  have been associated with inadequate trophoblast 
invasion, which results in impaired transformation of the spiral arteries in the placenta (Ball et al. 
2006; Brosens, Robertson & Dixon 1972; Khong et al. 1986; Reister et al. 2006). In an attempt 
to address this issue, we aimed to study trophoblast invasion as well as motility.  
Our hypothesis was that three well-known metastasis-associated proteins (S100P, ezrin and 
IQGAP1) can equally play important roles in the migration and invasion of trophoblast cells. For 
this purpose, we chose three different, yet interacting (Heil et al. 2011; Koltzscher et al. 2003; 
Nammalwar, Heil & Gerke 2015), metastasis-associated proteins from three different families i.e. 
S100P, ezrin and IQGAP1, all of which are well-known effectors of tumour cell motility and 
invasion and metastasis (Chen et al. 2014; Clucas & Valderrama 2014; Johnson, Sharma & 
Henderson 2009), and studied their role in the motility and invasion of trophoblast cell lines.  
By comparing DAB signals, though IHC, we showed high expression of S100P, ezrin and 
IQGAP1 in human placenta sections from early gestational age  (Figure 3.2, Figure 4.2 and Figure 
5.2). It was shown that expression level of these proteins gradually declines throughout gestation 
(Figure 3.2, Figure 4.2 and Figure 5.2). High expression levels of these three proteins during the 
first trimester suggests their role in early placenta development, during which most of trophoblast 
motility and invasion takes place (Caniggia et al. 2000). 
All three proteins were shown to be expressed in the cytoplasm of cyto- and syncytiotrophoblasts, 
colocalising with the trophoblast marker cytokeratin 7 (Figure 3.3, Figure 4.3 and Figure 5.3). 
Through colocalisation with the marker HLA-G, the expression of these three proteins was also 
confirmed in an invasive subpopulation of trophoblasts, located at the tip of trophoblastic 
columns, known as EVTs (Figure 3.3, Figure 4.3 and Figure 5.3). Interestingly, the highest levels 
of these proteins were detected in the apical membrane of syncytiotrophoblasts as well as EVTs 
(Figure 3.3, Figure 4.3 and Figure 5.3). Unlike ezrin and IQGAP1, staining by IHC showed 
occasional nuclear localisation of S100P in syncytiotrophoblasts and EVTs (Figure 3.3).   
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Through western blot analysis, we detected IQGAP1 and ezrin in all of our trophoblast cell lines, 
Jeg-3, BeWo, HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5, while S100P was only detectable 
in the choriocarcinoma cell lines Jeg-3 and BeWo, and not in the first trimester EVT cell lines: 
HTR8/SVneo, SW71, SGHPL-4 and SGHPL-5 (Figure 3.4, Figure 4.4 and Figure 5.4). Primary 
EVTs isolated from first trimester placenta did express our three proteins (Figure 3.26, Figure 
4.18 and Figure 5.12). We also showed S100P expression modifications, when Jeg-3 cells were 
grown in “physiological-like” microenvironments i.e. on fibronectin, Matrigel and 2% gelatine, 
while none of these conditions induced S100P expression in our EVT cell lines (Figure 3.5). 
We then attempted to look at the localisation of these three metastasis-associated proteins in our 
trophoblast cell lines through immunofluorescence staining. S100P immunofluorescence staining 
did not provide a clear view but showed cytoplasmic and nuclear localisation of the protein (data 
not shown). Ezrin (Figure 4.5) and IQGAP1 (Figure 5.5) were localised within the cytoplasm as 
well as the plasma membrane in all trophoblast cell lines, except for Jeg-3 and SGHPL-4, which 
showed cytoplasmic ezrin expression only (Figure 4.5). IQGAP1 also showed peri-nuclear 
localisation in the trophoblast cell lines and was detected within the nucleus in HTR8/SVneo and 
SW71 (Figure 5.5). Active ezrin localised within the cortex via interaction with PIP2 in the 
membrane, while the closed inactive ezrin is mainly located within the cytoplasm (Fehon, 
McClatchey & Bretscher 2010). Changes in the localisation of ezrin in the membrane and 
microvilli (either decrease or increase) have been associated with enhanced motility, invasion and 
proliferation in cancer cells (Arslan et al. 2012; Di Cristofano et al. 2010; Curto & McClatchey 
2004; Elzagheid et al. 2008; Sarrio et al. 2006; Schlecht et al. 2012). The phosphorylated (active) 
form of ezrin has been shown to localise within long spike projections from the plasma membrane 
of gastric cells (Zhou et al. 2005). Here, phospho-ezrin (at Thr567) was shown to be localised 
within the membrane as well as long membrane projections in primary EVTs, and these 
projections were more abundant and longer in EVTs isolated from first trimester placenta 
compared with second trimester (Figure 4.19). Membrane IQGAP1 at the invasive front of cells 
has been associated with metastasis  (McDonald et al. 2007; Nabeshima et al. 2002), while 
nuclear IQGAP1, which was reported to involve only a small proportion of total IQGAP1, has 
been reported to be involved in DNA replication (Bielak-Zmijewska et al. 2008; Johnson et al. 
2011). Moreover, both ezrin, and IQGAP1 have been shown to be present in placental microvilli 
(Berryman & Bretscher 2000). 
We then aimed to find out about the role of these three metastasis-associated proteins in 
trophoblast cell lines. For this purpose, we knocked down the expression of these three proteins 
though siRNA delivery (Figure 3.6, Figure 4.6 and Figure 5.6), and found out, trough transwell 
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assays, that reduction in the expression of either of these proteins resulted in significant reduction 
in cell motility (Figure 3.9, Figure 4.8 and Figure 5.8) and invasion (Figure 3.10, Figure 4.9 and 
Figure 5.9). S100P expression in HTR8/SVneo cells (which do not endogenously express S100P), 
at similar levels to Jeg-3, significantly enhanced their motility (Figure 3.12) and invasion (Figure 
3.13). While these three metastasis-associated proteins, i.e. S100P (Arumugam et al. 2005; Jiang 
et al. 2011; Liu et al. 2017), ezrin (Fan et al. 2011; Meng et al. 2010; Tang et al. 2019; Zhang et 
al. 2014) and IQGAP1 (Diao et al. 2017; Dong et al. 2008; Hu et al. 2019) have previously been 
shown to enhance cancer cell motility and invasion, here we report their involvement in 
trophoblast motility and invasion for the first time, and as the main discovery in this piece of 
work. Knocking down or expression induction of S100P (Figure 3.15 and Figure 3.17 and Tabrizi 
et al. 2018), and down regulation of ezrin (Figure 4.7) or IQGAP1 (Figure 5.7) did not affect the 
viability of our trophoblast cell lines, similar to what was shown in some types of tumour cells 
(Barry et al. 2013; Dong et al. 2008; Du et al. 2012; Horwitz et al. 2016; Hsu et al. 2015). 
Additionally, we also suggested that S100P can regulate trophoblast motility (Figure 3.21) and 
invasion (Figure 3.22) from a pathway that involves a pool of S100P that is extracellular 
membrane-bound and/or soluble in the stroma. Furthermore, we showed that ezrin inhibition 
affects primary EVT morphology (Figure 4.20) and downregulates motility and invasion in these 
cells (Figure 4.21 and Figure 4.22, respectively) as well asHTR8/SVneo cells (Figure 4.15 and 
Figure 4.16 respectively). 
Trophoblasts have been shown to bind to fibronectin through integrins α5β1 and 
αvβ3 (Burrows et al. 1995). The assembly of FAs, which bind to the cytoplasmic part of 
clustered integrins, have been shown to be regulated, at least partially, through insulin-like 
growth factor-I signalling in trophoblasts (Kabir-Salmani et al. 2002). Moreover, alterations 
in FAs have been reported to play an important role in trophoblast fusion (Ishikawa et al. 2014). 
Here, in an attempt to learn about the possible mechanisms involved in trophoblast motility and 
invasion, we looked at how FA dynamics are regulated by our three proteins. We showed that the 
expression of S100P in HTR8/SVneo cells reduced the relative size and the number of FAs 
(Figure 3.14), while knocking down S100P  in Jeg-3 and BeWo (Tabrizi et al. 2018) and IQGAP1 
in SW71 cells  (Figure 5.11) increased their relative size and number. More mature FAs are a 
sign of a higher ratio of FA formation relative to its turnover, which are mostly seen in stationary 
cells (Nagano et al. 2012). The FAs were not affected in Jeg-3 cells when extracellular S100P 
was inhibited and in HTR8/SVneo and SW71 when ezrin was knocked down. This lack of an 
effect on FAs might have been due to the fact that only a small percentage of cell adhesion 
strength is linked with FA assembly (Gallant, Michael & García 2005), and because we did a 
limited FA analysis on fixed cells, which might have represented only a “snapshot” of a highly 
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dynamic process, which cannot guarantee to provide a holistic view. Interestingly, unlike ezrin 
knockdown, the inhibition of ezrin significantly increased the number and the relative size of FAs 
in HTR8/SVneo (Figure 4.17), but not in primary EVTs (Figure 4.23). This was in line with the 
greater effectiveness of the ezrin inhibitor on the motility and invasion of HTR8/SVneo (Figure 
4.15 and Figure 4.16 80% and 70%, respectively) compared with the primary EVTs (Figure 4.21 
and Figure 4.22 30% and 20%, respectively). 
EGF is one of the main regulators of the placental development and trophoblast migration and 
invasion during early gestation (Bass et al. 1994; Han et al. 2010; Maruo et al. 1995). Upon EGF 
stimulation, and subsequent Ca2+ elevation, ezrin and S100P colocalise in microvillar cell 
protrusions. The hydrophobic residues in the C-terminal hand of S100P have been shown to 
compete (at least partially) with PIP2 in binding to the F2 lobe of ezrin N-ERMAD (in a Ca2+-
dependent manner), resulting in ezrin activation by unmasking its F-actin binding site 
(Austermann et al. 2008; Koltzscher et al. 2003). EGF also stimulates the interaction between the 
other (non-canonical) EF hands ofS100P and the IQ domain of IQGAP1 (also in a Ca2+-dependent 
manner), resulting in the inhibition of IQGAP1 and therefore interfering with the downstream 
MAPK pathway (Heil et al. 2011). On the other hand, following the conformational change in 
ezrin upon binding to the membrane PIP2, the N-ERMAD domain of the protein has been shown 
to interact with the IQ domain in IQGAP1 in a Ca2+-independent manner (and without a 
requirement for ezrin phosphorylation), resulting in IQGAP1 recruitment to the cell cortex 
(Nammalwar, Heil & Gerke 2015). In line with this, we also detected reduced cortical IQGAP1 
in HTR8/SVneo, following ezrin inhibition (data not shown). Moreover, an elevation in 
intracellular Ca2+  was shown to recruit S100P to the ezrin-IQGAP1 complex (Nammalwar, Heil 
& Gerke 2015). Furthermore, ezrin plays an important role in EGF-induced tumour cell motility 
and invasion (Y. Wang et al. 2014) and IQGAP1 mediates EGF-induced MAPK activation though 
binding to B-Raf, MEK, ERK and EGFR and the phosphorylation of EGFR (McNulty et al. 
2011). Additionally, the transcription factor SP1, a member of  SP/KLF family, also might link 
these three proteins at the transcriptional level as it has been shown to promote ezrin (Gao et al. 
2009) and IQGAP1 expression (Jin et al. 2019), while S100P has been shown to include a 
SP/KLF-binding site in its promoter region (Gibadulinova et al. 2008). Interestingly, 
trophoblastic SP1 was shown to be more frequent in placental villi sections from early gestation 
compared with term samples (Knofler et al. 2004). 
Based on our observation of a high degree of expression of these three proteins in trophoblasts 
during the first trimester, we suggest that the S100P, ezrin and IQGAP1 might form a complex 
and link the trophoblast membrane with F-actin and regulate cytoskeleton dynamics upon EGF 
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stimulation, similar to what was shown in other cell types (Nammalwar, Heil & Gerke 2015). 
These proteins are also suggested to further regulate actin dynamics by the potential recruitment 
of other IQGAP1-binding proteins such as Cdc42 and Rac1 to the complex (Nammalwar, Heil & 
Gerke 2015).  
To conclude, we showed that three different metastasis-associated proteins i.e. S100P, ezrin and 
IQGAP1, colocalise in cytotrophoblasts, syncytiotrophoblasts and EVTs from first trimester 
placenta sections. We also showed that these three proteins play important roles in trophoblast 
migration and invasion and are involved in placenta development. However, we have yet to 
determine the mechanisms involved in these two pathways in trophoblasts and we still do not 
know whether these three proteins work together in trophoblasts to make motility and invasion 
possible. 
6.2. Future work 
To have a better view of some of the processes carried out in this study, further investigation can 
be carried out as follows: 
➢ We showed the colocalisation of our three proteins: S100P, ezrin and IQGAP1 in 
trophoblasts though IHC; therefore it would be useful to have a closer look at how these 
three proteins colocalise within primary trophoblasts by immunofluorescence staining.  
➢ Having shown that the localisation of phospho-ezrin is significantly different between 
the first trimester and second trimester primary EVTs, it is equally important to find out 
whether there are differences in the localisation patterns of the total pool of ezrin, S100P 
and IQGAP1 in first, second and third trimester EVTs, though both epifluorescence and 
confocal microscopy. 
➢ Motility changes in this study were studied though transwell assays. It would perhaps be 
useful to confirm our results using other methods such as scratch assay or using the Dunn 
chemotaxis chamber. 
➢ It would be interesting to investigate trophoblast invasion in more details by investigating 
the effect of knocking down our three proteins on the activity of ECM-degrading 
enzymes.  
➢ We studied how our three proteins affect the FA dynamics in trophoblasts, by targeting 
paxillin, one of the many components of the multi-protein FA complex. Studying the 
other components such as vinculin, zyxin and VASP separately or at the same time might 
give us a better view of the process.  
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➢ Ezrin inhibition did not show the same level of effect on the motility and invasion of 
primary EVTs or their FAs, as we saw in HTR8/SVneo cells; therefore, it would be 
interesting to see whether the application of our ezrin inhibitor, NSC668394, on EVTs at 
higher concentrations and for longer periods would further reduce their motility and 
invasion and affect FA dynamics.  
➢ Boyden chamber assays with primary EVT might show more prominent results if they 
were optimised accordingly. 
➢ Having shown the importance of ezrin phosphorylation on Thr567 in trophoblast motility 
and invasion, it would be interesting to see how other phosphorylation sites such as 
tyrosine 477, serine 66, threonine 235, and tyrosine 145 might regulate the mentioned 
pathways as well as the morphology of trophoblasts. 
➢  Having shown the expression pattern of ezrin in placenta, at different stages of gestation, 
though IHC, it would be useful to find out about the expression pattern of the 
phosphorylated form of the protein in the same organ. 
➢ In this study we used HTR8/SVneo, SW71 and Jeg-3 to study the role of ezrin and 
IQGAP1 in their motility and invasion, but it would be equally informative to see how 
these two proteins regulate the mentioned pathways in our other trophoblast cell lines, 
since all of them expressed these two proteins. 
➢ IQGAP1-null mice are viable (Li et al. 2000; Sbroggio et al. 2011); therefore, they could 
be used to compare placenta and/or foetus development in the absence and presence of 
IQGAP1.  
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